EXHIBIT 10.13
                             JOINT VENTURE AGREEMENT
Collectible Concepts Group, Inc. ("CCGI") and Pivotal Self Service Tech, Inc.
("PVSS"), (the "Parties" or "Joint Venturers" if referred to collectively, or
the "Party" or Joint Venturer" if referred to singularly), by this Agreement
associate themselves as business associates, and not as partners, in the
formation of a joint venture (the "Joint Venture"), for the purpose of engaging
generally in the business provided for by terms and provisions of this
Agreement.
1.   Name of the Joint Venture. The name of the Joint Venture will be MightyCell
     Batteries, and may sometimes be referred to as "MightyCell" or the "Joint
     Venture" in this Agreement. The principal office and place of business
     shall be located in 1600 Lower State Road, Doylestown, PA 18901.
2.   Scope of the Joint Venture Business. The Joint Venture is formed for the
     purpose of engaging generally in the business of marketing batteries and
     related products, (the "Products") that include the display of licensed
     logos, images, brand names and other labels that differentiate them from
     the branding (the "PVSS Products") under which PVSS and/or its affiliates,
     sell to retailers and distributors in the normal course of their business.
     Without in any way limiting the generality of the foregoing, the business
     of the Joint Venture shall include:
          (a)  The purchase of Products for resale;
          (b)  The acquisition of a license(s) permitting the use of selected
               images in the Products;
          (c)  The sale and distribution of the Products to retailers and
               distributors; and,
          (d)  The transaction of such other and further business as is
               necessary, advisable, or incidental to the business of the Joint
               Venture.
          (e)  Develop a global marketing program for licensed Products
     Exhibit A attached hereto, describes by way of example but not limitation
     the responsibilities of the Joint Venturers
3.   Capital Contributions. Except as agreed upon by mutual consent, the Joint
     Venturers shall not be required to make any capital contribution to the
     Joint Venture.
4.   Offices of the Joint Venture. The principal place of business of the Joint
     Venture shall be at 1600 Lower State Road, in the City of Doylestown, Bucks
     County, Pennsylvania, but may maintain such other offices as the Joint
     Venturers may deem advisable at any other place or places within or without
     the Commonwealth of Pennsylvania.
5.   Powers and Authority of the Joint Venturers. The Joint Venturers shall have
     full and complete charge of all affairs of the Joint Venture. The Joint
     Venturers recognize that both of the Joint Venturers are and will continue
     to be engaged in the conduct of their respective businesses for their own
     account. Neither Joint Venturer shall be entitled to compensation for
     services rendered to the Joint Venture as such, but each Joint Venturer
     shall be reimbursed for all direct expenses, including travel, office, and
     all other out-of-pocket expenses incurred in the operation of the affairs
     of the Joint Venture and the promotion of its businesses.
     It is agreed that either Joint Venturer shall, except as provided for
     below, have authority to execute instruments of any character relating to
     the affairs of the Joint Venture; provided, that without the written
     consent or approval of both of the Joint Venturers: (i) the Joint Venture
     shall incur no liability of any sort, nor any indebtedness for borrowed
     funds; (ii) no assets owned in the name of the Joint Venture be disposed
     of; and (iii) no commitment to purchase any item for the Joint Venture
     shall be made.
                                       39
6.   Division of Income and Losses. All income and credits, and all losses and
     deductions shall be owned and shared among the Joint Venturers as follows:
     50% to Collectible Concepts Group, Inc.
     50% to Pivotal Self Service Tech, Inc.
     Depreciation and all other charges and expenses, which are not expressly
     apportioned by this Agreement, shall be apportioned in accordance with
     generally accepted accounting principles, consistently applied.
7.   Accounting Provisions. The Joint Venturers shall maintain adequate books
     and records to be kept of all the Joint Venture activities and affairs
     conducted pursuant to the terms of this Agreement. All direct costs and
     expenses, which shall include any insurance costs in connection with the
     distribution of the Products or operations of the Joint Venture, or if the
     business of the Joint Venture requires additional office facilities than
     those now presently maintained by each Joint Venturer, such item shall bepaid by the Joint Venture. The fiscal year of the Joint Venture shall be
     the calendar year, and shall use the cash basis of accounting. If requested
     by a Joint Venturer, the Joint Venture books and records shall be audited
     as of the close of each year by an independent accountant acceptable to
     both Joint Venturers. All books and records of every kind and character, of
     the Joint Venture, and other information, shall be kept at the principal
     office of the Joint Venture, or at such other place or places as may be
     agreed upon by the Joint Venturers, and shall be fully available to each
     Joint Venturer or his duly authorized representative, all at reasonable
     times. The books of the Joint Venture shall represent the complete record
     and report of business operations, including a balance sheet and income and
     expense statements reflecting all receipts and disbursements of the Joint
     Venture, and such reports shall be submitted to the Joint Venturers on a
     regular basis.
8.   Term of Joint Venture. The Joint Venture shall commence on the 1st of
     March, 2003, and shall be effective until February 28, 2004 unless extended
     by written agreement of the Joint Venturers not less than thirty (30) days
     prior to scheduled termination.
9.   Distributions. During the term of the Joint Venture, no interest shall be
     allowed to any Joint Venturer upon the amount of his contribution. No Joint
     Venturer shall withdraw, transfer or have paid to him in any manner any
     part of his capital contribution or account, or any other funds or property
     of the Joint Venture without the consent of both Joint Venturers; provided,
     however, there may be distributed to the Joint Venturers, from time to
     time, so much of the gross income of the Joint Venture as shall not be
     needed to defray the necessary and expected costs and expenses of the Joint
     Venture business. Distributions may only be made if after any distribution
     is made, the Joint Venture assets are in excess of all liabilities of the
     Joint Venture. Each distribution shall be made ratably to the Joint
     Venturers according to their prorata interest in the Joint Venture as shown
     in Section 6.
10.  Internal Revenue Code Election. The Joint Venturers agree and declare that
     this association for the carrying on of a joint venture business operation
     does not, and is not intended to create a partnership, for either legal or
     United States income tax purposes, each Party recognizing that the other is
     willing and able to contribute capital, labor, and services for the
     operation of a successful joint venture business. Further, each Party
     elects under the authority of Section 761(a) of the Internal Revenue Code
     of 1986 (the "Code"), as amended and all successor statutes, to be excluded
     from the application of all of the provisions of Subchapter K of Chapter 1
     of the Subtitle A of the Code, and the Parties agree that the election out
     of Subchapter K of Chapter 1 of Subtitle A of the Code shall, if necessary,
     be manifested by their execution and filing of all appropriate
     documentation. The Parties also declare that they are not making any
     agreement to undertake any business other than that set forth in this
     Agreement; and nothing in this Agreement is to be construed as a limitation
     of the powers or rights of either Party to carry on his separate business
     for his sole benefit; provided, however, the Parties shall cooperate with
     each other according to the terms and spirit of this Agreement in the
     performance of their joint venture business operation.
11.  Procedure on Termination and Liquidation. On any termination of the Joint
     Venture, its debt shall be paid or provided for in a manner satisfactory to
     the Joint Venturers. Then, any unexpended portion of Joint Venture funds
     shall be distributed to the Joint Venturers in accordance with their
     prorata ownership in the Joint Venture and all other assets of the Joint
     Venture shall be distributed as undivided interests to the Joint Venturers
     ratably according to their prorata interests in the Joint Venture as set
     forth in Section 6. If any asset is not capable of being distributed on an
     undivided basis, the Parties shall agree on a price for such asset and it
     shall be distributed to one Party and a corresponding balance, in cash or
     property, shall be made of the Joint Venture assets so that each Party
     receives his proportionate share of all the Joint Venture assets.
12.  Sale or Purchase of Interest of Joint Venturer Prohibited. No Joint
     Venturer shall be authorized or empowered to mortgage, hypothecate, pledge,
     sell, or transfer, an interest in the Joint Venture, nor confer on any
     successor or assignee the right to become a Joint Venturer without the
     consent of the other Joint Venturer.
13.  Notice. Any notice which a Joint Venturer shall have occasion to give to
     the other Joint Venturer shall be deemed sufficient notice for all purposes
     as to its contents if given in writing, hand delivered, by fax, or prepaid
     mail, to the address of such Joint Venturer as set out below his signature.
14.  Construction. The Joint Venturers declare that in entering into this
     Agreement, they have contracted with reference to the laws of the
     Commonwealth of Pennsylvania, and the construction and interpretation of
     the terms and provisions of this Agreement shall be interpreted and
     construed under the laws of the Commonwealth of Pennsylvania, except in
     such cases and to such extent as the laws of another jurisdiction shall
     necessarily control.
15.  Benefit. This Agreement shall be binding on the Joint Venturers and their
     respective heirs, successors, executors, administrators, and assigns.
16.  Counterparts. This Agreement may be signed in counterparts and shall be
     deemed one original instrument.For Collectible Concepts Group, Inc.
By: ____________________________________
Its:  ____________________________________
Date: ___________________________________
For Pivotal Self Service Tech, Inc.
By: ___________________________________
Its: ____________________________________
Date: __________________________________
EXHIBIT A
                     GENERAL RESPONSIBILITIES OF THE PARTIES
Collectible Concepts Group will:
     1)   Obtain any licenses deemed by the Joint Venturers to add value in the
          marketing of the Products
     2)   Prepare any artwork necessary for the reproduction of licensed or
          branded images for the purpose of manufacturing the Products and / or
          packaging
     3)   In concert with PVSS, appoint appropriate sales agents and / or
          representatives and distributors to sell the Products into specific
          retail channels
     4)   Prepare marketing materials for sales agents', representatives' and
          distributors' use in presentations to prospective clients
     5)   Engage in any support activities required to promote and sell the
          Products
     6)   Provide fulfillment services through affiliates for final distribution
          of the Products
Pivotal Self Service Tech, Inc. will:
     1)   Provide the Products in accordance with the specifications and
          quantities and time frames designated by CCGI
     2)   Provision any additional Products deemed by the Joint Venturers to be
          salable through the channels established by CCGI
     3)   Negotiate such favorable pricing and terms with the suppliers of the
          Products so as to assure the viability of the Joint Venture offerings
          and the continuity of Product availability to the customers of the
          Joint Venture
     4)   Provide alternate fulfillment and distribution services of the
          Products as backup to those provided by CCGI
                                       40Exhibit 10.1
JOINT VENTURE AGREEMENT
THIS JOINT VENTURE AGREEMENT (the “Agreement”) made and entered into this 20th day of Friday, March 2020 (the “Execution Date”),
BETWEEN:
BorrowMoney.com, inc of 512 Bayshore DR, suite 201 Fort Lauderdale FL 33304, and JVLS, LLC dba Vaccines 2Go of 4060
Johns Creek Parkway Suite H Suwanee, GA 30024 (individually the “Member” and collectively the “Members”).
BACKGROUND:
A. The Members wish to enter into an association of mutual benefit and agree to jointly invest and set up a joint venture enterprise.
B. This Agreement sets out the terms and conditions governing this association.
IN CONSIDERATION OF and as a condition of the Members entering into this Agreement and other valuable consideration, the receipt and
sufficiency of which consideration is acknowledged, the Members agree as follows:
Formation
1. By this Agreement the Members enter into a joint venture (the “Venture”) in accordance with the laws of the State of Florida. The rights
and obligations of the Members will be as stated in the applicable legislation of the State of Florida (the “Act”) except as otherwise
provided here.
Name
2. The business name of the Venture will be BM&V2GO.
Page 1 of 13Purpose
3. The exclusive purpose of the Venture (the “Purpose”) will be IT Development. internet Back office Maintenance And Deployment of
medical Service.
Term
4. The duration of this Venture (the “Term”) will begin on March 1, 2020 and continue in full force and effect until February 28, 2025 or as
otherwise provided in this Agreement.
5. The Term may be extended with the unanimous consent of all Members.
Place of Business
6. The principal office of the business of the Venture will be located at 512 Bayshore Drive Suite 201 Fort Lauderdale, FL 33304 or such other
place as the Members may from time to time designate.
Business Management
7. The following managers (the “Managers”) have been appointed by the Members to manage the Venture:
● Aaldo PIscitello
● Jody Stewart
8. Except as otherwise provided in this Agreement, the individual Managers may be appointed, replaced, or removed upon unanimous
consent of the Members.
9. The Managers will have a primary duty to the best interest of the Venture and not directly to any individual Member.
10. Within the limits of the Purpose of the Venture and the terms of this Agreement, the Managers, acting jointly, will have full authority to
bind the Members in all matters relating to the direction, control and management of the Venture. Conduct and actions of the Managers
will be dictated by policy and procedure established by the Members. Authority to bind the Venture in contract or in any third party
business relation lies exclusively with the Managers, acting jointly.
11. The Managers will jointly decide major issues concerning the Venture. Where Managers are unable to reach agreement in deciding major
issues, approval by a majority vote of the Members at a regular or special meeting will be required.
Page 2 of 13Management Duties
12. Except as otherwise specified in this agreement, the duties and obligations of the Managers in relation to the Venture will include the
following:
a. managing the day to day business of the Venture;
b. monitoring, controlling and directing the financial, business and operational affairs of the Venture;
c. proper maintenance of books of account and financial records according to accepted accounting practices;
d. monitoring, analyzing and acting on all issues over which it would have express or implied authority according to this
Agreement; and
e. all responsibilities attached to hiring of production and administration staff including any required labor negotiations, and all
responsibilities attached to hiring of third party contractors.
Member Duties
13. Each Member will be responsible for its respective duties as follows:
Page 3 of 13Member Duties Description
BorrowMoney.com,
inc
*HTML code, build, deploy and maintain all technical aspect requirements including a database for
medical dispatch personal & product service as needed, including activity information, data storage and
backup. provided by three qualified assigned Borrowmoney.com, inc. employees/personal
JVLS, LLC dba
Vaccines 2Go
$60,000.00 USD From Monthly Government , City And State, And Or Private Awarded Contracts. Plus
(10%) Of Any Generated Gross Revenue From Awarded Contract, In Addition to The Total
Contributions.
14. Duties of Members may be amended, from time to time, by decision of the Members, provided that the Members’ interests are not affected
except with the unanimous consent of the Members.
Capital Contributions
15. Each of the Members has contributed to the capital of the Venture, in cash or property in agreed upon value, as follows (the “Capital
Contribution”):
Member Contribution Description Agreed Value
BorrowMoney.com, inc 1, 500 square feet of Leased/rent office Space Including
specified Description of duty* $3,500,000.00 USD
JVLS, LLC dba
Vaccines 2Go
$60,000.00 USD From Monthly Government , City And State,
And Or Private Awarded Contracts. Plus (10%) Of Any
Generated Gross Revenue, In Addition to The Total
Contributions.
$3,500,000.00 USD
16. All Members will contribute their respective Capital Contributions fully and on time.
Page 4 of 13Withdrawal of Capital
17. No Member will have the right to demand or withdraw any portion of their capital contribution without the express written consent of the
remaining Members.
18. The Members will not be personally liable for the return of all or part of the Capital Contributions of a Member, except as otherwise
provided in this Agreement.
Additional Capital
19. Capital Contributions may be amended from time to time, according to the requirements of the Venture, by decision of the Members as
recommended by the Managers. Where Members’ interests are affected, additional capital contributions (the “Additional Capital
Contributions”) must have the unanimous consent of the Members.
20. Any advance of money to the Venture by any Member in excess of the amounts provided for in this Agreement or subsequently agreed to
as an Additional Capital Contribution will be deemed a debt due from the Venture rather than an increase in Capital Contribution of the
Member. This liability will be repaid with interest at such rates and times to be determined by a majority of the Members. This liability will
not entitle the lending Member to a greater voting power. Such debts may have preference or priority over any other payments to
Members as may be determined by a majority of the Members.
Capital Accounts
21. An individual capital account will be maintained for each Member and their initial Capital Contribution will be credited to this account.
Any additional, approved contributions to the Venture’s capital made by a Member will be credited to that Member’s individual Capital
Account.
Interest on Capital
22. No borrowing charge or loan interest will be due or payable to any Member on any Capital Contribution or on their Capital Account
despite any disproportion that may from time to time arise among the Capital Accounts of the Members.
Page 5 of 13Books of Account
23. Accurate and complete books of account of the transactions of the Venture will be kept in accordance with generally accepted accounting
principles (GAAP) and at all reasonable times will be available and open to inspection and examination by any Member. The books and
records of the Venture will reflect all the Venture’s transactions and will be appropriate and adequate for the business conducted by the
Venture.
Banking and Venture Funds
24. The funds of the Venture will be placed in such investments and banking accounts as will be designated by the Members. Venture funds
will be held in the name of the Venture and will not be commingled with those of any other person or entity.
Member Meetings
25. Regular Member meetings will be held quarterly. Minutes of the meetings will be maintained on file.
26. Any Member can call a special meeting to resolve urgent issues that require a vote and that cannot wait for the next regularly scheduled
meeting. When calling a special meeting, all Members must be provided with reasonable notice. Where a special meeting has been called,
the meeting will be restricted to the specific purpose for which the meeting was called.
27. All meetings will be held at a time and in a location that is reasonable, convenient and practical considering the situation of all Members.
28. Any vote required by the Members will be determined such that each Member receives one vote carrying equal weight.
Amendments
29. This Agreement may be amended only with the unanimous consent of all Members.
Admitting a new Member
30. New Members may be admitted into the Venture only with the unanimous consent of the existing Members. The new Member agrees to be
bound by all the covenants, terms, and conditions of this Agreement, inclusive of all current and future amendments. Further, a new
Member will execute such documents as are needed or required for this admission. Any new Member will receive a business interest in the
Venture as determined by all other Members.
Page 6 of 13Dissociation of a Member
31. Where a Member is in breach of this Agreement and that Member has not remedied the breach on notice from the Venture and after a
reasonable period then the remaining Members will have the right to terminate this Agreement with regard to that individual defaulting
Member (an “Involuntary Withdrawal”) and take whatever action necessary to protect the interests of the Venture.
32. If the Venture is harmed as the result of an individual Member’s action or failure to act, then that individual Member will be liable for that
harm. If more than one Member is at fault then they will be jointly and severally liable for that harm.
33. Each Member will indemnify the remaining Members against all losses, costs and claims that may arise in the event of the Venture being
terminated as a result of breach of the Agreement by that Member.
34. If a Member is placed in bankruptcy, or withdraws voluntarily from the Venture, or if there is an Operation of Law against a Member, the
other Members will be entitled to proceed as if the Member had breached this Agreement.
35. Distribution of any amount owing to a dissociated Member will be made according to the percentage of ownership as described in the
Valuation of Interest or as otherwise may be agreed in writing.
Dissolution of the Joint Venture
36. The Venture will be dissolved and its assets liquidated in the event of any of the following:
a. the Term expires and is not extended;
b. a unanimous vote by the Members to dissolve the Venture;
c. on satisfaction of the Purpose;
d. loss or incapacity through any means of substantially all of the Venture’s assets; or
e. where only one Member remains.
Page 7 of 13Liquidation
37. On dissolution, the Venture will be liquidated promptly and within a reasonable time.
38. On the liquidation of the Venture assets, distribution of any amounts to Members will be made in proportion to their respective capital
accounts or as otherwise may be agreed in writing.
Valuation of Interest
39. In the absence of a written agreement setting a value, the value of the Venture will be determined based on the fair market value appraisal
of all Venture assets (less liabilities) in accordance with generally accepted accounting principles (GAAP) by an independent accounting
firm agreed to by all Members. An appraiser will be appointed within a reasonable period of the date of withdrawal or dissolution. The
results of the appraisal will be binding on all Members. A withdrawing Member’s interest will be based on the proportion of their
respective capital account less any outstanding liabilities a Member may have to the Venture. The intent of this section is to ensure the
survival of the Venture despite the withdrawal of any individual Member.
40. No allowance will be made for goodwill, trade name, patents or other intangible assets, except where those assets have been reflected on
the Venture books immediately prior to valuation.
Transfer of Member Interest
41. A Member may assign their proprietary assets and their rights in distribution interest in the Venture. Such assignment will only include
that Member’s economic rights and interests and will not include any other rights of that Member nor will it include an automatic
admission as a Member of the Venture or the right to exercise any management or voting interests. A Member who assigns any or all of
their Venture interest to any third party will relinquish their status as Member including all management and voting rights. Assignment of
Member status, under this clause, including any management and voting interests, will require the consent of all the remaining Members.
Page 8 of 13Management Voting
42. Any management vote required will be determined such that each Manager receives one vote carrying equal weight.
Force Majeure
43. A Member will be free of liability to the Venture where the Member is prevented from executing their obligations under this Agreement in
whole or in part due to force majeure where the Member has communicated the circumstance of that event to any and all other Members
and taken any and all appropriate action to mitigate that event. Force majeure will include, but not be limited to, earthquake, typhoon,
flood, fire, and war or any other unforeseen and uncontrollable event.
Duty of Loyalty
44. Provided a Member has the consent of the majority of the other Members, the Members to this Agreement and their respective affiliates
may have interests in businesses other than the Venture. Neither the Venture nor any other Member will have any rights to the assets,
income or profits of any such business, venture or transaction. Any and all businesses, ventures or transactions with any appearance of
conflict of interest must be fully disclosed to all other Members. Failure to disclose any potential conflicts of interest will be deemed an
Involuntary Withdrawal by the offending Member and may be treated accordingly by the remaining Members.
Confidentiality
45. All matters relating to this Agreement and the Venture will be treated by the Members as confidential and no Member will disclose or allow
to be disclosed any Venture matter or matters, directly or indirectly, to any third party without the prior written approval of all Members
except where the information properly comes into the public domain.
46. This section will survive for one year after the expiration or termination of this Agreement or dissolution of the Venture.
Language
47. The Members expressly state that the English language is to be the language of choice for this Agreement and all other notices and
agreements required by the Venture.
Page 9 of 13Insurance
48. The Venture will insure all its assets against loss where reasonable and standard practice in the industry.
Indemnification
49. Each Member will be indemnified and held harmless by the Venture from any and all harm or damages of any nature relating to the
Member’s participation in Venture affairs except where such harm or damages results from gross negligence or willful misconduct on the
part of the Member.
Liability
50. No Member will be liable to the Venture or to any other Member for any error in judgment or any act or failure to act where made in good
faith. The Member will be liable for any and all acts or failures to act resulting from gross negligence or willful misconduct.
Liability Insurance
51. The Venture may acquire insurance on behalf of any Member, employee, agent or other person engaged in the business interest of the
Venture against any liability asserted against them or incurred by them while acting in good faith on behalf of the Venture.
Covenant of Good Faith
52. Members will use their best efforts, fairly and in good faith to facilitate the success of the Venture.
Joint Venture Property
53. Where allowed by statute, title to all Venture property, including intellectual property, will remain in the name of the Venture. Where joint
ventures are not recognized by statute as separate legal entities, Venture property, including intellectual property, will be held in the name
of one or more Members. In all cases Venture property will be applied by the Members exclusively for the benefit and purposes of the
Venture and in accordance with this Agreement.
Jurisdiction
54. The Members submit to the jurisdiction of the courts of the State of Florida for the enforcement of this Agreement and for any arbitration
award or decision arising from this Agreement.
Page 10 of 13Mediation and Arbitration
55. In the event a dispute arises out of, or in connection with, this Agreement, the Members will attempt to resolve the dispute through
friendly consultation.
56. If the dispute is not resolved within a reasonable period then any or all outstanding issues may be submitted to mediation in accordance
with any statutory rules of mediation. If mediation is not successful in resolving the entire dispute or is unavailable, any outstanding
issues will be submitted to final and binding arbitration in accordance with the laws of the State of Florida. The arbitrator’s award will be
final, and judgment may be entered upon it by any court having jurisdiction within the State of Florida.
Warranties
57. All Members represent and warrant that they have all authority, licenses and permits to execute and perform this Agreement and their
obligations under this Agreement and that the representative of each Member has been fully authorized to execute this Agreement.
58. Each Member represents and warrants that this Agreement is not in violation of any and all agreements and constitutional documents of
the individual Member.
Definitions
59. For the purpose of this Agreement, the following terms are defined as follows:
a. “Capital Contributions” The capital contribution to the Venture actually made by the Members, including property, cash and any
additional capital contributions made.
b. “Majority Vote” A Majority Vote is any amount greater than one-half of the authorized votes.
c. “Operation of Law” The Operation of Law means rights or duties that are cast upon a party by the law, without any act or
agreement on the part of the individual including but not limited to an assignment for the benefit of creditors, a divorce, or a
bankruptcy.
Page 11 of 13Miscellaneous
60. This Venture is termed a contractual joint venture and will not constitute a partnership. Members will provide services to one another on
an arms’ length basis while remaining independent business entities. There will be no pooling of profits and losses. Each Member is
responsible only for its own actions and no Member is an agent for any other Member. Members will not be jointly or severally liable for
the actions of the other Members.
61. Time is of the essence in this Agreement.
62. This Agreement may be executed in counterparts. Facsimile signatures are binding and are considered to be original signatures.
63. Headings are inserted for the convenience of the Members only and are not to be considered when interpreting this Agreement. Words in
the singular mean and include the plural and vice versa. Words in the masculine gender include the feminine gender and vice versa. Words
in the neuter gender include the masculine gender and the feminine gender and vice versa.
64. If any term, covenant, condition or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, it is the Members’ intent that such provision be reduced in scope by the court only to the extent deemed necessary by that
court to render the provision reasonable and enforceable and the remainder of the provisions of this Agreement will in no way be affected,
impaired or invalidated as a result.
65. This Agreement contains the entire agreement between the Members. All negotiations and understandings have been included in this
Agreement. Statements or representations which may have been made by any Member in the negotiation stages of this Agreement may in
some way be inconsistent with this final written Agreement. All such statements are declared to be of no value in this Agreement. Only
the written terms of this Agreement will bind the Members.
66. This Agreement and the terms and conditions contained in this Agreement apply to and are binding upon the Member’s successors,
assigns, executors, administrators, beneficiaries, and representatives.
67. Any notices or delivery required here will be deemed completed when hand-delivered, delivered by agent, or seven (7) days after being
placed in the post, postage prepaid, to the Members at the addresses contained in this Agreement or as the Members may later designate
in writing.
Page 12 of 1368. All of the rights, remedies and benefits provided by this Agreement will be cumulative and will not be exclusive of any other such rights,
remedies and benefits allowed by law.
IN WITNESS WHEREOF the Members have duly affixed their signatures under hand and seal on this 20th day of March 2020.
BorrowMoney.com, inc (Member)
Per: /s/ Aldo Piscitello
(SEAL)
Aldo Piscitello President
JVLS, LLC dba Vaccines 2Go (Member)
Per: /s/ Jody Stewart
Jody Stewart (Mar 20, 2020) (SEAL)
Jody Stewart
Page 13 of 13Exhibit 10.11
AMENDMENT AND TERMINATION
OF
JOINT VENTURE AGREEMENT
This AMENDMENT AND TERMINATION OF JOINT VENTURE AGREEMENT (this “Amendment”) is made and entered
into effective as of October 30, 2019 (the “Effective Date ”) by and among (1) Veoneer AB, a Swedish corporation (“Veoneer
AB”) and Veoneer US, Inc., a Delaware corporation (“Veoneer US” and together with Veoneer AB, the “Veoneer Parties ”), and
(2) Nissin Kogyo Co., Ltd., a Japanese corporation (“Nissin”), Nissin Kogyo Holdings USA, Inc., an Ohio corporation (“Nissin
Holding”) and Zhongshan Nissin Industry Co., Ltd., a Peoples’ Republic of China company (“NBZ” and together with Nissin and
Nissin Holding, the “Nissin Parties ”), as an amendment to that certain Joint Venture Agreement dated March 7, 2016 by and among
Autoliv ASP, Inc. (“Autoliv ASP”), Autoliv AB (“Autoliv AB ”) and Autoliv Holding, Inc. (“Autoliv Holding” and together with
Autoliv ASP and Autoliv AB, the “Autoliv Parties”) and the Nissin Parties, as amended, supplemented or otherwise modified from
time to time in accordance with the terms thereof and in effect on the date hereof (the “JV Agreement ”). Capitalized terms not
defined in this Amendment shall have the meanings as assigned thereto in the JV Agreement.
RECITALS
(A)The Autoliv Parties and the Nissin Parties entered into the JV Agreement as of March 7, 2016 to engage in the JV Business
through Veoneer Nissin Brake Systems Japan, Co., Ltd. (“VNBJ”), Veoneer Nissin Brake Systems America, LLC (whose corporate
name has since been changed to Veoneer Brake Systems, LLC, “VNBA”), Veoneer Nissin Brake Systems (Zhongshan), Co., Ltd.
(“VNBZ”) and Autoliv Nissin Brake Research Asia Co., Ltd. (“ANRA”);
(B)The Autoliv Parties, the Veoneer Parties and the Nissin Parties entered into that certain Addendum to Joint Venture Agreement as
of September 3, 2018 pursuant to which (i) Autoliv ASP assigned the JV Agreement as well as all the rights and obligations
thereunder to Veoneer US and ceased to be a party thereto and (ii) each of Autoliv AB and Autoliv Holding assigned the JV
Agreement as well as all the rights and obligations thereunder to Veoneer AB and ceased to be a party thereto;
(C)Notwithstanding the preceding paragraph (B), Autoliv AB remains a party to the JV Agreement only in relation to ANRA and
only to the extent necessary to deal with the liquidation proceedings of ANRA;
(D)Nissin and the Veoneer Parties entered into that certain VNBA Separation Agreement as of June 14, 2019 pursuant to which,
among other things, Nissin Holding sold, and Veoneer Roadscape Automotive, Inc. purchased, as of June 28, 2019, all of Nissin
Holding’s membership interests in VNBA;
(E)The Veoneer Parties and the Nissin Parties entered into that certain Amendment to Joint Venture Agreement as of June 28, 2019
pursuant to which, among other things, the JV Agreement ceased to have any application or effect to VNBA as of June 28, 2019;
(F)Honda Motor Co., Ltd. (“Honda”), as of the Effective Date, Nissin and Veoneer AB entered into those certain (1) VNBJ Share
Purchase Agreement, pursuant to which Veoneer AB is selling, and Honda and Nissin are purchasing, all of Veoneer AB’s
outstanding shares in VNBJ (the “VNBJ SPA,” and the consummation of the transactions pursuant to the terms of the VNBJ SPA,
the “VNBJ Closing ”) and (2) VNBZ Share Purchase Agreement, pursuant to which Veoneer AB is selling, and Honda and Nissin
are purchasing, all of Veoneer AB’s equity interests in VNBZ (the “VNBZ SPA,” and the consummation of the transactions pursuant
to the terms of the VNBZ SPA, the “VNBZ Closing”); and(A)Upon the later of the VNBJ Closing and the VNBZ Closing, no Veoneer Party will hold any equity interest in any of the
Companies.
NOW, THEREFORE, the Veoneer Parties and the Nissin Parties hereby agree as follows:
Article 1.Amendment and Termination of JV Agreement
a.As of the VNBJ Closing, except as expressly set forth in this Amendment, the JV Agreement shall immediately cease to have any
application or effect with respect to VNBJ, all rights and obligations with respect to VNBJ under the JV Agreement shall terminate
and all references to “Company” or “Companies” in the JV Agreement (either in the body of the JV Agreement or its schedules and
other attachments) shall read and be interpreted to mean VNBZ and/or ANRA except as the context otherwise requires.
b.As of the VNBZ Closing, except as expressly set forth in this Amendment, the JV Agreement shall immediately cease to have any
application or effect with respect to VNBZ, all rights and obligations with respect to VNBZ under the JV Agreement shall terminate
and all references to “Company” or “Companies” in the JV Agreement (either in the body of the JV Agreement or its schedules and
other attachments) shall read and be interpreted to mean VNBJ and/or ANRA except as the context otherwise requires.
c.Except as expressly set forth in this Amendment and notwithstanding anything to the contrary contained in the JV Agreement
(including Section 9.3.11 (Termination and Survival)), (a) effective as of the later of the VNBJ Closing and the VNBZ Closing, the JV
Agreement shall terminate in its entirety with respect to the Veoneer Parties and (b) after the later of the VNBJ Closing and the
VNBZ Closing, the Veoneer Parties shall cease to be a party to the JV Agreement and shall have no further obligations with respect
thereto. For clarity, upon the later of the VNBJ Closing and the VNBZ Closing, the JV Agreement will remain in full force and effect
in accordance with the terms thereof solely between the Nissin Parties and Autoliv AB with respect to the liquidation proceedings of
ANRA.
d.Notwithstanding Article 1.1, Article 1.2 and Article 1.3 above, the termination of the JV Agreement with respect to VNBJ, VNBZ
or the Veoneer Parties shall not release any Veoneer Party or any Nissin Party from liability for the breach of any of its
representations, warranties, covenants or agreements set forth in the JV Agreement that arise prior to the VNBJ Closing or the
VNBZ Closing, as applicable.
Article 2.D&O Indemnity
Notwithstanding Article 1.1, Article 1.2 and Article 1.3 above, the Nissin Parties agree to cause each of VNBJ and VNBZ to comply
with Sections 4.3.2 and 4.3.3 of the JV Agreement with respect to the indemnification or reimbursement, as applicable, of all
Directors and Officers (except those individuals resigning pursuant to Section 6.2.6 of the VNBJ SPA and Section 6.2.6 of the VNBZ
SPA) with respect to any Liabilities arising prior to the VNBJ Closing or the VNBZ Closing, as applicable.
Article 3.Governing Law
This Amendment shall be governed by and construed in accordance with the laws of Japan.
Article 4.Effectiveness
This Amendment shall only become effective upon the VNBJ Closing with respect to Article 1.1 and the VNBZ Closing with respect
to Article 1.2, and shall terminate without any force or effect in the event that the VNBJ SPA and the VNBZ SPA are terminated in
accordance with the terms thereof.
(The remainder of this page has intentionally been blank. )IN WITNESS WHEREOF, each of the Veoneer Parties and the Nissin Parties has caused this Amendment to be executed through
its duly authorized representative effective as of the date first above written.
Veoneer AB
By: /s/ Mats Backman
Name: Mats Backman
Title: Director
By: /s/ Amelie Wendels
Name: Amelie Wendels
Title: Director
Veoneer US, Inc.
By: /s/ Eric R. Swanson
Name: Eric R. Swanson
Title: President & Secretary
Nissin Kogyo Co., Ltd.
By: /s/ Yasushi Kawaguchi
Name: Yasushi Kawaguchi
Title: Representative Director, President
for and on behalf of each of the Nissin Parties
Signature Page to Amendment and Termination of Joint Venture AgreementIN WITNESS WHEREOF, each of the following companies hereby acknowledges and agrees to be bound by the terms and
conditions set forth in this Amendment:
Veoneer Nissin Brake Systems Japan Co., Ltd.
By: /s/ John T. Jensen
Name: John T. Jensen
Title: President, Representative Director
Veoneer Nissin Brake Systems (Zhongshan) Co., Ltd.
By: /s/ Steven M. Rodé
Name: Steven M. Rodé
Title: Director
Signature Page to Amendment and Termination of Joint Venture AgreementExhibit A
JOINT FILING AGREEMENT
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange
Act”) the undersigned hereby agree to the joint filing of Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P., Clarus IV-D, L.P., Clarus IV GP, L.P.,
Blackstone Clarus GP L.P., Blackstone Clarus GP L.L.C., Blackstone Holdings II L.P., Blackstone Holdings I/II GP L.L.C., The Blackstone Group Inc.,
Blackstone Group Management L.L.C. and Stephen A. Schwarzman, on behalf of each of them of any filing required by such party under Section 13 of the
Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with respect to securities
of Galera Therapeutics, Inc., a Delaware corporation, and further agree to the filing, furnishing, and/or incorporation by reference of this Agreement as an
exhibit thereto. Each of them is responsible for the timely filing of such filings and any amendments thereto, and for the completeness and accuracy of the
information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning
the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Agreement shall remain
in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such
revoking party. This Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned hereby execute this Agreement this 14th  day of February 2020.
CLARUS IV-A, L.P.
By: Clarus IV GP, L.P., its general partner
By: Blackstone Clarus GP L.P., its general partner
By: Blackstone Clarus GP L.L.C., its general partner
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
CLARUS IV-B, L.P.
By: Clarus IV GP, L.P., its general partner
By: Blackstone Clarus GP L.P., its general partner
By: Blackstone Clarus GP L.L.C., its general partner
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
CLARUS IV-C, L.P.
By: Clarus IV GP, L.P., its general partner
By: Blackstone Clarus GP L.P., its general partner
By: Blackstone Clarus GP L.L.C., its general partner
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
[Galera Therapeutics, Inc. – Joint Filing Agreement]CLARUS IV-D, L.P.
By: Clarus IV GP, L.P., its general partner
By: Blackstone Clarus GP L.P., its general partner
By: Blackstone Clarus GP L.L.C., its general partner
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
CLARUS IV GP, L.P.
By: Blackstone Clarus GP L.P., its general partner
By: Blackstone Clarus GP L.L.C., its general partner
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
BLACKSTONE CLARUS GP L.P.
By: Blackstone Clarus GP L.L.C., its general partner
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
BLACKSTONE CLARUS GP L.L.C.
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
BLACKSTONE HOLDINGS II L.P.
By: Blackstone Holdings I/II GP L.L.C., its general partner
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
BLACKSTONE HOLDINGS I/II GP L.L.C.
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
THE BLACKSTONE GROUP INC.
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
[Galera Therapeutics, Inc. – Joint Filing Agreement]BLACKSTONE GROUP MANAGEMENT L.L.C.
By: /s/ John G. Finley
Name: John G. Finley
Title: Chief Legal Officer
/s/ Stephen A. Schwarzman
Stephen A. Schwarzman
[Galera Therapeutics, Inc. – Joint Filing Agreement]EXHIBIT 10.3
                             JOINT VENTURE CONTRACT
                          CHAPTER 1 GENERAL PROVISIONS
        In accordance with the Law of the People's Republic of China on Joint
Ventures Using Chinese and Foreign Investment (the "Joint Venture Law") and
other relevant Chinese laws and regulations, Fengfan Group Limited Liability
Company and Valence Technology Inc., in accordance with the principle of
equality and mutual benefit and through friendly consultations, agree to jointly
invest to establish a joint venture enterprise in Baoding City, Hebei Province
of the People's Republic of China.
                       CHAPTER 2 PARTIES TO THIS CONTRACT
Article 1      Parties to this Joint Venture Contract
1.      Baoding Fengfan Group Limited Liability Company (hereinafter referred to
        as Party A), established and existing under the laws of the People's
        Republic of China ("PRC"), registered with the No. 1306001000338
        Business License in China.
        Legal address: 8 Fuchang Road, Baoding City, Hebei Province, PRC
        Legal Representative of Party A:
               Name:  Mengli Chen
               Position:  CHAIRMAN AND GENERAL MANAGER
               Nationality:  Chinese
2.      Valence Technology, Inc., (hereinafter referred to as Party B),
        established and existing under the laws of the State of Delaware in the
        United States of America ("USA").
        Registered address: 301 Conestoga Way, Henderson, Nevada 89015, USA
        Legal Representative of Party B:
               Name:  Stephan B. Godevais
               Position:  CHAIRMAN AND CEO
               Nationality:  United States of America
3.      Each of the Parties hereby represents and warrants to the other Party
        that, as of the date hereof and as of the Effective Date:
                                     Page 1
        (1)    such Party is duly organized, validly existing and in good
               standing under the laws of the place of its establishment or
               incorporation;
        (2)    such Party has all requisite power and approval required to enter
               into this Contract and, upon the Effective Date, will have all
               requisite power and approval to perform fully each and every one
               of its obligations hereunder;
        (3)    such Party has taken all internal and corporate actions necessary
               to authorize it to enter into this Contract and its
               representative whose signature is affixed hereto is fully
               authorized to sign this Contract and to bind such Party thereby;
        (4)    upon the Effective Date, this Contract shall be legally binding
               on such Party;
        (5)    neither the signature of this Contract nor the performance of its
               obligations hereunder will conflict with, or result in a breach
               of, or constitute a default under, any provision of the Articles
               of Association (in the case of Party A) or the Certificate of
               Incorporation or By-Laws (in the case of Party B) of such Party,
               or any law, regulation, rule, authorization or approval of any
               government agency or body, or of any contract or agreement, to
               which such Party is a party or subject;
        (6)    no lawsuit, arbitration, other legal or administrative
               proceeding, or governmental investigation is pending, or to the
               best of such Party's knowledge threatened, against such Party
               that would affect in any way its ability to enter into or perform
               this Contract; and
        (7)    all documents, statements and information of or derived from anygovernmental body of China in the possession of such Party
               relating to the transactions contemplated by this Contract which
               may have a material adverse effect on such Party's ability to
               fully perform its obligations hereunder, or which if disclosed to
               the other Party, would have a material effect on the other Party'
               willingness to enter into this Contract, have been disclosed to
               the other Party, and no document previously provided by such
               Party to the other Party contains any untrue statement of
               material fact or omits to state any material fact necessary in
               order to make the statements contained therein not misleading.
                             CHAPTER 3 DEFINITIONS
Unless otherwise provided herein, the following words and terms used in this
Contract shall have the meanings set forth below:
Article 2
"Affiliate" means, in relation to Party A, any enterprise or other entity which,
directly or indirectly, controls, or is controlled by, Party A; the term
"control" meaning ownership of fifty percent (50%) or more of the registered
capital or voting stock or the power to appoint the general manager, factory
chief or other principal person in charge of an enterprise or other entity.
                                     Page 2
"Affiliate" means, in relation to Party B, any company which, through ownership
of voting stock or otherwise, directly or indirectly, is controlled by, under
common control with, or in control of, Party B; the term "control" meaning
ownership of fifty percent (50%) or more of the voting stock or the power to
appoint or elect a majority of the directors or the power to direct the
management of a company.
Article 3
"Articles of Association" means the Articles of Association of the Joint Venture
Company signed by Party A and Party B simultaneously with this Contract in
Baoding, People's Republic of China.
Article 4
"Board of Directors" means the board of directors of the Joint Venture Company.
Article 5
"Business License" means the business license of the Joint Venture Company
issued by the State Administration for Industry and Commerce or the competent
local Administration for Industry and Commerce.
Article 6
"CEO" means the general manager of the Joint Venture Company. "Deputy CEO" means
the deputy general manager of the Joint Venture Company.
Article 7
" China" or "PRC" means the People's Republic of China.
Article 8
"Company Establishment Date" means the date of issuance of the Business License.
Article 9
"Contract Term" means the term of this Contract as set forth in Chapter 18,
including any extension thereof.
Article 10
"Effective Date" means the effective date of this Contract, which shall be the
date on which this Contract and the Articles of Association have been approved
by the Examination and Approval Authority.
                                     Page 3
Article 11
"Examination and Approval Authority" means the Ministry of Foreign Trade and
Economic Co-operation or other foreign trade and economic department with
authority to approve this Contract and the Articles of Association.
Article 12
"Plant" means [definition to be added].
Article 13"Joint Venture Company" means [FengFan - Valence Battery Company, Ltd.], the
Sino-foreign equity joint venture limited liability company formed by Party A
and Party B pursuant to this Contract.
Article 14
"Joint Venture Products" means technologically advanced batteries, including but
not limited to lithium phosphate batteries, lithium cobalt oxide batteries and
lithium manganese oxide batteries.
Article 15
"Management Personnel" means the Joint Venture Company's CEO, Deputy CEO, Chief
Financial Officer and other management personnel who report directly to the CEO.
Article 16
"Renminbi" or "RMB" means the lawful currency of China.
Article 17
"Site" means [definition to be added].
Article 18
"Contract for Technology Investment" means the contract for investment of
technology in the form of technology license and services, signed by Party B and
Party A simultaneously with the signature of this Contract, and which shall be
ratified by the Board of Directors of the Joint Venture Company following its
establishment, pursuant to which Party B will license to the Joint Venture
Company the right to use the proprietary technology (including patented
technology), related documentation and operational know-how, and provide
technologically advanced management support and technical assistance for the
production of the Joint Venture Products, which contract is attached hereto as
Appendix 2.
                                     Page 4
Article 19
"Third Party" means any natural person, legal person or other organisation or
entity other than the Parties to this Contract or the Joint Venture Company
Article 20
"Three Funds" means the Joint Venture Company's reserve fund, expansion fund and
employee bonus and welfare fund as stipulated in the Joint Venture Regulations.
Article 21
"United States Dollars" or "US$" means the lawful currency of the United States
of America.
Article 22
"Working Personnel" means all employees and staff of the Joint Venture Company
other than the Management Personnel.
      CHAPTER 4 ESTABLISHMENT AND LEGAL FORM OF THE JOINT VENTURE COMPANY
Article 23
The Parties hereby agree to establish the Joint Venture Company in accordance
with the laws and regulations of the PRC.
Article 24
Name of Joint Venture Company in Chinese characters: [**[VALENCE IN
CHINESE] ********]
Joint Venture Company in English:  [FENGFAN - VALENCE BATTERY COMPANY, LTD.]
Legal address of Joint Venture Company: [Baoding City High and New Technology
Zone, Baoding City, Hebei Province, the People's Republic of China.]
Article 25
The Joint Venture Company shall be an enterprise legal person under the laws of
China. The activities of the Joint Venture Company shall be governed by the
laws, decrees, rules and regulations of China, and its lawful rights and
interests shall be protected by the laws, decrees, rules and regulations of
China.
                                     Page 5
Article 26The organization form of the Joint Venture Company is a limited liability
company. The liability of each Party to the Joint Venture Company shall be
limited to contributing the full amount of its share of the Joint Venture
Company's registered capital. Unless otherwise provided pursuant to a written
agreement signed by a Party and a creditor of the Joint Venture Company,
creditors of the Joint Venture Company and other claimants against the Joint
Venture Company shall have recourse only to the assets of the Joint Venture
Company and shall not have rights to seek compensation, damages or other
remedies from any of the Parties. Subject to the foregoing, the Parties shall
share the Joint Venture Company's profits, and bear the losses and risks arising
from their investments in the Joint Venture Company, in proportion to their
respective shares of the Joint Venture Company's registered capital.
       CHAPTER 5 THE PURPOSE, SCOPE AND SCALE OF PRODUCTION AND BUSINESS
Article 27
The purpose of the Joint Venture Company is to use advanced technology and
scientific management techniques to produce and sell the Joint Venture Products,
to improve the quality and increase the value and competitiveness of such
products, to develop and introduce new products and to obtain satisfactory
economic benefits for the Parties.
Article 28
The Joint Venture Company's scope of business shall be the design, manufacture
and sale of technologically advanced batteries, including but not limited to
lithium iron magnesium phosphate batteries, lithium cobalt oxide batteries and
lithium manganese oxide batteries.
Article 29
The goal is to produce one hundred million (100,000,000) watt-hours per year
with target annual sales of Sixty Million United States Dollars (US$60,000,000).
The Board of Directors will determine the Joint Venture Company's actual
production levels based on relevant market and operating conditions.
          CHAPTER 6 TOTAL AMOUNT OF INVESTMENT AND REGISTERED CAPITAL
Article 30
The Joint Venture Company's total amount of investment shall be Twenty-Nine
Million Nine Hundred Thousand United States Dollars (US$29,900,000).
                                     Page 6
Article 31
The Joint Venture Company's registered capital shall be Twenty-Nine Million Nine
Hundred Thousand United States Dollars (US$29,900,000), including:
Party A's contribution to the registered capital of the Joint Venture Company
shall be Fourteen Million Six Hundred Fifty-One Thousand United States Dollars
(US$14,651,000), representing a forty-nine percent (49%) share of the Joint
Venture Company's registered capital. Party B's contribution to the registered
capital of the Joint Venture Company shall be Fifteen Million Two Hundred Forty
Nine Thousand United States Dollars (US$15,249,000), representing a fifty-one
percent (51%) share of the Joint Venture Company's registered capital.
Article 32     The Method of Investment
Party A's total contribution (US$14,651,000) to the registered capital shall be
invested as cash. US$7,000,000 of this contribution is used for the Joint
Venture Company's initial purchase of foreign equipment from Party B and the
remainder is used for purchase of foreign and domestic
equipment, and land use rights and construction of workshops in China. (If the
contribution is in RMB, it shall be converted using the median rate for buying
and selling for foreign currency announced by the People's Bank of China on the
date of investment).
Party B's total contribution (US$15,249,000) to the registered capital shall be
invested as follows:
        (1)    use of technology in accordance with the Contract for Technology
               Investment, which is attached hereto as Appendix 2, which the
               parties agree to be valued at US$5,900,000; and
        (2)    production equipment, in accordance with the Contract for
               Equipment Investment and Purchase ( Appendix 3 hereto), which
               equipment the parties agree to be valued at US$9,349,000.
(If any part of the contribution is in RMB, the investment shall be converted
using the median rate for buying and selling for foreign currency announced by
the People's Bank of China on the date of investment).
Article 33
The Joint Venture Company's registered capital shall be contributed according to
both Parties' proportion of investment. The detailed method, quantity and timingof the contributions are shown in Appendix 1.
                                     Page 7
Article 34
No Party shall be obligated to make any contribution to the Joint Venture
Company's registered capital if any of the following conditions have not been
satisfied or waived in writing by both parties:
        (1)    this Contract and the Articles of Association have been signed by
               both Parties, and approved by the Examination and Approval
               Authority without altering their terms and conditions, unless
               each Party has been notified in advance of and consented in
               writing to such alterations ;
        (2)    the Business License has been issued without altering the Joint
               Venture Company's business scope as set forth in Article28,
               unless each Party has been notified in advance of and consented
               in writing to such alteration;
        (3)    signature by the parties thereto of all the Contract for
               Technology Investment, the forms of which are annexed to this
               Contract and, where required by law, approval or registration of
               such contracts by the relevant government approval authority
               without altering their terms and conditions, unless each Party
               has been notified in advance of and consented in writing to such
               alterations; and
        (4)    [the Parties have taken those steps necessary for the
               identification and securing of an operating site suitable for the
               JV Company's purposes].
Article 35
Each time a Party makes a contribution to the Joint Venture Company's registered
capital, a Chinese registered accountant appointed by the Board of Directors
shall promptly verify the contribution and issue a capital verification report
to the Joint Venture Company. Within sixty (60) days from receipt of the capital
verification report, the Joint Venture Company shall issue an investment
certificate to such Party in the form prescribed by the Joint Venture
Regulations, signed by the Chairman and the Vice-Chairman of the Board and
chopped with the Joint Venture Company's chop. Each investment certificate shall
indicate the amount of the capital contribution and the date on which such
contribution was made, and a copy shall be submitted to the Examination and
Approval Authority for the record. The CEO shall maintain a file of all capital
verification reports and copies of all investment certificates that have been
issued to the Parties.
Article 36
Any increase in the registered capital of the Joint Venture Company shall
require the written consent of each Party and the unanimous approval of the
Board of Directors. All increases in registered capital must be approved by the
Examination and Approval Authority in accordance with relevant law.
                                     Page 8
Article 37
Unless it obtains written consent of the other Party and approval of the
Examination and Approval Authority, no party to this Contract can transfer all
or part of its interest in the registered capital of the Joint Venture Company
to a Third Party. Each Party agrees promptly to take all actions and to sign all
documents, and to cause its appointees on the Board of Directors promptly to
take all actions and sign all documents, that are legally required to effect a
transfer of registered capital for which the foregoing consent has been
obtained. Upon receipt of approval from the Examination and Approval Authority,
the Joint Venture Company shall register the change in ownership with the
competent Administration for Industry and Commerce.
Article 38
If there is a difference between the total amount of investment and the
registered capital or if the Joint Venture Company needs working capital, the
Joint Venture Company and, if entrusted by the Joint Venture Company, either
party to this Contract may negotiate to obtain loans from banks or other
authorized lenders. Such loans may be secured by the guarantee, mortgage and
pledge of the Joint Venture Company. Any loans provided by the parties to the
Joint Venture Company or any guarantees or securities provided by the parties to
secure loans to the Joint Venture Company shall only be provided by both parties
and shall be provided in proportion to each party's interest in the Joint
Venture Company.
Article 39No Party shall mortgage, pledge or otherwise encumber all or any part of its
share of the Joint Venture Company's registered capital without the prior
written consent of the other Party.
                    CHAPTER 7 RESPONSIBILITIES OF EACH PARTY
Article 40
Responsibilities of Party A
In addition to its other obligations under this Contract, Party A shall have the
following responsibilities:
o       Handle all applications to the relevant Examination and Approval
        Authority in China, register and obtain the Business License necessary
        for the establishment of the Joint Venture Company. Party A shall
        provide Party B with copies of all such approvals and licenses and all
        notices, letters and other correspondence submitted to or received from
        the Examination and Approval Authority, the competent Administration for
        Industry and Commerce and other Chinese government departments in
        respect of the Company.
                                     Page 9
o       Assist the Joint Venture Company, upon request, in processing the
        application for the right to the use of a site to the authority in
        charge of the land.
o       Assist the Joint Venture Company, upon request, in organizing the design
        and construction of the premises and other facilities of the Joint
        Venture Company.
o       Assist the Joint Venture Company, upon request, in processing import
        customs declarations for the machinery and equipment which is provided
        as investment or purchased in accordance with this Contract, and
        arranging the transportation of the same within the Chinese territory.
o       Assist the Joint Venture Company, upon request, in contacting providers
        and arranging fundamental facilities such as water, electricity,
        transportation etc.
o       Assist the Joint Venture Company, upon request, in applying for all
        licenses and permits required for the operation of the Joint Venture
        Company's business.
o       Assist the Joint Venture Company, upon request, in applying for all
        possible preferential tax treatment and other preferential treatment.
o       Assist the Joint Venture Company, upon request, in recruiting Chinese
        management personnel, technical personnel, workers and other required
        personnel.
o       Assist the Joint Venture Company, upon request, in obtaining all
        necessary entry visas, work permits, residence permits and other
        necessary help for personnel working at the Joint Venture Company.
o       Assist the Joint Venture Company, upon request, in obtaining and
        maintaining a Foreign Exchange Registration Certificate;
o       Implementing its obligations, if any, stated in the Schedule of Capital
        Contributions, the Contract for Investment of Technology, the Contract
        for Equipment Investment and Purchase, and the Contract for Export
        Sales, which documents are attached hereto as Appendices 1 to 4
o       Be responsible for handling other matters entrusted by the Joint Venture
        Company.
Article 41
Responsibilities of Party B
In addition to its other obligations under this Contract, Party B shall have the
following responsibilities:
o       Upon request by the Joint Venture Company, handle the purchase of
        equipment, machinery, tools and other materials entrusted by the Joint
        Venture Company.
                                    Page 10
o       Providing necessary technical personnel to the Joint Venture Company for
        installing and testing equipment, and being responsible for assisting
        with the operation of the equipment.
o       Training the management personnel, technical personnel and operation
        workers of the Joint Venture Company in accordance with the provisionsof the Contract for Technology Investment.
o       Implementing its obligations stated in the Schedule of Capital
        Contributions, the Contract for Investment of Technology, the Contract
        for Equipment Investment and Purchase, and the Contract for Export
        Sales, which documents are attached hereto as Appendices 1 to 4.
o       Be responsible for handling other matters entrusted by the Joint Venture
        Company.
                              CHAPTER 8 TECHNOLOGY
Article 42
Party A and Party B shall sign the Contract for Technology Investment
simultaneously with the signature of this Contract, and pursuant to the Contract
for Technology Investment shall license to the Joint Venture Company the right
to utilize proprietary technology (including patented technology), related
documentation and know-how for the production of the Joint Venture Products. The
Contract for Technology Investment is attached hereto as Appendix 2.
The technology license fee of Five Million Nine Hundred Thousand United States
Dollars (US$5,900,000) shall be deemed to be paid by the Joint Venture Company
and shall constitute part of Party B's contribution to the registered capital of
the Joint Venture Company in accordance with Article 32 of this Contract. The
Contract for Technology Investment shall be signed by the Parties simultaneously
with the signing of this Joint Venture Contract and shall come into effect upon
its approval by the Examination and Approval Authority. The Board of Directors
shall ratify the Contract for Technology Investment at the first meeting of the
Board of Directors.
Party B and the Joint Venture Company shall comply with the provisions of the
Contract for Technology Investment, and Party B further warrants that the
technology provided in accordance with the Contract for Technology Investment is
complete, correct, effective and can fulfil the technological goals set forth in
the Contract for Technology Investment.
Article 43
Party B will provide to the Joint Venture Company new inventions, creations and
technology related to the Lithium Iron Magnesium Phosphate powder manufacture
and battery manufacture and Bellcore battery configuration at no additional
charge. The Joint Venture Company may manufacture products using such new
inventions, creations and technology on the same terms as other batteries are
manufactured, under the Contract for Technology Investment. Improvements for all
other batteries may be licensed to the Joint Venture Company on terms to be
agreed by the Party B and the Joint Venture Company.
Article 44
                                    Page 11
Party A and Party B shall sign the Contract for Technology Investment
simultaneously with the signature of this Contract, and pursuant to the
Technical Service Contract shall provide technical services to the Joint Venture
Company, which shall reimburse to Party B the direct expenses incurred in China
for those Party B personnel rendering such services. The form of the Contract
for Technology Investment is attached hereto as Appendix 2.
Article 45
The parties to this Contract agree that the technology, documentation and
know-how provided under the Contract for Technology Investment and the technical
services provided under the Contract for Technology Investment are provided for
the use of the Joint Venture Company. Party A hereby undertakes to Party B and
the Joint Venture Company that:
        (1)    Party A and its Affiliates shall not at any time during or after
               the Contract Term use such technology and know-how except for the
               purpose of marketing and selling batteries produced by the Joint
               Venture Company;
        (2)    In respect of such technology and know-how, Party A and its
               Affiliates shall comply with the confidentiality obligations set
               forth in Chapter 17 of this Contact; and
        (3)    Breach of this Article by Party A shall be deemed to be a
               material breach of this Contract.
Article 46
Party B and its Affiliates guarantee that following the Effective Date of this
Contract, it will not further transfer to any Third Party: i) the proprietary
technology for production of Powder (as defined below) to be made into Batteries
(as defined below) or ii) the proprietary technology for production of Batteries
that use the Bellcore configuration. Party B also guarantees that any new
inventions and improvements in the proprietary technology for production of
Batteries shall be provided to the Joint Venture Company at no fee, excepting
reimbursement of any direct travel or communication costs required for theprovision of such technology, consistent with the terms of the Contract for
Technology Investment.
In this Article, "Powder" shall mean the Cathode Active Materials (defined
below) required for the fabrication of the Batteries. In this paragraph,
"Batteries" shall mean and include any aggregate of components or compositions
of matter primarily adapted for storing or providing electrical energy and which
include a positive and negative electrode, at least one of which shall include
materials made from Cathode Active Materials, and the other shall include a
carbonaceous anode material. "Cathode Active Material(s)" shall mean Lithium
Cobalt Oxide, Lithium Manganese Dioxide, Lithium Nickel Oxide, Lithium Nickel
Cobalt Oxide, Lithium Manganese Oxide Spinel and Lithium Iron Magnesium
Phosphate, and Lithium Phosphate material.
                                    Page 12
Article 47
Until such time that the Joint Venture Company is capable of providing
cost-effective, high quality Powder that satisfies all technical specifications
identified by Party B, the Parties agree that either Party B or the Joint
Venture Company shall have the right to purchase Powder from a Third Party. In
no circumstances shall the Joint Venture Company offer the Powder for sale to
Third Parties.
Both Party A and Party B agree that they will not compete with the Joint Venture
Company or with each other utilizing knowledge or expertise or production
capabilities gained from the Joint Venture Company or gained from the Parties'
respective technology contributions thereof.
                CHAPTER 9 SALE OF PRODUCTS AND USE OF TRADEMARK
Article 48
The Joint Venture Company may sell the Joint Venture Products in the domestic
and overseas markets, and may entrust Third Party's to sell the Joint Venture
Products with approval from the Board of Directors.
Article 49
It is the intention of the parties that no less than 50% of the Joint Venture
Products should be sold overseas.
Article 50
Each Party retains all ownership to its trademarks, service marks, logos, trade
names, and similar designations identified in Exhibit B of the Contract for
Technology Investment and any other such marks which such Party may from time to
time designate in writing, and the other Party and the Joint Venture Company
will neither register or use, directly or indirectly, any mark that is identical
or confusingly similar to Valence's marks or any translations or
transliterations thereof, anywhere in the world. Notwithstanding the foregoing,
the Joint Venture Company may register its own trademarks, service marks, logos
and trade names, and it may use the marks owned by a Party without compensation,
provided that the use is in accordance with terms of a written trademark license
contract signed with that Party.
                       CHAPTER 10 THE BOARD OF DIRECTORS
Article 51
The date of registration of the Joint Venture Company shall be the date of the
establishment of the board of directors of the Joint Venture Contract.
                                    Page 13
Article 52
The Board of Directors shall comprise seven (7) directors, three (3) of whom
shall be appointed by Party A and four (4) of whom shall be appointed by Party
B. The chairman of the board shall be appointed by Party A, and its
vice-chairman by Party B.
Article 53
Directors shall be appointed for a term of four (4) years, provided that the
Party who has appointed a director may remove that director and appoint a
replacement at any time. A director may serve consecutive terms if reappointed
by the Party that originally appointed him/her. If a seat on the Board of
Directors is vacated by the retirement, resignation, disability or death of a
director or by the removal of such director by the Party who originally
appointed him/her, the Party who originally appointed such director shall
appoint a successor to serve out such director's term. At the time this Contract
is signed and each time a director is appointed or replaced, each Party shall
notify the other Party in writing of the names of its appointees or
replacements.Article 54
The Board of Directors shall be the highest authority of the Joint Venture
Company. It shall decide all matters of major importance to the Joint Venture
Company. The following matters shall require the unanimous assent of all the
directors:
o       Amendment of the Articles of Association;
o       Termination and dissolution of the Joint Venture Company;
o       Merger of the Joint Venture Company with another organization;
o       Major investment by the Joint Venture Company;
o       Distribution of profit of the Joint Venture Company;
o       The recruitment and dismissal of the Senior Management Personnel of the
        Joint Venture Company;
o       Transfer of a part of all of either Party's interest in the registered
        capital of the Joint Venture Company;
o       Increase and decrease of the Joint Venture Company's registered
        capital; and
o       The examination and approval of the annual financial report of the Joint
        Venture Company.
Article 55
Except for the matters stipulated in the above article, all other matters shall
be decided by the assent of a majority of the directors present in person or by
proxy at a duly convened meeting of the board of
                                    Page 14
directors, provided however that at least one member of the Board of Directors
nominated by each Party assents to such decision of the Board
If a vote on any resolution (other than resolutions requiring unanimous assent)
results in a failure to obtain an affirmative vote, then the directors promptly
shall endeavour to resolve the matter through further consultations. Any
director shall have the right to call a meeting for a second vote on the matter
after seven (7)days has elapsed from the first vote. If the second vote also
results in a failure to obtain an affirmative vote, then the Chairman and
Vice-Chairman of the Board shall jointly refer the matter to the highest
executive officer of each Party within seven (7) days from the second vote, and
they shall endeavour to agree on a resolution of the matter, which resolution
shall be binding upon the Board of Directors and the Joint Venture Company. If
the highest executive officers of each Party are unable to resolve the matter
within thirty (30) days from the date of receipt of the referral from the
Chairman and Vice-Chairman of the Board, the resolution shall be deemed not to
have been passed by the Board of Directors.
If the non-passage under this Article 55 of a resolution concerning management
or financial matters results in a material adverse effect on the economic
benefits derived by one or both Parties from their respective investments in the
Joint Venture Company, then a Party whose benefits are adversely and materially
affected may terminate this Contract.
Article 56
Party A shall designate a director to serve as Chairman of the Board and Party B
shall designate another director to serve as Vice-Chairman of the Board. The
Chairman of the Board shall be the legal representative of the Joint Venture
Company, but shall have only the authority delegated to him/her by the Board of
Directors, and no individual member of the Board of Directors shall
contractually or otherwise bind the Joint Venture Company without the prior
written authorization of the Board of Directors. The Party appointing the
Chairman of the Board shall be responsible for all losses and liabilities that
the Joint Venture Company may incur as a result of the Chairman of the Board
exceeding the scope of authority stipulated in this Contract. Whenever the
Chairman of the Board is unable to perform his responsibilities for any reason,
he shall authorise the Vice-Chairman of the Board to represent him. If the
Vice-Chairman is not available, the Chairman of the Board shall authorise
another director to represent him/her.
Article 57
The Joint Venture Company shall indemnify each director against all claims and
liabilities incurred by reason of his being a director of the Joint Venture
Company, provided that the director's acts or omissions giving rise to such
claim or liability did not constitute intentional misconduct or gross negligence
or a violation of criminal laws.
Article 58
The first meeting of the Board of Directors shall be held within one (1) month
from the Company Establishment Date. Thereafter, the Board of Directors shall
hold at least one (1) regular meeting in each calendar year. Upon the writtenrequest of two (2) or more of the directors of the Joint Venture
                                    Page 15
Company specifying the matters to be discussed, the Chairman of the Board shall
within thirty (30) days of receipt thereof convene an interim meeting of the
Board of Directors. Meetings shall be held at the registered address of the
Joint Venture Company or such other address in China or abroad as may be agreed
by the Chairman of the Board and the Vice-Chairman of the Board. The Chairman of
the Board shall set the agenda for Board meetings after consultation with the
Vice-Chairman of the Board and the Chairman shall be responsible for convening
and presiding over such meetings. Board meetings may be attended by directors in
person or by telephone, video conference or by proxy.
Article 59
Five (5) directors present in person or by proxy shall constitute a quorum for
all meetings of the Board of Directors. If at any properly convened meeting, no
quorum is constituted because less than five (5) directors are present in person
or by proxy, then the Chairman of the Board may call another meeting with seven
(7) days notice to each director. All directors receiving notice of such second
meeting shall be deemed to be present at such meeting.
Article 60
If a director is unable to attend a Board of Directors meeting, he may issue a
proxy and entrust a representative to attend the meeting on his behalf. The
representative so entrusted shall have the same rights and powers as the
director who entrusted him. One person may represent more than one director by
proxy.
Article 61
The Board of Directors will cause complete and accurate minutes (in both English
and Chinese) to be kept of all Board meetings. The Chinese and English text of
all resolutions to be adopted by the Board of Directors at Board meetings shall
be agreed by the directors at the Board meeting and recorded by the secretary
appointed for the meeting, and those members approving the resolutions shall
sign such records. Draft minutes of all meetings of the Board of Directors shall
be distributed to all the directors as soon as practicable after each meeting
but not later than thirty (30) days from the date of such meeting. The final
minutes shall be completed by the Chairman and the Vice-Chairman and distributed
to each director and each Party not later than sixty (60) days after the
relevant meeting. The Joint Venture Company shall maintain a file of all Board
meeting minutes and make the same freely available to the Parties and their
authorized representatives.
Article 62
The Board of Directors may adopt any resolution without a meeting if all of the
directors then holding office consent in writing to such action. Such written
consent may be signed by the directors in different counterparts, shall be filed
with the minutes of the Board of Directors proceedings and shall have the same
force and effect as a unanimous vote of the directors present at a duly
constituted meeting of the Board.
                                    Page 16
Article 63
Directors shall serve without any remuneration, but all reasonable costs
incurred by the directors in attending Board meetings (including but not limited
to travel expenses) shall be borne by the Joint Venture Company.
                  CHAPTER 11 BUSINESS MANAGEMENT ORGANISATION
Article 64
The Joint Venture Company shall establish a business management organization to
be in change of the day-today operation and management of the Joint Venture
Company.
Article 65
The Joint Venture Company's business management organization shall be under the
leadership of a CEO, who shall report directly to the Board of Directors. In
addition to the CEO, the Joint Venture Company shall have a Deputy CEO, Chief
Financial Officer, Director of Sales, Director of Human Resources, Director of
Manufacturing, and Director of Research and Development (together with the CEO,
the "Senior Management Personnel"). The CEO shall be in charge of the day-to-day
operation and management of the Joint Venture Company. The Deputy CEO shall
assist the CEO in his work and shall report to the CEO. Other department
directors shall report directly to the CEO.
Article 66The CEO shall be nominated by Party B, and the Deputy CEO shall be nominated by
Party A The Chief Financial Officer shall be nominated by Party A, and an
Assistant Financial Officer may be nominated by Party B. The Chief Financial
Officer must consult with the Assistant Financial Officer, if any, on all
important financial matters. Each officer nominated by a party or parties in
accordance with this paragraph shall be appointed by the Board of Directors. The
other Management Personnel shall be nominated by the CEO and appointed by the
Board of Directors. The Board may dismiss any Management Personnel. All
replacements for any of the Management Personnel, whether by reason of the
retirement, resignation, disability or death of a manager or of the removal of a
manager by the Board of Directors or by the Party which nominated him, shall be
nominated and appointed in the same manner as the original appointee. Other
details of management shall be decided by the CEO.
Article  67
The CEO shall be in charge of the day-to-day operation and management of the
Joint Venture Company and shall carry out all matters entrusted by the Board of
Directors. The Deputy CEO shall assist the CEO in his work and shall report to
the CEO.
                                    Page 17
Article 68
The CEO, Deputy CEO and all other Management Personnel shall perform their
duties on a full-time basis and shall not concurrently serve as a manager, an
employee or a consultant of any other company or enterprise, nor shall they
serve as a director of, or hold any interest in, any company or enterprise that
competes with the Joint Venture Company.
Article 69
The Joint Venture Company's basic departmental structure and other management
positions reporting directly to the CEO shall be approved by the Board of
Directors based on proposals formulated by the CEO. The details of the Joint
Venture Company's organizational structure and all other employment positions
shall be determined by the CEO.
Article 70
Both Chinese and English shall be used concurrently as the management languages
of the Joint Venture Company.
Article 71
In case of graft or serious dereliction of duty on the part of the CEO, Deputy
CEO and other management personnel of the Joint Venture Company, the Board of
Directors shall have the power to dismiss such individuals at any time pursuant
to the provisions of relevant PRC law.
                   CHAPTER 12 SITE FOR JOINT VENTURE COMPANY
Article 72
Party A confirms that it will procure for use of the Joint Venture Company a
site to be further identified and agreed by the Parties. The site shall be in
the Baoding High Technology Development Zone, shall have granted land use
rights, and shall have utilities that may be directly connected by the Joint
Venture Company at the site.
The Parties shall further agree on the size and standards of the building to be
constructed to meet the Joint Venture Company's operating needs.
                 CHAPTER 13 PURCHASE OF EQUIPMENT AND MATERIALS
Article 73
                                    Page 18
The Joint Venture Company has the right to purchase equipment, machinery, raw
materials, etc. required for the Joint Venture Company's production and
operations. In its purchase of required equipment, instruments, raw materials,
fuel, parts, and means of transportation etc., the Joint Venture Company shall
give first priority to purchase of same in China where relevant purchase terms
conditions are the same or more favorable.
Article 74
The Joint Venture Company may entrust Party A or Party B to purchase the items
listed in the above article. Any party so entrusted shall use its best endeavors
to accomplish the purpose of the entrustment. The price shall be fair and
reasonable. The party so entrusted shall follow the internationally accepted
procedures to purchase materials when their quantity is large. The other party
and the Joint Venture Company shall supervise the action of purchasing.Article 75
A list of equipment that the Joint Venture Company intends to import as Party
B's capital contribution and as purchase from Party B for the commencement of
the Joint Venture Company's production and operations is set forth as Appendix 3
to this Contract.
                          CHAPTER 14 LABOR MANAGEMENT
Article 76
Matters relating to the recruitment, wages, insurance, welfare, dismissal of the
staff and workers of the Joint Venture Company shall be handled in accordance
with the LABOR LAW OF THE PEOPLE'S REPUBLIC OF CHINA and the REGULATIONS OF THE
PEOPLE'S REPUBLIC OF CHINA ON LABOR MANAGEMENT IN FOREIGN INVESTMENT ENTERPRISES
and related PRC regulations. The Joint Venture Company's internal labor policies
shall be established pursuant to relevant PRC laws and regulations, and approved
by the Board of Directors.
Article 77
The Joint Venture Company shall adopt a labor contract system. The wages,
welfare, labor insurance and other rights and obligations of working personnel
and Management Personnel shall be regulated through individual or group labor
contracts.
Article 78
Expatriate management personnel and Chinese management personnel in the same
position shall receive equivalent salary and benefits.
Article 79
Employees will be selected according to their professional qualifications,
language abilities, individual characteristics and working experience. The
specific number and qualifications of the Working Personnel shall be determined
by the CEO in accordance with the operating needs of the
                                    Page 19
Joint Venture Company. All employees hired by the Joint Venture Company must
complete satisfactorily a six-month probationary period of employment before
they will be considered regular employees of the Joint Venture Company.
Article 80
Except as provided in Article 78, expatriate personnel and Chinese personnel in
the same position shall be treated equally and without discrimination.
Article 81
Working Personnel shall have the right to establish a labor union in accordance
with the LABOR UNION LAW OF THE PEOPLE'S REPUBLIC OF CHINA and develop
activities pursuant to related regulations. In accordance with relevant PRC
regulations, the Joint Venture Company shall allot each month two percent (2%)
of the total amount of the real wages received by the Joint Venture Company
staff and workers for payment into a labor union fund, such payment to be an
expense of the Joint Venture Company. The labor union may use these funds in
accordance with the relevant control measures for labor union funds formulated
by the All China Federation of Labor Unions.
                  CHAPTER 15 FINANCIAL AFFAIRS AND ACCOUNTING
Article 82
The Chief Financial Officer and Assistant Financial Officer of the Joint Venture
Company, under the leadership of the CEO, shall be responsible for the financial
management of the Joint Venture Company. The CEO, the Chief Financial Officer
and Assistant Financial Officer shall prepare the Joint Venture Company's
accounting system and procedures in accordance with the relevant PRC laws and
regulations, and submit the same to the Board of Directors for adoption.
Article 83
The Joint Venture Company shall adopt Renminbi as its bookkeeping base currency,
but may also adopt United States Dollars or other foreign currencies as
supplementary bookkeeping currencies. The debit and credit method, as well as
the accrual basis of accounting, shall be adopted as the methods and principles
for keeping accounts.
Article 84
The Joint Venture Company shall adopt the calendar year as its fiscal year. The
Joint Venture Company's first fiscal year shall commence on the date that the
Joint Venture Company receives a business license and shall end on the
immediately succeeding December 31.
Article 85
All accounting records, vouchers, books and statements of the Joint Venture
Company must be made and kept in Chinese. All financial statements and reportsof the Joint Venture Company shall also be made and kept in English.
                                    Page 20
Article 86
For the purpose of preparing the Joint Venture Company's accounts and
statements, calculation of profits to be distributed to the Parties, and for any
other purposes where it may be necessary to effect a currency conversion, such
conversion shall be made using the median rate for buying and selling for such
currency announced by the People's Bank of China on the date of actual receipt
or payment by the Joint Venture Company.
Article 87
The Parties shall have full and equal access to the Joint Venture Company's
accounts, which shall be kept at the legal address of the Joint Venture Company.
In addition, each Party at its own expense and upon advance notice to the Joint
Venture Company may appoint an accountant (which may be either an accountant
registered abroad or registered in China), to audit the accounts of the Joint
Venture Company on behalf of such Party. Reasonable access to the Joint Venture
Company's financial records shall be given to such auditor and such auditor
shall keep confidential all documents under his auditing.
Article 88
The Joint Venture Company shall furnish to the Parties unaudited financial
reports on a monthly and quarterly basis so that they may continuously be
informed about the Joint Venture Company's financial performance.
Article 89
An accountant registered in China and independent of any Party shall be engaged
by and at the expense of the Joint Venture Company as its auditor to examine and
verify the Joint Venture Company's annual financial statements and report. The
Joint Venture Company shall submit to the Parties an annual statement of final
accounts (including the audited profit and loss statement and the balance sheet
for the fiscal year) after the end of the fiscal year, together with the audit
report of the Chinese registered accountant.
Article 90
The Joint Venture Company shall separately open foreign exchange accounts and
Renminbi accounts at banks within China approved by the State Administration of
Exchange Control. Following approval by the State Administration of Exchange
Control, the Joint Venture Company may also open foreign exchange bank accounts
outside China. The Joint Venture Company shall apply for and maintain a Foreign
Exchange Registration Certificate in accordance with applicable legal
requirements. The Joint Venture Company shall abide by the regulations of the
PRC concerning foreign exchange control and handle foreign exchange transaction
pursuant to such regulations.
Article 91
After the payment of income taxes by the Joint Venture Company, the Board of
Directors will determine the annual allocations to each of the Three Funds from
the after-tax net profits. The sum
                                    Page 21
of the allocations to the Three Funds for any fiscal year shall be determined by
the Board and shall not exceed ten percent (10%) of the after-tax profit for
that year so as to ensure the Joint Venture Company's smooth operation.
Article 92
The distribution of the Joint Venture Company's after-tax profits to the Parties
shall be carried out according to related laws and the Joint Venture Company's
actual conditions. The Board of Directors shall once every year by a formally
adopted resolution decide the amount of after-tax profit of the Joint Venture
Company (after allocations to the Three Funds) to be retained in the Joint
Venture Company for expanding its production and operations and the amount to be
distributed to the Parties in proportion to their respective shares of the Joint
Venture Company's registered capital. All remittances of profits and other
payments out of China to Party B shall be made to a foreign bank account
designated by Party B in United States Dollars or other freely convertible
foreign currencies in accordance with the foreign exchange regulations of China.
                       CHAPTER 16 TAXATION AND INSURANCE
Article 93
The Joint Venture Company shall pay all taxes and duties required under the
national and local laws and regulations of China. The Joint Venture Company's
Chinese and expatriate personnel shall pay individual income tax in accordance
with the INDIVIDUAL INCOME TAX LAW OF THE PEOPLE'S REPUBLIC OF CHINA.Article 94
The Joint Venture Company, at its own expense, shall take out and maintain at
all times during the Contract Term with insurance companies insurance against
loss or damage by fire, natural disasters and other risks of types and in
amounts as may be recommended by the CEO and decided by the Board of Directors.
The property, transport and other items of insurance of the Joint Venture
Company will be denominated in Chinese and foreign currencies, as appropriate.
Article 95
The Joint Venture Company shall take out the required insurance from an
insurance company or organization permitted by Chinese laws and regulations to
provide such insurance.
                           CHAPTER 17 CONFIDENTIALITY
Article 96
Prior to and during the Contract Term, each Party has disclosed or may disclose
to the other Party, including without limitation through technology transfer or
license agreements, confidential and proprietary information and materials
concerning their respective businesses, financial condition, proprietary
technology, research and development, and other confidential matters.
Furthermore,
                                    Page 22
during the Contract Term, the Parties may obtain such confidential and
proprietary information concerning the Joint Venture Company and the Joint
Venture Company may obtain such confidential and proprietary information of the
Parties. Each of the Parties and the Joint Venture Company receiving all such
information as aforesaid (hereinafter referred to "Confidential Information")
shall, during the Contract Term, or during the term of the Joint Venture Company
and for two (2) years after the early termination or dissolution of the Joint
Venture Company prior to the expiration of the Contract Term:
        (1)    maintain the confidentiality of such Confidential Information;
               and
        (2)    not disclose it to any person or entity, except to their
               respective employees who need to know such Confidential
               Information to perform their work responsibilities.
The above provisions shall not apply to Confidential Information that:
        (1)    can be proved to have been known by the receiving party by
               written records made prior to disclosure by the disclosing party;
        (2)    is or becomes public knowledge otherwise than through the
               receiving party's breach of this Contract;
        (3)    was obtained by the receiving party from a Third Party having no
               obligation of confidentiality with respect to such Confidential
               Information; or
        (4)    is required by order of any competent court or governmental
               authority to be disclosed.
Each Party shall advise its directors, senior staff, and other employees
receiving such Confidential Information of the existence of and the importance
of complying with the obligations set forth in this Article.
Article 97
If required by any Party, the Joint Venture Company shall execute a separate
secrecy agreement with provisions similar to those set out above with respect to
Confidential Information obtained by the Joint Venture Company from such Party
or its Affiliates.
Article 98
Each of the Parties and the Joint Venture Company shall formulate rules and
regulations to cause its directors, senior staff and other employees, and those
of their Affiliates, also to comply with the confidentiality obligations set
forth in this Chapter 17. All directors, managers and other employees of the
Joint Venture Company shall be required to sign a confidentiality undertaking in
a form acceptable to all Parties.
                                    Page 23
Article 99
If any Party or the Joint Venture Company breaches the provisions of this
Chapter 17, it shall be liable for damages accrued to the other Party or theJoint Venture Company as a result of such breach. The payment of damages shall
be without prejudice to any other rights or remedies accrued at the date of such
breach.
Article 100
This Chapter 17 and the obligations and benefits hereunder shall survive the
expiration or early termination of this Contract and shall remain in effect for
the periods stated herein, notwithstanding the dissolution or liquidation of the
Joint Venture Company.
               CHAPTER 18 ENVIRONMENTAL PROTECTION AND COMPLIANCE
Article 101
Party B warrants that to the best of its knowledge those products that are
properly manufactured pursuant to the terms of the Contract for Technology
Investment and other written instructions from Party B shall comply with those
relevant PRC environmental laws and regulations existing and in effect as of the
date of the Parties' signature of this Contract.
Article 102
Following the establishment of the Joint Venture Company, if PRC environmental
laws and regulations are amended such that the rights or interests of the Joint
Venture Company or either Party's interest therein are affected, then the
Parties shall discuss in good faith regarding a suitable approach to address
such regulatory change, consistent with Article 119 hereto.
                            CHAPTER 19 CONTRACT TERM
Article 103
The Contract Term shall extend for a period of fifty (50) years. The date that
the Business License is issued is the Establishment Date of the Joint Venture
Company. Upon the agreement of all Parties and the unanimous consent of the
Board of Directors, an application to extend the Contract Term may be made to
the Examination and Approval Authority no less than six (6) months prior to the
expiration of the Contract Term.
                                    Page 24
                     CHAPTER 20 TERMINATION AND LIQUIDATION
Article 104
Each Party shall have the right to terminate this Contract prior to the
expiration of the Contract Term by written notice to the other Party if any of
the following events occur:
        (1)    in the event that either party fails to make its capital
               contribution, in whole or in part, within [90] days of the due
               date, or in the event that any of the conditions precedent set
               forth in Article 34 of this Contract have not been satisfied or
               waived within [120] days of the date on which this Contract is
               signed by the parties;
        (2)    the other Party materially breaches this Contract or materially
               violates the Articles of Association, and such breach or
               violation is not cured within sixty (60) days of written notice
               to the breaching/violating Party;
        (3)    the Joint Venture Company or the other Party becomes bankrupt, or
               is the subject of proceedings for liquidation or dissolution, or
               ceases to carry on business, or becomes unable to pay its debts
               as they come due;
        (4)    the other Party transfers all or any part of its share of the
               Joint Venture Company's registered capital in violation of the
               provisions of this Contract;
        (5)    any government authority having authority over any Party requires
               any provision of this Contract or the Articles of Association to
               be revised in such a way as to cause significant adverse
               consequences to the Joint Venture Company or any Party;
        (6)    the conditions or consequences of Force Majeure prevail with the
               result of a major impairment to the functioning of the Joint
               Venture Company for a period in excess of six (6) months and the
               Parties have been unable to find an equitable solution; or
        (7)    the Parties cannot implement the economic adjustment described in
               Article 119.
Article 105
If any Party gives notice to terminate this Contract pursuant to Article 104,
the Parties shall endeavour to resolve the problem through negotiation and
agreement. If, within thirty (30) days of receipt of such notice, the Parties
have not agreed in writing to continue this Contract, then each Party and the
directors appointed by each Party shall be deemed to have agreed to terminatethis Contract and dissolve the Joint Venture Company. An application for the
same shall forthwith be submitted to the Examination and Approval Authority.
Article 106
Following an application to dissolve the Joint Venture Company pursuant to
Article 105, the Board of Directors shall forthwith appoint a liquidation
committee which shall have the power to represent the Joint Venture Company in
all legal matters. The liquidation committee shall value and liquidate
                                    Page 25
the Joint Venture Company's assets in accordance with the applicable Chinese
laws and regulations and the principles set forth herein.
Article 107
The liquidation committee shall be made up of three (3) members, of whom one (1)
member shall be nominated by Party A and two (2) members shall be nominated by
Party B. Members of the liquidation committee may, but need not be, directors or
senior employees of the Joint Venture Company. The liquidation committee may
engage a lawyer and an accountant registered in China to assist the liquidation
committee. When permitted by Chinese law, any Party may also appoint
professional advisors to assist the liquidation committee. The Board of
Directors shall report the formation of the liquidation committee to the
department in charge of the Joint Venture Company.
Article 108
The liquidation committee shall conduct a thorough examination of the Joint
Venture Company's assets and liabilities, on the basis of which it shall develop
a liquidation plan, which, if approved by the Board of Directors, shall be
executed under the liquidation committee's supervision.
Article 109
In developing and executing the liquidation plan, the liquidation committee
shall use every effort to obtain the highest possible price for the Joint
Venture Company's assets and, subject to compliance with PRC foreign exchange
control regulations, sell such assets for United States Dollars or other freely
convertible foreign currencies.
Article 110
The liquidation expenses, including remuneration to members and the lawyers and
accountants assisting the liquidation committee, shall be paid out of the Joint
Venture Company's assets in priority to the claims of other creditors.
Article 111
After the liquidation and division of the Joint Venture Company's assets and the
settlement of all of its outstanding debts, the balance shall be paid over to
the Parties in proportion to their respective shares of the registered capital
of the Joint Venture Company.
Article 112
On completion of all liquidation work, the liquidation committee shall provide a
liquidation completion report approved by the Board of Directors to the
Examination and Approval Authority, hand in the Joint Venture Company's business
license to the original registration authority and complete all other
formalities for nullifying the Joint Venture Company's registration. Party B
shall have a right to obtain copies of all of the Joint Venture Company's
accounting books and other documents at their own expense but the originals
thereof shall be left in the care of Party A.
                                    Page 26
                          CHAPTER 21 BREACH OF CONTRACT
Article 113
In the event that a breach of contract committed by a Party to this Contract
results in the non- performance of or inability to perform this Contract or its
appendices fully, the liabilities arising from the breach of this contract or
its Appendices shall be borne by the Party in breach. In the event that a breach
of contract is committed by more than one Party, each such Party shall bear its
individual share of the liabilities arising from the breach of contract.
                            CHAPTER 22 FORCE MAJEURE
Article 114
"Force Majeure" shall mean all events which were unforeseeable at the time this
Contract was signed, the occurrence and consequences of which cannot be avoided
or overcome, and which arise after the Effective Date and prevent total orpartial performance by any Party./ Such events shall include earthquakes,
typhoons, flood, fire, war and any other instances which cannot be foreseen,
avoided or overcome, including instances which are accepted as force majeure in
general international commercial practice.
Article 115
If an event of Force Majeure occurs, a Party's obligations under this Contract
affected by such an event shall be suspended during the period of delay caused
by the Force Majeure and shall be automatically extended, without penalty, for a
period equal to such suspension. The Party claiming Force Majeure shall promptly
inform the other Party in writing and shall furnish within fifteen (15) days
thereafter sufficient evidence of the occurrence and duration of such Force
Majeure. The Party claiming Force Majeure shall also use all reasonable
endeavours to terminate the Force Majeure. In the event of Force Majeure, the
Parties shall immediately consult with each other in order to find an equitable
solution and shall use all reasonable endeavours to minimize the consequences of
such Force Majeure.
                        CHAPTER 23 SETTLEMENT OF DISPUTES
Article 116
In the event a dispute arises in connection with the interpretation or
implementation of this Contract, the Parties shall attempt in the first instance
to resolve such dispute through friendly consultations. If the dispute is not
resolved through consultations within sixty (60) days after one Party has served
a written notice on the other Party requesting the commencement of
consultations, then any Party may refer the dispute to arbitration in Singapore
under the auspices of the Singapore International Arbitration Centre in
accordance with the rules of that Centre for the time being in force and the
provisions of Article 117 of this Contract.
                                    Page 27
Article 117
There shall be three (3) arbitrators, one (1) of whom shall be appointed by
Party A, one (1) of whom shall be appointed by Party B, and one (1) of whom
shall be appointed by the arbitration tribunal. The arbitration award shall be
final and binding on the Parties. When any dispute occurs and when any dispute
is under arbitration, except for the matters under dispute, the Parties shall
continue to exercise their other respective rights and fulfil their other
respective obligations under this Contract. In any arbitration proceeding, any
legal proceeding to enforce any arbitration award and in any legal action
between the Parties pursuant to or relating to this Contract, each Party
expressly waives the defense of sovereign immunity and any other defence based
on the fact or allegation that it is an agency or instrumentality of a sovereign
state.
                            CHAPTER 24 APPLICABLE LAW
Article 118
The formation, validity, interpretation and implementation of this Contract, and
any disputes arising under this Contract, shall be governed by the published
laws of the People's Republic of China. If there is no published law in China
governing a particular matter relating to this Contract, reference shall be made
to general international commercial practices.
Article 119
If one Party's economic benefits are adversely and materially affected by the
promulgation of any new laws, rules or regulations of China or the amendment or
interpretation of any existing laws, rules or regulations of China after the
Effective Date of this Contract, the Parties shall promptly consult with each
other and use their best endeavours to implement any adjustments necessary to
maintain each Party's economic benefits derived from this Contract on a basis no
less favourable than the economic benefits it would have derived if such laws,
rules or regulations had not been promulgated or amended or so interpreted. If
it is not possible to implement such adjustments, a Party may terminate this
Contract pursuant to Chapter 20 of this Contract.
                       CHAPTER 25 MISCELLANEOUS PROVISIONS
Article 120
To the extent permitted by Chinese law, failure or delay on the part of any
Party hereto to exercise a right under this Contract and the Appendices hereto
shall not operate as a waiver thereof; nor shall any single or partial exercise
of a right preclude any other future exercise thereof.
Article 121
Except as otherwise provided herein, this Contract may not be assigned in whole
or in part by any Party without the prior written consent of the other Party and
the approval of the Examination and Approval Authority.
                                    Page 28Article 122
This Contract is made for the benefit of Party A and Party B and their
respective lawful successors and assignees and is legally binding on them. This
Contract may not be amended orally, and any amendment hereto must be agreed to
in a written instrument signed by all of the Parties and approved by the
Examination and Approval Authority before taking effect.
Article 123
Subject to the provisions of Article 118 hereof, the invalidity of any provision
of this Contract shall not affect the validity of any other provision of this
Contract.
Article 124
This Contract is written and signed in the Chinese language in six (6) originals
and in the English language in six (6) originals. Both language versions shall
be equally valid and in the event of any discrepancy between the two versions,
the wording in dispute shall be interpreted in accordance with the purpose of
this Contract.
Article 125
This Contract and the Appendices hereto constitute the entire agreement between
the Parties with respect to the subject matter of this Contract and supersede
all prior discussions, negotiations and agreements between them with respect to
the subject matter of this Contract. In the event of any conflict between the
terms and provisions of this Contract and the Articles of Association, the terms
and provisions of this Contract shall prevail.
Article 126
This Contract shall take effect after it is approved by the Examination and
Approval Authority.
Article 127
Any notice or written communication provided for in this Contract from one Party
to the other Party or to the Joint Venture Company shall be made in writing in
Chinese and English and may be sent telegram, telex or facsimile transmission,
or by courier service delivered letter or by post. Any communication sent by
facsimile transmission or e-mail shall be confirmed by courier service delivered
letter or by post. The date of receipt of a notice or communication hereunder
shall be deemed to be fourteen (14) days after the letter is given to the
courier service or postal service, or one (1) working day after sending in the
case of facsimile or e-mail, provided it is evidenced by a confirmation receipt
and the confirmation letter is sent by courier delivered letter or post. All
notices and communications shall be sent to the appropriate address set forth
below, until the same is changed by notice given in writing to the other Party.
PARTY A:
Fengfan Group Limited Liability Company
8 Fu Chang Road,
                                    Page 29
Baoding City, Hebei Province,
People's Republic of China
Facsimile No: (0312) 3236562
Telephone No: (0312) 322 5931
E-mail:
Representative: Chen Mengli
PARTY B:
Valence Technology, Inc.
301 Conestoga Way
Henderson Nevada 89015
U.S.A.
Facsimile No: (702) 558-1310
Telephone No: (702) 558-1073
Attention: General Counsel
E-mail:
THE JOINT VENTURE COMPANY:
Fengfan-Valence Battery Company, Ltd.Baoding City High and New Technology
Development Zone,
Baoding City, Hebei Province
People's Republic of ChinaAttention:            CEO
E-mail:
Article 128
The Appendices hereto listed below are made an integral part of this Contract
and are equally binding with these the provisions of this Contract:
Appendix 1     Schedule for Capital Contributions
Appendix 2     Contract for Technology Investment
Appendix 3     Contract for Equipment Investment and Purchase
Appendix 4     Export Sales Contract
                                    Page 30
IN WITNESS WHEREOF, the duly authorized representative of each Party has signed
this Contract in Baoding, People's Republic of China on November 8, 2002.
FENGFAN GROUP LIMITED                       VALENCE TECHNOLOGY, INC.
LIABILITY COMPANY
By: /S/ CHEN MENGLI                         By:  /S/ DEEPAK SWAMY
   ----------------------------                --------------------------------
Name:  CHEN MENGLI                          Name:  DEEPAK SWAMY
Title: CHAIRMAN OF THE BOARD                Title: VICE PRESIDENT OF LICENSING
                                                   OPERATIONS
Nationality: P.R. CHINA                     Nationality:  AMERICAN
                                    Page 31
                                    Page 31Exhibit 10.12.1
Confidential
Execution Version
[***] Certain information in this document has been excluded because it both (i) is not material and (ii) would likely cause competitive harm to
the registrant if publicly disclosed.
JOINT VENTURE AGREEMENT
by and among
Aizu Fujitsu Semiconductor Limited
Fujitsu Semiconductor Limited
and
Transphorm, Inc.
Date
May 23, 2017Confidential
Execution Version
TABLE OF CONTENTS
Page
Article I Definitions 1
Article II Representations and Warranties of the Parties 4
2.1 Representations and Warranties of AFSL and FSL 4
2.2 Representations and Warranties of TPH-A and TPH 6
Article III Operation of the Company 7
3.1 Activities 7
3.2 Cash Requirement of the Company 7
3.3 Business Plan 7
3.4 Independent Entity 8
Article IV Management of the Company 8
4.1 Board 8
4.2 Composition of the Board 8
4.3 Board Observers 9
4.4 Meetings; Quorum 9
4.5 Personnel; Representative Director 9
4.6 Statutory Auditors 9
4.7 Actions Requiring Unanimous Board Approval 9
4.8 Agreement Regarding Board 12
4.9 Procedure in the Event of Failure to Agree 12
Article V Covenants 13
5.1 Capital Accounts 13
5.2 Provision of Support Services 13
5.3 GaN Equipment 13
5.4 Ancillary Agreements 13
5.5 Other Existing Agreements 14
5.6 Ownership of IP 14
5.7 Sufficiency of IP 14
5.8 Cooperation 14
5.9 Delivery of Financial Statements; Inspection Rights 14
5.10 TPH’ s Stockholder Approval 15
Article VI Rights and Obligations of FSL, TPH AND TPH-A 15
6.1 FSL 15
6.2 TPH 15
6.3 TPH-A 15
Article VII Term and Termination 15
7.1 Termination Prior to the Effective Date 15
-i-Confidential
Execution Version
TABLE OF CONTENTS
(continued)
Page
7.2 Effect of Termination Prior to the Effective Date 16
7.3 Termination After the Effective Date 16
7.4 Dissolution and Winding-up 17
7.5 Shareholder Calls Upon Breach 17
7.6 Shareholder Calls Upon Bankruptcy After the Effective Date 18
7.7 Survival of Provisions After the Effective Date 19
7.8 Cooperation 19
Article VIII Transfer Restrictions 19
8.1 Restrictions on Transfers 19
8.2 Permissible Transfers 19
Article IX Put Option and Call Option 19
9.1 AFSL’s Right to Require the Purchase of the Shares by TPH or TPH-A 19
9.2 TPH-A’s Right to Require the Purchase of the Shares from FSL or AFSL 20
9.3 Conditions to Put Option or Call Option Closing 21
9.4 Other Obligations 22
Article X Treatment of Employees 22
10.1 New Terms and Conditions for Employment 22
10.2 Representations and Warranties Regarding Employment 22
Article XI Miscellaneous 23
11.1 No Partnership 23
11.2 Limitations on Parties’ Authority 23
11.3 Indemnification 23
11.4 Confidentiality 24
11.5 Access to Company Information After the Put Closing Date or the Call Closing Date 24
11.6 Expenses 24
11.7 Notices 25
11.8 Successors and Assigns 26
11.9 Waiver 26
11.10 Announcements 26
11.11 Entire Agreement 26
11.12 Amendments 26
11.13 Limitations on Rights of Third Persons 26
11.14 Governing Law; Language 26
11.15 Resolution of Disputes 26
11.16 Severability 27
11.17 Execution in Counterparts 28
11.18 Titles and Headings 28
11.19 Counsel only to TPH and TPH-A 28
-ii-Confidential
Execution Version
JOINT VENTURE AGREEMENT
THIS JOINT VENTURE AGREEMENT (“Agreement”) is made as of this 23rd day of May, 2017 by and among Aizu
Fujitsu Semiconductor Limited (“AFSL”), a kabushiki kaisha incorporated in Japan, with an address at No.4 Kogyo Danchi,
Monden-Machi, Aizu Wakamatsu, Fukushima, Japan, Fujitsu Semiconductor Limited (“FSL”), a kabushiki kaisha incorporated
in Japan, with an address at Shin-Yokohama Chuo Building, 2-100-45, Shin-Yokohama, Kohoku-Ku, Yokohama, Kanagawa,
Japan, as a one hundred percent (100%) shareholder of AFSL, and Transphorm, Inc. (“TPH”), a corporation incorporated in
Delaware, with an address at 75 Castilian Drive, Goleta, California 93117, U.S.A. (collectively referred to as the “Parties” and
individually, a “Party”).
W I T N E S S E T H:
WHEREAS, Aizu Fujitsu Semiconductor Wafer Solution Limited (“AFSW” or the “ Company”), a kabushiki kaisha
incorporated in Japan, with an address at No.3 Kogyo Danchi, Monden-Machi, Aizu Wakamatsu, Fukushima, Japan has been
engaged with the business of 150mm wafer foundry services and other services related thereto (the “Business”).
WHEREAS, prior to the Effective Date (as defined below), TPH intends to incorporate a new wholly-owned subsidiary
(“TPH-A”) and make it a Party hereto.
WHEREAS, with the consent of the Parties and the board of directors of the Company, AFSL has entered into the Shares
Purchase Agreement dated May 23, 2017 (the “SPA”), by and among the Parties hereof, pursuant to which AFSL will sell and
transfer [***] shares of the issued and outstanding shares in the Company (representing [***] of the issued and outstanding shares
in the Company) to TPH-A; and
WHEREAS, the Parties intend to regulate and agree upon the organization and operation of the Company and each
Party’s rights and obligations and other matters regarding the Company; and
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the Parties agree as follows:
ARTICLE I
DEFINITIONS
As used in this Agreement, the following terms shall have the following meanings:
1.1 “Affiliate” of AFSL, FSL, TPH-A or TPH, as the case may be, means a Person or group of Persons: (a) which owns
or Controls, directly or indirectly, AFSL, FSL, TPH-A or TPH; (b) which is owned or Controlled, directly or indirectly, by AFSL,
FSL, TPH-A or TPH; or (c) which is owned or Controlled, directly or indirectly, by any Person described in Section 1.1(a) or (b).
1.2 “AFSW Secondment Agreement” has the meaning ascribed to that term in the SPA.Confidential
Execution Version
1.3 “Amended Process Development Agreement” has the meaning ascribed to that term in Section 2.1.7.
1.4 “Ancillary Agreements” means the SPA, the AFSW Secondment Agreement, the TPH-J Secondment Agreement,
the Wafer Supply Agreement, the Joinder Agreement, the Process Development Amendment and the Services Agreement
Amendment.
1.6 “Board” means the board of directors of the Company.
1.7 “Business” has the meaning ascribed to that term in the Recitals.
1.8 “Business Day ” means any day other than a Saturday, Sunday or public holiday under the laws of Japan, or any
other day on which banking institutions are authorized to close in Tokyo, Japan or in New York, New York, USA.
1.9 “Business Plan” has the meaning ascribed to that term in Section 3.3.1.
1.10 “Call Shares” means any and all Shares held by AFSL or FSL or any other Person Controlled by AFSL or FSL, as
the case may be, on the date of the Call Exercise Notice.
1.11 “Change of Control Transaction” means either (a) the acquisition of the Company by an entity not affiliated with
FSL or TPH by means of any transaction or series of related transactions (including, without limitation, any stock acquisition,
merger, demerger or share exchange but excluding any sale of stock for capital raising purposes) other than a transaction or series
of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such
transaction or series of related transactions retain, immediately after such transaction or series of related transactions, as a result of
shares in the Company held by such holders prior to such transaction or series of related transactions, at least a majority of the
total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity (or if
the Company or such other surviving or resulting entity is a wholly-owned Subsidiary (hereinafter defined) immediately following
such acquisition, its parent); or (b) a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets
of the Company and its Subsidiaries taken as a whole by means of any transaction or series of related transactions with a party
other than FSL or its Affiliates or TPH or its Affiliates, except where such sale, lease, transfer, exclusive license or other disposition
is to a wholly owned Subsidiary of the Company.
1.12 “Company Assets” has the meaning ascribed to that term in the SPA.
1.13 “Control” means the power, right or authority to direct or cause the direction of the management or policies of a
Person, or to elect a majority of the board of directors or similar governing body of a Person, whether through the ownership of
securities or similar ownership interest, by contract or otherwise, and references to “change of control” include the transfer,
disposition or relinquishment, whether directly or indirectly, of Control.
1.14 “Designated Individuals” has the meaning ascribed to that term in Section 4.9.
1.15 “Designated Nuclear Waste” has the meaning ascribed to that term in the SPA.
- 2-Confidential
Execution Version
1.16 “Director” has the meaning ascribed to that term in Section 4.2.
1.17 “Effective Date” means the date that the Initial Closing occurs.
1.18 “Encumbrance” has the meaning ascribed to that term in the SPA.
1.19 “Funded Work” has the meaning ascribed to that term in Section 2.1.7.
1.20 “GaN Equipment” has the meaning ascribed to that term in Section 5.3.
1.21 “GaN Wafers” has the meaning ascribed to that term in the Amended Process Development Agreement.
1.22 “Governmental Authority” means any government, state (or any subunit thereof), political subdivision or regulatory
authority, whether domestic, foreign or multinational, or any agency, authority, bureau, commission, department, or court of any
government state, political subdivision or regulatory authority or similar body or instrumentality thereof, or any federal state, local,
governmental, foreign or arbitral tribunal.
1.23 “Governmental Approvals” mean all consents, approvals, orders, permits or authorizations of, and registrations,
declarations and filings with, and expirations of waiting periods imposed by, any court, legislative body, administrative agency,
commission or other Governmental Authority and required in connection with the transactions contemplated herein.
1.24 “Harmful Materials” has the meaning ascribed to that term in the SPA.
1.25 “Initial Closing” has the meaning ascribed to that term in the SPA.
1.26 “Intellectual Property Rights” has the meaning ascribed to that term in the SPA.
1.27 “Japanese GAAP” means generally accepted accounting principles in Japan.
1.28 “Joinder Agreement” has the meaning ascribed to that term in Section 6.3.
1.29 “Joint Venture” means the operation of the Company pursuant to this Agreement from the Effective Date to the
earliest to occur of: (i) the Put Closing Date (hereinafter defined), (ii) the Call Closing Date (hereinafter defined), or (iii) termination
of this Agreement pursuant to Article VII hereof.
1.30 “Laws” means laws, statutes, ordinances, rules requirements, decrees, orders or regulations.
1.31 “Net Book Value” has the meaning ascribed to that term in the SPA.
1.32 “Option Starting Date” means February 1, 2020.
1.33 “Person” includes any individual, company, corporation, firm, partnership, joint venture, association, organization or
trust in each case whether or not having a separate legal identity.
- 3-Confidential
Execution Version
1.34 “Pro Rata Ownership” means for any Shareholder, the ratio equal to the total number of Shares held by such
Shareholder at any given time to the total number of outstanding Shares at such time.
1.35 “Process Development Amendment” has the meaning ascribed to that term in the SPA.
1.36 “Put Shares” means any and all Shares held by AFSL or FSL or any other Person Controlled by AFSL or FSL, as
the case may be, on the date of the Put Exercise Notice.
1.37 “Sale Shares” has the meaning ascribed to that term in the SPA.
1.38 “Section” means a section of this Agreement.
1.39 “Seller Disclosure Schedule” has the meaning ascribed to that term in the SPA.
1.40 “Services Agreement Amendment” has the meaning ascribed to that term in the SPA.
1.41 “Shareholder” means each Person that holds Shares.
1.42 “Shares” means the shares of authorized and outstanding capital of the Company.
1.43 “Shares Purchase Price” has the meaning ascribed to that term in the SPA.
1.44 “SPA” has the meaning ascribed to that term in the Recitals.
1.45 “Subsidiary” means a Person in which a Party hereto beneficially owns at least fifty percent (50%) of the equity
interest or voting power of such Person.
1.46 “Tax” has the meaning ascribed to that term in the SPA.
1.47 “Tax Return” has the meaning ascribed to that term in the SPA.
1.48 “TPH-J” means Transphorm Japan, Inc., a kabushiki kaisha  incorporated in Japan, which is a wholly-owned
Subsidiary of TPH.
1.49 “TPH-J Secondment Agreement” has the meaning ascribed to that term in the SPA.
1.50 “Wafer Supply Agreement” has the meaning ascribed to that term in the SPA.
Unless the context clearly requires otherwise, reference to the singular shall include the plural, reference to the plural shall
include the singular and reference to a gender shall include all genders.
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF THE PARTIES
2.1 Representations and Warranties of AFSL and FSL. AFSL and FSL hereby represent and warrant to TPH-A and TPH
as of the date hereof and as of the Effective Date as follows:
- 4-Confidential
Execution Version
2.1.1 Organization. Each of AFSL and FSL is a kabushiki kaisha, duly organized, validly existing and in good
standing under the laws of Japan, and has the corporate power and authority to execute, deliver and perform its obligations under
this Agreement.
2.1.2 Authorization; Execution and Delivery; Enforceability. All corporate action on the part of AFSL and FSL
necessary for the authorization, execution and delivery of this Agreement and for the performance of all of their respective
obligations hereunder has been taken. This Agreement has been duly executed and delivered by each of AFSL and FSL and
constitutes a valid and legally binding obligation of each of them.
2.1.3 Government and Other Consents. No consent, authorization, license, permit, registration or approval of, or
exemption or other action by, any Governmental Authority, or any other Person, is required in connection with AFSL’s or FSL’s
execution, delivery and performance of this Agreement.
2.1.4 Effect of Agreement. Except as set forth in Section 3.2.3 of the Seller Disclosure Schedule, each of AFSL’s
and FSL’s execution, delivery and performance of this Agreement will not (i) violate the Articles of Incorporation of either of them
or any provision of Law, (ii) violate any judgment, order, writ, injunction or decree of any court applicable to AFSL, FSL or the
Company, (iii) result in the breach of, give rise to a right of termination, cancellation or acceleration of any obligation with respect
to (presently or with the giving of notice, the passage of time or both), or otherwise be in conflict with any term of, or affect the
validity or enforceability of, any agreement or other commitment to which AFSL, FSL or the Company is a party and which would
materially and adversely affect either of them or the Company, or (iv) result in the creation of any lien, pledge, mortgage, claim,
charge or encumbrance upon any assets of AFSL, FSL or the Company.
2.1.5 Litigation. There are no actions, suits or proceedings pending or, to either AFSL’s or FSL’s knowledge,
threatened, against AFSL or FSL before any Governmental Authority which question AFSL’s or FSL’s right to enter into or
perform this Agreement, or which question the validity of this Agreement.
2.1.6 Equipment. FSL (as of the date hereof) and the Company (as of the Effective Date) have valid and perfected
ownership of all GaN Equipment, free and clear of any Encumbrances. There are no third party agreements or licenses with
respect to any software or firmware required to operate any GaN Equipment.
2.1.7 Sufficiency of IP. As of the Effective Date, the Intellectual Property Rights owned by the Company, together
with the Intellectual Property Rights licensed to TPH pursuant to (i) that certain Process Technology Development Services
Agreement, dated as of November 28, 2013, by and between FSL and TPH, and (ii) the Process Development Amendment ((i)
and (ii) collectively, the “Amended Process Development Agreement”), shall constitute all Intellectual Property Rights owned
by FSL, AFSL, Fujitsu Limited or their Affiliates that are or will be necessary for the continued operation of the Business for GaN
Wafers following the Effective Date in the manner conducted as of the Effective Date. For the avoidance of doubt, the Business
does not include the Company’s performance of the GaN work commissioned and funded by Fujitsu Limited and its Affiliates
- 5-Confidential
Execution Version
(including Fujitsu Laboratories Ltd., but excluding FSL and AFSL) to the Company (such work, the “Funded Work”).
2.2 Representations and Warranties of TPH-A and TPH.
2.2.1 TPH hereby represents and warrants to AFSL and FSL as of the date hereof and as of the Effective Date as
follows:
(i) Organization. TPH is a corporation, duly organized, validly existing and in good standing under the laws
of the State of Delaware, and has the corporate power and authority to execute, deliver and perform its obligations under this
Agreement.
(ii) Authorization; Execution and Delivery; Enforceability. All corporate action on the part of TPH
necessary for the authorization, execution and delivery of this Agreement and for the performance of all its obligations hereunder
has been taken. This Agreement has been duly executed and delivered by TPH and constitutes a valid and legally binding
obligation of TPH.
(iii) Government and Other Consents. No consent, authorization, license, permit, registration or approval
of, or exemption or other action by, any Governmental Authority, or any other Person, is required in connection with TPH’s
execution, delivery and performance of this Agreement.
(iv) Effect of Agreement. TPH’s execution, delivery and performance of this Agreement will not (i) violate
the Certificate of Incorporation or Bylaws of TPH, or any provision of Law, (ii) violate any judgment, order, writ, injunction or
decree of any court applicable to TPH, (iii) result in the breach of, give rise to a right of termination, cancellation or acceleration of
any obligation with respect to (presently or with the giving of notice, the passage of time or both), or otherwise be in conflict with
any term of, or affect the validity or enforceability of, any agreement or other commitment to which TPH is a party and which
would materially and adversely affect it or the Company, or (iv) result in the creation of any lien, pledge, mortgage, claim, charge or
encumbrance upon any assets of TPH.
(v) Litigation. There are no actions, suits or proceedings pending or, to TPH’s knowledge, threatened,
against TPH before any Governmental Authority which question TPH’s right to enter into or perform this Agreement, or which
question the validity of this Agreement.
2.2.2 TPH-A hereby represents and warrants to AFSL and FSL as of the date of the Joinder Agreement and as of
the Effective Date as follows:
(i) Organization. TPH-A is a kabushiki kaisha, duly organized, validly existing and in good standing under
the laws of Japan, and has the corporate power and authority to execute, deliver and perform its obligations under this Agreement.
(ii) Authorization; Execution and Delivery; Enforceability. All corporate action on the part of TPH-A
necessary for the authorization, execution and delivery of the Joinder Agreement, and for the performance of all its obligations
thereunder and hereunder has been taken.
- 6-Confidential
Execution Version
The Joinder Agreement has been duly executed and delivered by TPH-A and constitutes a valid and legally binding obligation of
TPH-A.
(iii) Government and Other Consents. No consent, authorization, license, permit, registration or approval
of, or exemption or other action by, any Governmental Authority, or any other Person, is required in connection with TPH-A’s
execution, delivery and performance of the Joinder Agreement and this Agreement.
(iv) Effect of Agreement. TPH-A’s execution, delivery and performance of the Joinder Agreement and this
Agreement, as applicable, will not (i) violate the Articles of Incorporation of TPH-A, or any provision of Law, (ii) violate any
judgment, order, writ, injunction or decree of any court applicable to TPH-A, (iii) result in the breach of, give rise to a right of
termination, cancellation or acceleration of any obligation with respect to (presently or with the giving of notice, the passage of time
or both), or otherwise be in conflict with any term of, or affect the validity or enforceability of, any agreement or other commitment
to which TPH-A is a party and which would materially and adversely affect it or the Company, or (iv) result in the creation of any
lien, pledge, mortgage, claim, charge or encumbrance upon any assets of TPH-A.
(v) Litigation. There are no actions, suits or proceedings pending or, to TPH-A’s knowledge, threatened,
against TPH-A before any Governmental Authority which question TPH-A’s right to enter into or perform this Agreement and the
Joinder Agreement, or which question the validity of this Agreement and the Joinder Agreement.
ARTICLE III
OPERATION OF THE COMPANY
3.1 Activities. The Company shall manufacture the semiconductor products for which AFSL/FSL or TPH-A/TPH-J/TPH
places an order to the Company from time to time during the term of this Agreement, using the technologies made available by
AFSL/FSL and TPH-A/TPH-J/TPH, respectively. With the consent of the Board in compliance with Section 4.7, the Company
may manufacture semiconductor products directly for Persons who are not parties to this Agreement.
3.2 Cash Requirement of the Company. All cash requirements of the Company shall be satisfied from cash generated by
the operations of the Company, from external financing (on a non-recourse basis and without guarantees of the Shareholders or
their Affiliates) procured by the Company in its own name, from financing by the Shareholders (the burden of such financing shall
be allocated to a Shareholder based on Pro Rata Ownership) and from the initial capitalization.
3.3 Business Plan.
3.3.1 Conduct of Business. The Company shall conduct its Business in conformity with a business plan jointly
prepared and agreed to by the Parties on or prior to the Effective Date, as may be amended from time to time after the Effective
Date with the unanimous approval of the Board (the “Business Plan”). In case where the Parties have not agreed on the Business
Plan as of the date hereof, then the Parties shall continue to discuss in good faith immediately following the execution of this
Agreement and agree on the Business Plan prior to the Effective Date.
- 7-Confidential
Execution Version
3.3.2 Treatment of the Business Plan. The Parties expect the Company to comply with the Business Plan;
provided, however, deviations from the Business Plan that result in an increase or decrease of less than twenty percent (20%) of
the original cost or revenue to the Company attributable to such item as set forth in the Business Plan shall not require the consent
of the Parties, so long as all such deviations in any given quarter do not represent a deviation of more than ten percent (10%) of
total revenue or total expense, as the case may be, in the aggregate for the quarter in which the deviation occurs. No Party shall,
however, have any assurance that the Company will achieve the Business Plan, except as to the number of wafers that each of
FSL/AFSL and TPH/TPH-A commits to purchase in the Business Plan. In the event that FSL/AFSL or TPH/TPH-A, as
applicable, has failed to purchase its applicable number of wafers in accordance with the Business Plan, then such Party shall
compensate the Company for the shortfalls in the actual revenue of the Company attributable to its failure to purchase such wafers
versus its share of the planned revenue set forth in the Business Plan. As soon as it becomes practicable after the end of each
quarter, but not later than thirty (30) days thereafter, the Parties shall review the actual revenue of the Company versus the
Business Plan based on the wafer loading by each of FSL/AFSL and TPH/TPH-A for the previous quarter, and if there are any
shortfalls in revenue from the Business Plan in such quarter, the compensation for such shortfalls shall be made by a Party who
caused such shortfalls to the Company within sixty (60) days after the end of the fiscal year of the Company where such quarter
resides. For the avoidance of doubt, (i) if a Party, its Affiliate or another third party purchases such Party’s committed number of
wafers in the Business Plan, such Party shall not be deemed to have caused a shortfall in the revenue of the Company and (ii) the
revenue attributable to a Party’s failure to purchase its number of wafers in accordance with the Business Plan shall equal (A) the
number of wafers not purchased, multiplied by (B) the agreed price (as set forth in the Business Plan) per wafer.
3.3.3 Revised Budget. The budget of the Company shall be reviewed quarterly and may be revised by the
Company with the unanimous approval of the Board. Such revised budget shall be deemed as the then-current Business Plan.
3.4 Independent Entity. The Company shall be operated as an independent business entity, even though the Parties may
provide products, personnel and services.
ARTICLE IV
MANAGEMENT OF THE COMPANY
4.1 Board. Except where the approval of the Shareholders is required by applicable Laws, the Articles of Incorporation or
this Agreement, the business and affairs of the Company shall be managed by the Board.
4.2 Composition of the Board. The Board shall consist of five (5) members (each, a “Director”), three (3) of whom shall
be nominated by AFSL and two (2) of whom shall be nominated by TPH-A, and each Shareholder shall vote all of its Shares in
favor of the election of the Directors nominated by the other. Each of AFSL and TPH-A shall have the right to nominate a
replacement for any Director previously nominated by it, and each shall vote all of its Shares in favor of the election of such
replacement. A Director nominated by AFSL shall be a Chairman of the Board for all meetings. In the event that a Shareholder
who is entitled to nominate a Director seeks to remove such
- 8-Confidential
Execution Version
Director by written notice to the Company, all Shareholders shall be obligated to vote their Shares in favor of such removal.
4.3 Board Observers. Representatives of TPH and FSL may attend and participate in any meeting of the Board, but shall
in all other respects be a nonvoting observer.
4.4 Meetings; Quorum.
4.4.1 Regular meetings of the Board shall be held at least once per three (3) months at such place and time as set
forth in notices provided to the Directors at least ten (10) Business Days in advance of such meeting. Special meetings of the
Board shall be held upon notice of not less than three (3) Business Days setting forth an agenda or purpose for the meeting;
provided, however, that any Director may waive compliance with such notice requirement before or after the meeting. Special
meetings of the Board may be called by at least two (2) Directors upon three (3) Business Days’ notice to the Chairman, which
notice shall include an agenda for such meeting.
4.4.2 Any Director may propose items for the agendas of any meeting of the Board whether in advance or at such
meeting.
4.4.3 A quorum shall be deemed to exist for purposes of Board actions so long as at least a majority of the total
number of Directors then in office are present, provided that proper notice of such Board meeting has been given, in accordance
with Section 4.4.1, to each of the Directors then in office. Directors may participate in Board meetings in person or electronically
(including video or audio conference) in accordance with the Japanese Companies Act.
4.4.4 Proceedings of Board meetings shall be in Japanese/English, as the case may be, and a record of each Board
meeting shall be made in Japanese and English, and sent promptly to each Shareholder. In the event of a conflict between the
English and Japanese versions, the Japanese version shall control.
4.4.5 Minutes of the meetings of the Board shall be placed and duly maintained at the office of the Company.
4.4.6 Any action that may be taken at a meeting of the Board may be taken in writing in accordance with the
Company’s Articles of Incorporation.
4.5 Personnel; Representative Director. One of the Directors to be nominated by AFSL shall be the manager of the
Company, who shall also be the Representative Director (as defined under the Japanese Companies Act).
4.6 Statutory Auditors. The Company shall have one (1) statutory auditor. The statutory auditor shall be appointed by
AFSL, subject to the approval of TPH-A, which approval shall not be unreasonably withheld.
4.7 Actions Requiring Unanimous Board Approval. The Parties agree that the following matters require the unanimous
approval of the Directors present at a properly-noticed Board meeting,
- 9-Confidential
Execution Version
and no Shareholder shall convene a shareholders meeting with respect to the following matters without the prior written consent of
the other Shareholder:
4.7.1 revising the budget or Business Plan of the Company;
4.7.2 making any capital contribution in excess of the capital required pursuant to the Business Plan;
4.7.3 manufacturing semiconductor products directly for Persons who are not parties to this Agreement;
4.7.4 selling, transferring, leasing, assigning or otherwise disposing of the property or assets of the Company, or
contracting to do so, whether in a single transaction or series of related transactions;
4.7.5 consummating a Change of Control Transaction including without limitation merger, demerger, share
exchange, liquidating or dissolving the Company, the entering into of a composition with creditors or the authorization of any filing
for bankruptcy by the Company or the transformation of the Company into another type of legal entity;
4.7.6 entering into any agreement to effect a Change of Control Transaction or undertaking any action which
effects a Change of Control Transaction, except pursuant to the exercise of the Put Option or Call Option, calls pursuant to
Sections 7.5 and 7.6 and transfers permitted pursuant to Sections 8.1 and 8.2;
4.7.7 issuing any shares of the authorized capital of the Company or the authorization or issuance of any new class
or series of capital of the Company or any securities convertible into or exchangeable for any class or series of capital of the
Company;
4.7.8 recapitalizing, reclassifying, consolidating, subdividing or converting, or altering of any rights attaching to, any
class or series of authorized capital of the Company;
4.7.9 entering into any joint venture, partnership or profit-sharing agreement with any third party;
4.7.10 purchasing or otherwise acquiring, or agreeing to purchase or otherwise acquire material assets of any other
Person or any shares of capital stock of, or similar interest in, any other Person, or any other asset or group of assets, in a single
transaction or series of related transactions;
4.7.11 removing any Director during his/her term of office, unless such Director was requested to be removed by
the Shareholder that nominated him/her;
4.7.12 amending or repealing any provision of the Articles of Incorporation or other constituent documents of the
Company, including, without limitation, the changing of the business purpose of the Company;
- 10-Confidential
Execution Version
4.7.13 declaring or paying any dividend or distribution;
4.7.14 adopting or changing a significant tax or accounting practice or principle of the Company or making any
significant tax or accounting election by the Company;
4.7.15 making or changing any election in respect of Taxes, filing any amendment to a Tax Return, entering into any
agreement in respect of Taxes, settling, responding to, or making any filing or submission in respect of any audit, claim or
assessment in respect of Taxes, or consenting to any extension or waiver of the limitation period applicable to any claim or
assessment in respect of Taxes, other than those approved by the Directors nominated by TPH-A as immaterial or in the ordinary
course of the Business, such approval not to be unreasonably withheld;
4.7.16 settling or abandoning, on the part of the Company or any Party or Affiliate of any Party, any legal action
that is in the name of the Company or that directly affects the Company, which legal action (A) involves a claim or claims for
monetary damages, (B) involves a claim or claims by or against any Governmental Authority, (C) involves any claims raising
antitrust issues, or (D) involves a request for injunctive relief;
4.7.17 instituting or determining the strategy of any legal action in the name of the Company that (A) involves a
claim or claims for monetary damages, (B) involves a claim or claims by or against any Governmental Authority, (C) involves any
claims raising antitrust issues, or (D) involves a request for injunctive relief;
4.7.18 entering into or amending an agreement between the Company and a Party or its Affiliates, other than (A)
as expressly contemplated by this Agreement or the SPA, or (B) such amendments that result in an increase or decrease of less
than 20% of the original cost or revenue to the Company attributable to such agreement as set forth in the Business Plan, so long
as all such deviations in any given quarter do not represent a deviation of more than 10% of total revenue or total expense, as the
case may be, in the aggregate for the quarter in which the deviation occurs;
4.7.19 incorporating, liquidating, acquiring or transferring any legal entities;
4.7.20 carrying on any business other than the Business and the businesses currently conducted by the Company
as of the Effective Date;
4.7.21 creating, incurring, assuming or permitting to exist any indebtedness, except to the extent consistent with the
then-current Business Plan;
4.7.22 creating, incurring, assuming or permitting to exist, directly or indirectly, any lien or other encumbrance upon
any property, now owned or hereafter acquired, other than incidental liens or liens to secure indebtedness authorized pursuant to
Section 4.7.21;
4.7.23 making any loan or advance or the giving of any credit by the Company (other than normal trade credit) to
any Person or the giving of any guarantee or indemnity to secure the liabilities or obligations of any Person or the creation of any
mortgage, claim, charge, lien, security interest, easement, right of way, pledge or other encumbrance over the whole or any part of
the property or assets of the Company;
- 11-Confidential
Execution Version
4.7.24 entering into any contract, agreement, commitment, transaction or series of transactions requiring the
expenditure by the Company, or the making of any investment, which would exceed thirty million Japanese Yen (¥30,000,000) in
the aggregate, except for operational expenditures approved in the Business Plan;
4.7.25 making any material change in (A) the role and responsibility of certain Company employees specified as
“Key Employees” in the Appendix 1 attached hereto or (B) the Company’s organization;
4.7.26 adopting, materially amending or terminating any Employee Plan, entering into any change in control,
severance or similar agreement or any retention or similar agreement with any officer, employee, director or consultant of the
Company (including seconded employees), or hiring or making an offer to hire any new employee;
4.7.27 increasing or making any other change that would result in increased cost to the Company to the salary,
wage rate, incentive compensation opportunity, employment status, title of other compensation payable or to be become payable
to any current or former employee, officer, director, or consultant of the Company (including seconded employees);
4.7.28 entering into, amending or terminating any collective bargaining agreement, labor union contract, works
council agreement or other contract with any labor organization or union;
4.7.29 using any Company Assets for (A) the storage, manufacture, processing or disposal of any Harmful
Materials, except for the storage of the Designated Nuclear Waste to the extent and in the manner set forth in Article 3.18 of the
SPA, or (B) the processing or disposal of industrial waste; or
4.7.30 increasing or decreasing the size of the Board.
Notwithstanding the above, at the request of TPH or TPH-A, the Board shall, without following the procedures set forth in
this subsection, approve and direct management to make operational changes to portions of the Company that (i) are specific
solely to GaN operation or GaN Equipment and (ii) do not have a material and adverse effect on the Company’s profit and loss.
4.8 Agreement Regarding Board. Each Shareholder shall take all actions necessary to cause the Directors nominated by it
to abide by and implement all of the provisions of this Agreement.
4.9 Procedure in the Event of Failure to Agree. In the event that the Board has been unable to resolve any matter set forth
in Section 4.7 within thirty (30) Business Days after such matter was referred to the Board, then any Party may bring the matter to
the attention of the Chief Executive Officer of FSL and the Chief Executive Officer of TPH (the “Designated Individuals”) for a
decision, which joint decision of the Designated Individuals shall be final and binding on the Company, and the Parties shall direct
the Directors nominated by them to exercise their voting rights and take all other necessary steps to ensure that such resolution is
fully and promptly carried into effect. Should no solution be agreed upon within sixty (60) days after submission of the matter to the
Designated Individuals, then any Party may refer the matter for resolution in accordance with the dispute resolution procedure set
forth in Section 11.15.
- 12-Confidential
Execution Version
ARTICLE V
COVENANTS
5.1 Capital Accounts. The capital accounts of each Shareholder shall be updated in proportion to such Shareholder’s Pro
Rata Ownership.
5.2 Provision of Support Services.
5.2.1 AFSL shall provide support services agreed upon by AFSL/FSL and the Company to the Company, with
adequate consideration to FSL/AFSL and/or FSL’s/AFSL’s designees, the detailed terms and conditions of which services shall be
the same as already have been provided in the applicable agreement(s) by and between AFSL/FSL and the Company (if any) or
shall be discussed and determined by the Parties.
5.2.2 TPH and TPH-A shall cause the Company to provide support services agreed upon by AFSL/FSL and the
Company to FSL/AFSL and/or FSL’s/AFSL’s designees, with adequate consideration to the Company, the detailed terms and
conditions of which services shall be the same as already have been provided in the applicable agreement(s) by and between
AFSL/FSL and the Company (if any) or shall be discussed and determined by the Parties.
5.3 GaN Equipment. During the term of this Agreement, TPH-A/TPH shall be responsible for the costs and expenses
agreed by the Parties to maintain and/or procure the equipment for wafer processing specified in the Appendix 2 attached hereto
and as amended from time to time upon the mutual agreement of the Parties (the “GaN Equipment”). At TPH’s sole option, TPH
or TPH-A may purchase the GaN Equipment by completion of payment of the purchase price or depreciation cost for such
equipment as set forth in Appendix 2. In such case: (i) TPH-A or TPH, as the case may be, shall acquire sole and exclusive title to
the GaN Equipment, free and clear of all Encumbrances, and none of FSL, AFSL or the Company shall have any right, title or
interest in such GaN Equipment, (ii) such GaN Equipment shall be clearly labeled as the property of TPH-A or TPH, as the case
may be, and (iii) FSL and AFSL shall cause to be assigned to TPH-A or TPH, as the case may be, all licenses and warranties for
such GaN Equipment and the software or firmware required to operate such GaN Equipment that are attached to, installed on, or
embodied in such GaN Equipment as of the Effective Date. During the term if this Agreement, the GaN Equipment shall be used
exclusively in GaN wafer processing, and shall not be used in the silicon wafer processing for AFSL’s or FSL’s current products.
In the event that the Company needs to use the GaN Equipment to provide products or services to any customer other than TPH-
A or TPH or their Affiliates prior to the Put Closing Date or the Call Closing Date, the Company shall reimburse TPH-A or TPH
for the use of such equipment in the manner to be discussed in good faith and agreed upon by the Parties, which reimbursement
may be offset against amounts otherwise owing from TPH-A or TPH, as the case may be, to the Company.
5.4 Ancillary Agreements. Prior to the Effective Date, the Parties shall take any actions necessary to cause the Wafer
Supply Agreement, the AFSW Secondment Agreement, TPH-J Secondment Agreement, the Joinder Agreement and the Process
Development Amendment to go into effect as of the Effective Date.
- 13-Confidential
Execution Version
5.5 Other Existing Agreements. The Parties shall ensure that the following agreements stay in full force and effect without
modification during the term of this Agreement unless they are terminated or modified pursuant to the terms and conditions
thereunder:
5.5.1 the Intellectual Property License Agreement, dated November 28, 2013, by and between TPH and Fujitsu
Limited;
5.5.2 the Secondment Agreement, dated as of January 31, 2014, by and between Fujitsu Limited and TPH-J; and
5.5.3 the Fujitsu intercompany license agreement and Fujitsu intercompany services agreement.
5.6 Ownership of IP. The Parties agree that the ownership of Intellectual Property Rights in technology developed by or
for the Company pursuant to an Ancillary Agreement shall be governed by such Ancillary Agreement.
5.7 Sufficiency of IP. FSL and AFSL represent and warrant that, as of the Put Closing Date or the Call Closing Date, the
Intellectual Property Rights owned by the Company, together with the Intellectual Property Rights licensed to TPH pursuant to the
Amended Process Development Agreement shall constitute all Intellectual Property Rights owned by FSL, AFSL, Fujitsu Limited
or their Affiliates that are or will be necessary for the continued operation of the Business for GaN Wafers following the Put
Closing Date or Call Closing Date in the manner conducted as of the Put Closing Date or Call Closing Date, as applicable. For the
avoidance of doubt, the Business does not include the Company’s performance of the Funded Work.
5.8 Cooperation. The Parties shall cooperate reasonably with each other to obtain and maintain all necessary approvals
and registrations to effect this Agreement and all related agreements and documents; provided, however, that the Parties shall not
be required to change any provision of this Agreement to obtain or maintain any such approvals or registrations.
5.9 Delivery of Financial Statements; Inspection Rights. The Parties shall cause the Company to deliver to each Party, at
the Company’s expense, (i) annual audited and quarterly and monthly unaudited financial statements prepared in accordance with
Japanese GAAP consistently applied, including any independent auditor’s report or opinion thereon, if any, and (ii) any information
necessary to enable a Party to prepare consolidated financial statements, in each case within sixty (60) days after the end of each
fiscal year of the Company and within thirty (30) days after the end of each quarterly accounting period of the Company and
calendar month. Each Party will indemnify the Company and hold it harmless for, from and against any claims, demands, costs or
expenses arising out of or relating to such consolidated financial statements, provided that such indemnity shall not apply to claims,
demands, costs or expenses to the extent they are related to the Company’s financial statements provided to such Party. In
addition to any inspection rights granted under Law, upon notice to the Company of at least twenty-four (24) hours, each Party
shall have full access to all properties, books of account, and records of the Company.
- 14-Confidential
Execution Version
5.10 TPH’s Stockholder Approval. TPH shall obtain approval of the acquisition of the Option Shares (as defined in the
SPA) from the requisite stockholders of TPH in accordance with Delaware Law and TPH’s Certificate of Incorporation and
Bylaws, which approval shall have been obtained prior to the Effective Date, to the extent such an approval is permissible under
Delaware Law.
ARTICLE VI
RIGHTS AND OBLIGATIONS OF FSL, TPH AND TPH-A
6.1 FSL. FSL, as a one hundred percent (100%) shareholder of AFSL, shall cause AFSL to perform all obligations of
AFSL hereunder.
6.2 TPH. Until TPH-A is incorporated and made a party hereto, TPH shall assume all obligations of TPH-A hereunder.
After TPH-A is incorporated and made a party hereto, TPH, as a one hundred percent (100%) shareholder of TPH-A, shall
cause TPH-A to perform all obligations of TPH-A hereunder.
6.3 TPH-A. TPH shall cause TPH-A to execute and deliver a joinder agreement to the Parties substantially in the form
attached hereto as Exhibit A (the “Joinder Agreement”), and TPH-A shall agree to be bound by the terms and conditions of this
Agreement and the SPA to be performed and complied with by TPH-A by executing and delivering the Joinder Agreement.
ARTICLE VII
TERM AND TERMINATION
7.1 Termination Prior to the Effective Date. This Agreement may be terminated prior to the Effective Date, and the Joint
Venture and the other transactions contemplated by this Agreement may be abandoned at any time prior to the Effective Date (by
written notification with respect to Sections 7.1.2 to 7.1.5 below), notwithstanding any requisite approval of this Agreement and
the transactions contemplated by this Agreement, as follows:
7.1.1 by mutual written consent duly executed by FSL and AFSL on the one hand, and TPH-A and TPH on the
other hand;
7.1.2 by either FSL or AFSL on the one hand, and TPH-A or TPH on the other hand, if the Effective Date shall
not have occurred on or before September 30, 2017 (the “Long Stop Date”), provided, however, that the right to terminate this
Agreement under this Section 7.1.2 shall not be available to any Party whose failure to fulfill any obligation under this Agreement
has been the cause of, or resulted in, the failure of the Effective Date to occur on or before the Long Stop Date; provided,
however, in the event that any required waiting period (and any extension thereof) under the applicable Laws relating to the
transactions contemplated hereby shall not have expired or terminated early before the Long Stop Date, the Long Stop Date shall
be extended until December 31, 2017;
7.1.3 by either FSL or AFSL on the one hand, and TPH-A or TPH on the other hand, upon the issuance of any
Order which is final and nonappealable which would (i) prevent the consummation of the sale of the Shares under the SPA, (ii)
prohibit TPH or TPH-A’s ownership or operation of any portion of the business of the Company, or (iii) compel FSL, AFSL or
the Company
- 15-Confidential
Execution Version
on the one hand, and TPH-A or TPH on the other hand, to dispose of or hold separate, as a result of the Joint Venture, any
portion of the business or assets of the Company;
7.1.4 by FSL or AFSL upon a breach of any representation, warranty, covenant or agreement on the part of TPH
or TPH-A set forth in this Agreement or the SPA, or if any representation or warranty of TPH or TPH-A in this Agreement or the
SPA shall have become untrue, in either case such that the conditions set forth in Article 7.2 of the SPA would not be satisfied
(“Terminating TPH Breach”); provided, however, that, if such Terminating TPH Breach is curable by TPH or TPH-A through
the exercise of such Party’s reasonable best efforts and for so long as such Party continues to exercise such reasonable best
efforts, FSL or AFSL may not terminate this Agreement under this Section 7.1.4 unless such breach is not cured within thirty (30)
days after written notice thereof is provided by FSL or AFSL to TPH and TPH-A pursuant to Section 11.7 (but no cure period is
required for a breach which, by its nature, cannot be cured); or
7.1.5 by TPH or TPH-A upon a breach of any representation, warranty, covenant or agreement on the part of
FSL or AFSL set forth in this Agreement or the SPA, or if any representation or warranty of FSL or AFSL in this Agreement or
the SPA shall have become untrue, in either case such that the conditions set forth in Article 7.1 of the SPA would not be satisfied
(“Terminating FSL Breach”); provided, however, that, if such Terminating FSL Breach is curable by FSL or AFSL through the
exercise of such Party’s reasonable best efforts and for so long as such Party continues to exercise such reasonable best efforts,
TPH or TPH-A may not terminate this Agreement under this Section 7.1.5 unless such breach is not cured within thirty (30) days
after written notice thereof is provided by TPH or TPH-A to FSL and AFSL pursuant to Section 11.7 (but no cure period is
required for a breach which, by its nature, cannot be cured).
7.2 Effect of Termination Prior to the Effective Date. In the event of termination of this Agreement pursuant to Section 7.1,
this Agreement shall forthwith become void and of no further force and effect, there shall be no liability under this Agreement on
the part of any Party or any of their respective officers or directors, and all rights and obligations of each Party hereto shall cease;
provided, however, that (i) Section 11.4 and Section 11.6 shall remain in full force and effect and survive any termination of this
Agreement and (ii) nothing herein shall relieve any Party from liability for the willful breach of any of its representations or
warranties or the breach of any of its covenants or agreements set forth in this Agreement.
7.3 Termination After the Effective Date.
7.3.1 After the Effective Date, this Agreement may be terminated on the date that the first of the following shall
occur:
(i) by mutual written consent duly executed by FSL and AFSL on the one hand, and TPH-A and TPH on
the other hand;
(ii) By FSL/AFSL or TPH/TPH-A, if there is only one (1) shareholder, whatsoever the reason, in the
Company;
- 16-Confidential
Execution Version
(iii) If the Put Option or Call Option is exercised, one (1) Business Day after the Put Closing Date or Call
Closing Date, as applicable;
(iv) By TPH/TPH-A, if FSL/AFSL has not exercised the Put Option within one hundred eighty (180) days
of the Option Starting Date; or
(v) By FSL/AFSL and TPH/TPH-A, if there is a change in the Control of the other and the
acquiring/succeeding entity causing such change in the Control is an entity that may be reasonably believed to be objectionable to
the Japanese Government and/or FSL including FSL’s Affiliates in case of the termination by FSL/AFSL or the US Government
and/or TPH in case of the termination by TPH/TPH-A, termination to be effective upon thirty (30) days’ notice of termination. By
way of example only, an entity that deals in weapons or weapon systems directly or indirectly may be deemed as such
objectionable entity.
7.3.2 In the event that any one of the following events applies to a Party, the other Party(ies) shall have the right to
terminate this Agreement at any time:
(i) it has breached any provisions of this Agreement and, after having received a written notice to cure the
breach from the other Party(ies), has failed to cure such breach within thirty (30) days after the receipt of such notice;
(ii) it has been subject to attachment, provisional disposition or has been subject to a procedure for the
collection of a tax delinquency; or
(iii) a petition for the commencement of any bankruptcy, civil rehabilitation, or corporation liquidation
procedure has occurred.
7.4 Dissolution and Winding-up. In case where this Agreement is terminated pursuant to Section 7.3 (except for the cases
of Section 7.3.1(ii) and (iii), and the cases where a Shareholder has exercised the right as specified in Section 7.4 or 7.5), the
Company shall be dissolved and wound up unless otherwise agreed by the Parties. In the absence of mutual agreement of the
Parties to dissolve and wind up the Company on such terms and conditions as they shall determine, the business and affairs of the
Company shall be dissolved and wound up in accordance with the Laws then in effect.
7.5 Shareholder Calls Upon Breach.
7.5.1 Calls by AFSL. If, after the Effective Date, TPH or TPH-A shall have materially breached any of its
representations or warranties contained in this Agreement or shall have failed to comply in any material respect with any of the
other covenants or agreements contained in this Agreement, which breach or failure shall not have been remedied within thirty (30)
days after written notice thereof (the “Default Notice”) has been given by AFSL to TPH/TPH-A, then AFSL shall have the
option of purchasing from TPH-A, and TPH-A shall be obligated to sell, all of the Shares then owned by TPH-A at a purchase
price per Share equal to the lesser of: (i) the Net Book Value as of the most recent month end (provided that, if the Net Book
Value is a negative amount, the product of the Net Book Value multiplied by such Sale Shares shall be deemed to be one Japanese
Yen (¥1)), or (ii) the Shares Purchase Price, divided by the number of Sale Shares. AFSL shall provide written notice of its
election (the “Election Notice”) to purchase the Shares owned by TPH-A within ten (10) Business Days following the expiration
of the thirty (30) day cure period set forth in the Default Notice. The closing of the purchase of the Shares owned by TPH-A
- 17-Confidential
Execution Version
shall take place within thirty (30) Business Days following the date of the Election Notice, or at such other time as the Parties may
mutually agree. At such closing, AFSL shall deliver to TPH-A, by wire transfer, the full amount of the purchase price in Japanese
Yen for such Shares as provided in this Section 7.5.1 against delivery by TPH-A of the following: (a) a sale agreement in form
reasonably satisfactory to AFSL containing among other things, a representation and warranty of TPH-A that it is, and AFSL shall
be, the beneficial owner of such Shares, with good title thereto, free and clear of all liens and other encumbrances; (b)
documentary evidence reasonably satisfactory to AFSL of the transfer to it of all of TPH-A’s Shares and (c) resignations of all
Directors, if any, on the Board appointed by TPH-A. Notwithstanding the remedies provided in this Section 7.5.1, AFSL/FSL
shall be entitled to all other remedies against TPH/TPH-A available at law or equity or under this Agreement.
7.5.2 Calls by TPH-A. If, after the Effective Date, FSL or AFSL shall have materially breached any of its
representations or warranties contained in this Agreement or shall have failed to comply in any material respect with any of the
other covenants or agreements contained in this Agreement, which breach or failure shall not have been remedied within thirty (30)
days after the Default Notice has been given by TPH-A to FSL/AFSL, then TPH-A shall have the option of purchasing from
AFSL, and AFSL shall be obligated to sell, all of the Shares then owned by AFSL at a purchase price per Share equal to the
lesser of: (i) the Net Book Value as of the most recent month end (provided that, if the Net Book Value is a negative amount, the
product of the Net Book Value multiplied by such Sale Shares shall be deemed to be one Japanese Yen (¥1)), or (ii) the Shares
Purchase Price, divided by the number of Sale Shares. TPH-A shall provide the Election Notice to purchase the Shares owned by
AFSL within ten (10) Business Days following the expiration of the thirty (30) day cure period set forth in the Default Notice. The
closing of the purchase of the Shares owned by AFSL shall take place within thirty (30) Business Days following the date of the
Election Notice, or at such other time as the Parties may mutually agree. At such closing, TPH-A shall deliver to AFSL, by wire
transfer, the full amount of the purchase price in Japanese Yen for such Shares as provided in this Section 7.5.2 against delivery by
AFSL of the following: (a) a sale agreement in form reasonably satisfactory to TPH-A containing among other things, a
representation and warranty of AFSL that it is, and TPH-A shall be, the beneficial owner of such Shares, with good title thereto,
free and clear of all liens and other encumbrances; (b) documentary evidence reasonably satisfactory to TPH-A of the transfer to it
of all of AFSL’s Shares and (c) resignations of all Directors, if any, on the Board appointed by AFSL. Notwithstanding the
remedies provided in this Section 7.5.2, TPH/TPH-A shall be entitled to all other remedies against FSL/AFSL available at law or
equity or under this Agreement.
7.6 Shareholder Calls Upon Bankruptcy After the Effective Date.
7.6.1 Calls by AFSL. After the Effective Date, in the event of (a) any distress, execution, sequestration or other
process being levied or enforced upon TPH or TPH-A; (b) the adjudication of TPH or TPH-A as a bankrupt or insolvent subject
to any insolvency or bankruptcy law; (c) the making by the TPH or TPH-A of an assignment for the benefit of creditors; (d) the
suspension of payments or a moratorium on payments to creditors; or (e) the appointment of a receiver or judicial manager or
trustee for the business or properties of TPH or TPH-A, then AFSL shall have the right to purchase the Shares of TPH-A in the
same manner and subject to the same terms and conditions as specified in Section 7.5.1.
- 18-Confidential
Execution Version
7.6.2 Calls by TPH-A. After the Effective Date, in the event of (a) any distress, execution, sequestration or other
process being levied or enforced upon FSL or AFSL; (b) the adjudication of FSL or AFSL as a bankrupt or insolvent subject to
any insolvency or bankruptcy law; (c) the making by the FSL or AFSL of an assignment for the benefit of creditors; (d) the
suspension of payments or a moratorium on payments to creditors; or (e) the appointment of a receiver or judicial manager or
trustee for the business or properties of FSL or AFSL, then TPH-A shall have the right to purchase the Shares of AFSL in the
same manner and subject to the same terms and conditions as specified in Section 7.5.2.
7.7 Survival of Provisions After the Effective Date. Sections 11.4, 11.6, 11.7, 11.14 and 11.15 shall specifically survive the
termination of this Agreement after the Effective Date. In case where this Agreement is terminated pursuant to Section 7.3.1(ii) and
(iii), Section 9.4, Article X, and Section 11.5 shall also specifically survive the termination of this Agreement after the Effective
Date.
7.8 Cooperation. During the term of the Joint Venture, each Party shall cooperate with the other and shall take all actions
necessary in order to consummate any sale and purchase of Shares, or dissolution and winding up of the Company.
ARTICLE VIII
TRANSFER RESTRICTIONS
8.1 Restrictions on Transfers. Except as set forth in this Article VIII, prior to the Option Starting Date, without the prior
written consent of the other Shareholders, no Shareholder may sell, assign, transfer, pledge, encumber or otherwise dispose of, by
operation of Law or otherwise, any of its Shares, or rights in or associated with such Shares, and any purported sale, assignment,
transfer, pledge, encumbrance or disposition by a Shareholder of its Shares in violation of this Article VIII shall be invalid and of no
force and effect.
8.2 Permissible Transfers. AFSL shall be entitled at any time to transfer all but not a portion of the Shares registered in its
name to FSL or any other entity Controlled by FSL, and TPH-A shall be entitled at any time to transfer all but not a portion of the
Shares registered in its name to TPH or any other entity Controlled by TPH; provided that FSL (or such other entity Controlled by
FSL) and TPH (or such other entity Controlled by TPH), as applicable, shall assume the obligations of AFSL and TPH-A, as
applicable, hereunder, as set forth in Article VI.
ARTICLE IX
PUT OPTION AND CALL OPTION
9.1 AFSL’s Right to Require the Purchase of the Shares by TPH or TPH-A.
9.1.1 As longs as AFSL and FSL are not in material and continuing breach of this Agreement or the Ancillary
Agreements, FSL or AFSL may trigger the option to sell the Put Shares to TPH-A or its designee (the “Put Option”) by providing
a written notice of the exercise of the Put Option (the “Put Exercise Notice”) simultaneously to the Company, TPH and TPH-A,
which notice states (i) such Party’s bona fide intention to exercise the Put Option, and (ii) the date on which such Party intends that
the Put Closing Date occur.
- 19-Confidential
Execution Version
9.1.2 FSL or AFSL may not exercise the Put Option for less than one hundred percent (100%) of the Shares held
by both FSL and AFSL or any Affiliate of FSL or AFSL, as the case may be.
9.1.3 FSL and AFSL may not exercise the Put Option prior to the Option Starting Date nor more than one
hundred eighty (180) days after the Option Starting Date.
9.1.4 The purchase price for the Put Shares (the “Put Option Price”) shall be the greater of (x) the amount in
Japanese Yen equal to the Net Book Value as of the most recently completed month end prior to the Put Closing Date, minus the
Net Book Value as of the most recently completed month end prior to the Effective Date, multiplied by the number of Put Shares,
or (y) one Japanese Yen (¥1).
9.1.5 Upon FSL’s or AFSL’s exercise of the Put Option, TPH-A shall be obliged to purchase or cause TPH-A’s
designees to purchase, and TPH shall be obliged to cause TPH-A or TPH-A’s designees to purchase, the Put Shares in
accordance with this Section 9.1. For the avoidance of doubt, the Put Option is the right of AFSL/FSL, and AFSL/FSL is not
obliged to exercise the Put Option.
9.1.6 Completion of the sale and purchase of the Put Shares pursuant to the exercise of the Put Option by
AFSL/FSL shall take place on the date specified in the Put Exercise Notice (which shall be a date after at least sixty (60) days
from the date of the Put Exercise Notice) (the “Put Closing Date”) and on which date:
(i) TPH-A shall, or shall cause its designees to, and TPH shall cause TPH-A or TPH-A’s designees to, pay
to AFSL the Put Option Price for the Put Shares by way of a bank transfer to the bank account as separately designated by
AFSL; and
(ii) in exchange for which, AFSL shall deliver to TPH-A or its designees duly executed a letter of request
to enter in the shareholder register of the Company the information that is required to be registered with regard to the Put Shares;
and
9.1.7 AFSL and TPH-A shall cause the Board to approve the share transfer of the Put Shares on or prior to the
Put Closing Date.
9.2 TPH-A’s Right to Require the Purchase of the Shares from FSL or AFSL.
9.2.1 As longs as TPH-A and TPH are not in material and continuing breach of this Agreement or the Ancillary
Agreements, TPH-A or TPH may trigger the option to purchase the Call Shares (the “Call Option”) by providing a written notice
of the exercise of the Call Option (the “Call Exercise Notice”) simultaneously to the Company, FSL and AFSL, which notice
states (i) such Party’s bona fide intention to exercise the Call Option, and (ii) the date on which such Party intends that the Call
Closing Date occur.
- 20-Confidential
Execution Version
9.2.2 TPH or TPH-A may not exercise the Call Option for less than one hundred percent (100%) of the Shares
held by both FSL and AFSL or any Affiliate of FSL or AFSL, as the case may be.
9.2.3 TPH-A and TPH may not exercise the Call Option prior to the Option Starting Date nor more than one
hundred eighty (180) days after the Option Starting Date.
9.2.4 The purchase price for the Call Shares (the “Call Option Price”) shall be the greater of (x) the amount in
Japanese Yen equal to the Net Book Value as of the most recently completed month end prior to the Call Closing Date, minus the
Net Book Value as of the most recently completed month end prior to the Effective Date, multiplied by the number of Call Shares,
or (y) one Japanese Yen (¥1).
9.2.5 Upon TPH-A’s or TPH’s exercise of the Call Option, AFSL/FSL shall be obliged to sell, or cause the holder
of the Call Shares to sell, the Call Shares to TPH-A or its designee in accordance with this Section 9.2. For the avoidance of
doubt, the Call Option is the right of TPH-A and TPH-A is not obliged to exercise the Call Option.
9.2.6 Completion of the sale and purchase of the Call Shares pursuant to the exercise of the Call Option by TPH-
A/TPH shall take place on the date specified in the Call Exercise Notice (which shall be a date after at least sixty (60) days from
the date of the Call Exercise Notice) (the “Call Closing Date”) and on which date:
(i) TPH-A shall, or shall cause its designees to, and TPH shall cause TPH-A or TPH-A’s designees to, pay
to AFSL the Call Option Price for the Call Shares by way of a bank transfer to the bank account as separately designated by
AFSL; and
(ii) in exchange for which, AFSL shall deliver to TPH-A or its designees duly executed a letter of request
to enter in the shareholder register of the Company the information that is required to be registered with regard to the Call Shares.
9.2.7 AFSL and TPH-A shall cause the Board to approve the share transfer of the Call Shares on or prior to the
Call Closing Date.
9.3 Conditions to Put Option or Call Option Closing. Each Party’s obligation to complete the Put Option or Call Option at
the Put Closing Date or Call Closing Date, as applicable, is subject to the fulfillment on or before such Put Closing Date or Call
Closing Date of each of the following conditions, unless waived in writing (where permissible) by the applicable party in such
closing:
9.3.1 TPH’s Stockholder Approval. The acquisition of the Option Shares (as defined in the SPA), shall have been
approved and adopted by the requisite stockholders of TPH in accordance with Delaware Law and TPH’s Certificate of
Incorporation and Bylaws, which approval shall have been obtained prior to the Effective Date, to the extent permissible under
Delaware Law.
9.3.2 No Order. No Governmental Authority or court of competent jurisdiction located or having jurisdiction over
any of the Parties in the United States shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation,
decree, judgment, injunction or other
- 21-Confidential
Execution Version
order, whether temporary, preliminary or permanent (each an “Order”) which is then in effect and has the effect of making the
closing of the Put Option or Call Option, as applicable, illegal or otherwise prohibiting consummation of the Put Option or Call
Option.
9.3.3 Governmental Approvals. All required authorizations, permits, consents, orders, actions or approvals of, or
declarations or filings with, or expirations or terminations of waiting periods imposed by, any Governmental Authority in the United
States, whether federal, state or local, that may be required, as well as any Governmental Authority in any other jurisdiction which
the parties mutually agree in good faith is required to be obtained, in each case, to consummate the Put Option or Call Option,
shall have been filed, occurred or been obtained, including that any required waiting period (and any extension thereof) under the
Hart-Scott-Rodino Act relating to the transactions contemplated by the Put Option or Call Option shall have expired or been
terminated early.
9.3.4 No Other Litigation. There shall not be pending any legal proceeding against or on behalf of any Party
preventing or prohibiting or seeking to prevent or prohibit the closing of the Put Option or the Call Option, as applicable.
9.4 Other Obligations.
9.4.1 After the Put Closing Date or Call Closing Date, as applicable, the Parties shall use their best efforts to
obtain and maintain all necessary approvals and registrations to effect this Agreement and all related agreements and documents;
provided, however, that the Parties shall not be required to change any provision of this Agreement or the SPA, and no Party shall
be required to divest any material business unless contemplated by this Agreement or the SPA.
9.4.2 For two (2) years after the Put Closing Date or Call Closing Date, as applicable, TPH shall make, and cause
TPH-A to make, every best effort to maintain the employees of the Company.
9.4.3 The Directors appointed by FSL or AFSL shall take whatever steps as are necessary to resign effective as of
the Put Closing Date or Call Closing Date, as applicable. Immediately after the Put Closing Date or Call Closing Date, as
applicable, TPH-A, TPH and the Company shall be prohibited from using the logo, trademark, corporate name and other
indications utilizing or showing the name of AFSL or its Affiliates (the “Fujitsu Logos”), and shall exclude the Fujitsu Logos from
any material of the Company. TPH/TPH-A shall change the corporate name of the Company.
ARTICLE X
TREATMENT OF EMPLOYEES
10.1 New Terms and Conditions for Employment. The terms and conditions of employment of any person employed by
the Company after the Put Closing Date or Call Closing Date, as applicable, shall be on terms and conditions satisfactory to the
Company, TPH and TPH-A.
10.2 Representations and Warranties Regarding Employment. FSL and AFSL represent and warrant to TPH and TPH-A,
as of the date hereof and as of the Put Closing Date or Call Closing Date, as applicable, that:
- 22-Confidential
Execution Version
10.2.1 FSL, AFSL and the Company do not have any pension liability in respect of the Company’s employees or
the Company’s pension plans;
10.2.2 there is no material labor dispute between FSL, AFSL or the Company, on the one hand, and the
Company’s employees, on the other hand or legal proceeding against FSL, AFSL or the Company related to the Company’s
employees; and
10.2.3 in the event of any liability to the Company’s employees to the extent related to their employment by the
Company, AFSL, FSL or AFSL/FSL’s Affiliates prior to the Put Closing Date or Call Closing Date, as applicable, AFSL and FSL
agree that such liability shall be borne solely by AFSL/FSL and not the Company or TPH-A/TPH.
ARTICLE XI
MISCELLANEOUS
11.1 No Partnership. None of the provisions of this Agreement shall be deemed to constitute a partnership between or
among the Parties and they shall have no authority to bind one another or the Company in any way.
11.2 Limitations on Parties’ Authority. None of the Parties shall have or hold itself out as having, any right, authority or
agency to act on behalf of any other Party or the Company in any capacity or in any manner except as specifically authorized in this
Agreement, and none of the Parties shall become liable to any other Parties or to any other Person by reason of any
representation, action or omission of any other Party contrary to this provision. Without limiting the generality of the foregoing, in
no event shall any Party have any liability or obligation for any debts, liabilities or contractual obligations of any other Party to any
other Person and each Party agrees to indemnify and hold harmless any other Party as to such debts, liabilities and contractual
obligations.
11.3 Indemnification.
11.3.1 Each Party agrees to indemnify, defend and hold harmless the Company and any other Party, its permitted
successors and assigns, from and against any and all losses, liabilities, claims, damages, costs and expenses including reasonable
legal fees and disbursements in connection therewith (collectively, “Claims”) asserted against or incurred by the Company or such
other Party which arise out of, result from, or may be payable by virtue of, any breach of any representation, warranty, covenant or
agreement made or obligation required to be performed by the indemnifying Party pursuant to this Agreement. Notwithstanding the
foregoing, claims related to the purchase of the Shares under the SPA shall be governed by the indemnification provisions set forth
in the SPA.
11.3.2 In the case of a third party Claim which is subject to indemnification under this Section 11.3, the
indemnifying Party shall be notified promptly in writing of the existence of any such Claim instituted at any time against or made
upon the indemnified Party or the Company by any third party, and shall be given the opportunity to defend the same with counsel
of its choice, in which defense the indemnified Party or the Company, as the case may be, shall cooperate. If the indemnifying
Party, after notification, fails promptly to undertake such defense, then the indemnified Party, or the Company, as the case may be,
may undertake the defense with counsel of its choice, in which case the indemnifying Party shall bear the cost of such defense,
including reasonable legal
- 23-Confidential
Execution Version
fees and disbursements in connection therewith, and shall pay the amount of any judgment or settlement.
11.4 Confidentiality.
11.4.1 All information, whether written or oral, relating to the Company, the Parties or their Affiliates, or their
respective businesses or operations, which includes but is not limited to information obtained as a proprietary right (“Confidential
Information”), disclosed by any Party (the “ Disclosing Party”) to any other Party (or its directors, officers, employees or
representatives) shall be kept strictly secret and confidential and shall not be disclosed to any Person except to the extent that any
such disclosure is necessary in connection with the performance of this Agreement, and except to the extent that (i) such
information is known to such other Parties when received or is or subsequently becomes lawfully obtained from other sources; (ii)
the duty as to confidentiality and non-use is waived in writing by the Disclosing Party; or (iii) disclosure of such information is
required by applicable Laws or is validly ordered by a Governmental Authority. The Parties further agree that they shall not use,
nor permit their respective Affiliates to use, any Confidential Information for any purpose whatsoever except in the manner
expressly provided or contemplated in this Agreement. Notwithstanding the foregoing, the treatment of any Confidential
Information disclosed pursuant to the Amended Process Development Agreement shall be governed solely by the Amended
Process Development Agreement.
11.4.2 Each of the Parties agrees to take, and to cause its respective Affiliates and the Company to take,
reasonably adequate security and precautionary measures to effect compliance with this Section 11.4 by directors, officers,
employees and agents of each of the Parties, their respective Affiliates and the Company who are given access to Confidential
Information.
11.4.3 Each of the Parties hereby acknowledges that the Disclosing Party would be irreparably harmed by a
breach of this Section 11.4 and it would not be possible to estimate damages resulting from such a breach. The Parties agree that
the Disclosing Party shall be entitled to injunctive relief to prevent a breach or continued breach of this Section 11.4, or any part of
it, and to secure the enforcement of this Section 11.4 and shall be entitled to recover from the other Parties reasonable legal fees
and all costs and expenses incurred in connection with such an action
11.5 Access to Company Information After the Put Closing Date or the Call Closing Date. In case it is necessary for
AFSL/FSL to access to any materials or information of the Company prepared or otherwise made on or before the Put Closing
Date or the Call Closing Date due to requirement by any Governmental Authority or any third party on or after the Put Closing
Date or the Call Closing Date, then, TPH/TPH-A shall fully cooperate, and shall cause the Company to fully cooperate, with
AFSL/FSL so that AFSL/FSL can access such materials or information.
11.6 Expenses. Except as otherwise expressly provided herein, Each Party shall pay their own expenses incurred in
connection with the execution of this Agreement and their respective performance of the obligations provided for herein, including
the expenses incurred by Directors nominated by the respective Shareholders in connection with attendance at meetings of the
Board.
- 24-Confidential
Execution Version
11.7 Notices. All notice, waivers and other communications required or permitted hereunder shall be in writing and shall be
deemed to have been duly given when delivered by hand or one (1) day after being sent by e-mail (with reasonable evidence of
transmission) and followed by registered mail or an internationally recognized overnight courier service if those to be notified,
including Shareholders, Directors and auditors, reside outside Japan, addressed to the Party to whom the notice is intended to be
given at the addresses specified below:
(a) If to AFSL:
No.4 Kogyo Danchi, Monden-Machi, Aizu Wakamatsu, Fukushima,
Japan
Aizu Fujitsu Semiconductor Limited
Attn: President and Representative Director
(b) If to FSL:
Shin-Yokohama Chuo Building, 2-100-45, Shin-Yokohama,
Kohoku-Ku, Yokohama, Kanagawa, Japan
Fujitsu Semiconductor Limited
Attn: Head of Corporate Management Unit
(c) If to TPH:
75 Castilian Drive
Goleta, CA 93117, U.S.A.
Transphorm, Inc.
Attn: Chief Executive Officer
With a copy, which shall not constitute notice, to each of:
Wilson Sonsini Goodrich & Rosati, P.C.
650 Page Mill Road
Palo Alto, CA 94304-1050, U.S.A.
Attn: Mark Bertelsen and Julia Reigel
and
Mori Hamada & Matsumoto
Marunouchi Park Building,
2-6-1 Marunouchi, Chiyoda-ku,
Tokyo 100-8222, Japan
Attn: Masujima Masakazu
or to such other address or addresses as any such Party may from time to time designate by written notice.
Notwithstanding the foregoing, the Parties acknowledge and agree that notice hereunder may be provided by e-mail, but such
notice shall not be deemed effective unless and until the Party to whom such notice was delivered confirms, in writing, receipt of
such notice.
- 25-Confidential
Execution Version
11.8 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties and their
permitted successors and assigns. Notwithstanding the foregoing, no rights, obligations or liabilities hereunder shall be assignable
by a Party without prior written consent of all of the other Parties; provided, however, that a Party shall not unreasonably withhold
its consent to the assignment of rights and obligations by the other Parties to its Affiliate if that Affiliate’s performance has been
guaranteed satisfactorily in form and substance by the assigning Party.
11.9 Waiver. No action taken pursuant to this Agreement shall be deemed to constitute a waiver of compliance with any
representation, warranty, covenant or agreement contained in this Agreement and shall not operate or be construed as a waiver of
a similar or dissimilar nature. A Party may by written notice (a) extend the time for performance of any of the obligations or other
actions of any other Parties under this Agreement, (b) waive any inaccuracies in the representations or warranties of any other
shareholder contained in this Agreement, or (c) waive or modify performance of any of the covenants or obligations of any other
Parties under this Agreement.
11.10 Announcements. FSL, AFSL TPH and TPH-A shall consult and confer with each other prior to making any public
announcement concerning any of the transactions contemplated in this Agreement.
11.11 Entire Agreement. This Agreement supersedes any previous agreement, whether written or oral, that may have been
made or entered into by and among the Parties or any of them or their representatives relating to the matters contemplated hereby.
This Agreement constitutes the entire agreement by and among the Parties with respect to the subject matter hereof.
11.12 Amendments. This Agreement may be amended or supplemented only by written agreement signed by the Parties.
11.13 Limitations on Rights of Third Persons. Nothing expressed or implied in this Agreement is intended or shall be
construed to confer upon or give any Person other than the Parties any rights or remedies under or by reason of this Agreement or
any transaction contemplated hereby, except the permitted assigns of the Parties.
11.14 Governing Law; Language. The English text of this Agreement shall control any interpretation of its provisions, and
this Agreement and the legal relations among the Parties and the Company shall in all respects be interpreted, construed and
governed by and in accordance with the laws of Japan.
11.15 Resolution of Disputes.
11.15.1 The Parties shall attempt in good faith to resolve any and all disputes arising out of or relating to this
Agreement through friendly consultations. If the Parties cannot resolve the dispute through friendly consultation, the provisions of
Section 11.15.2 to Section 11.15.4 shall apply with respect to such dispute.
11.15.2 Any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination or
invalidity hereof, shall be finally resolved exclusively by arbitration administered by the Hong Kong International Arbitration Centre
(“HKIAC”). The arbitration shall be conducted in accordance with the HKIAC Administered Arbitration Rules in effect at the
time of the arbitration, except as they may be modified by mutual agreement of the
- 26-Confidential
Execution Version
Parties. The seat of the arbitration shall be Hong Kong. The arbitration shall be conducted in the English language.
11.15.3 The arbitration shall be conducted by three (3) arbitrators. The Party initiating arbitration (the “Claimant”)
shall appoint an arbitrator in its request for arbitration (the “Request”). The other Party to the arbitration (the “Respondent”)
shall appoint an arbitrator within thirty (30) days of receipt of the Request and shall notify Claimant of such appointment in writing.
The first two (2) arbitrators appointed in accordance with this provision shall appoint a third arbitrator, who shall act as chair of the
tribunal. The arbitral award shall be in writing, state the reasons for the award, and be final and binding on the Parties. The award
may include an award of costs, including, without limitation, reasonable attorneys’ fees and disbursements. In addition to monetary
damages, the arbitral tribunal shall be empowered to award equitable relief.
11.15.4 The Parties agree that the arbitration shall be kept confidential, and that the costs of arbitration shall be
borne by the losing Party unless otherwise determined by the arbitration award. All payments made pursuant to the arbitration
decision or award and any judgment entered thereon shall be made in United States dollars, free from any deduction, offset or
withholding for taxes.
11.15.5 Notwithstanding this Section 11.15 or any other provision to the contrary in this Agreement, no Party shall
be obligated to follow the foregoing arbitration procedures where such Party intends to apply to any court of competent
jurisdiction for an interim injunction or similar equitable relief against any other Party, provided there is no unreasonable delay in the
prosecution of that application.
11.15.6 When any dispute occurs and when any dispute is under litigation or arbitration, except for the matters in
dispute, the Parties shall continue to fulfill their respective obligations and shall be entitled to exercise their rights under this
Agreement. However, this provision shall not apply to rights or obligations extinguished in connection with a valid termination of
this Agreement.
11.15.7 Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. Except
as set forth above, each of the Parties hereby irrevocably waives any and all right to trial by jury in any legal proceeding arising out
of or relating to this Agreement or the transactions contemplated hereby.
11.16 Severability. Each section and subsection of this Agreement constitutes a separate and distinct undertaking or
provision hereof. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and
valid under applicable Laws. In the event that any provision of this Agreement shall finally be determined by a competent court or
tribunal to be unlawful or unenforceable, such provision shall be deemed severed from this Agreement, but every other provision of
this Agreement shall remain in full force and effect, and in substitution for any such provision held unlawful or unenforceable, there
shall be substituted a provision of similar import reflecting the original intent of the Parties to the extent permissible under applicable
Laws.
- 27-Confidential
Execution Version
11.17 Execution in Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same agreement. The signature of each Party may be
evidenced by an electronic (e.g., pdf) copy of this Agreement bearing such signature and transmitted to the other Parties. Such
signature shall be valid and binding as if an original executed copy of this Agreement has been delivered.
11.18 Titles and Headings. Titles and headings to sections herein are inserted for convenience of reference only and are not
intended to be a part of or to affect the meaning or interpretation of this Agreement.
11.19 Counsel only to TPH and TPH-A. Wilson Sonsini Goodrich & Rosati, P.C. (“WSGR”) and Mori Hamada &
Matsumoto (“MHM”) are counsel solely to TPH-A and TPH. The other Parties to the Agreement acknowledge that they are not
relying on WSGR or MHM for advice in connection with the matters related to this Agreement and the transactions contemplated
hereby, and that they have had the opportunity consult counsel of their own choosing and have elected not to do so.
[Signature pages follow]
- 28-Confidential
Execution Version
IN WITNESS WHEREOF, the Parties have caused their respective duly authorized officers to execute this Agreement as
of the day and year first above written.
Aizu Fujitsu Semiconductor Limited
By: /s/ Atsuo Shimizu
Name: Atsuo Shimizu
Title: President and Representative Director
Fujitsu Semiconductor Limited
By: /s/ Kagemasa Magaribuchi
Name: Kagemasa Magaribuchi
Title: President and Representative Director
Transphorm, Inc.
By: /s/ Mario Rivas
Name: Mario Rivas
Title: Chief Executive Officer
Signature page to the Joint Venture AgreementConfidential
Execution Version
EXHIBIT A
FORM OF JOINDER AGREEMENT
This JOINDER (this “Joinder”), dated as of [● ●], 2017, is delivered pursuant to (a) Section 6.3 of that certain Joint
Venture Agreement dated as of May 23, 2017, by and among Aizu Fujitsu Semiconductor Limited (the “ Seller”), Fujitsu
Semiconductor Limited (“FSL”) and Transphorm, Inc. (“TPH”) (as such agreement may be amended, supplemented or modified
from time to time in accordance with its terms, the “Joint Venture Agreement”) and (b) Section 5.3.2 of that certain Shares
Purchase Agreement dated as of May 23, 2017, by and among the Seller, FSL and TPH (as such agreement may be amended,
supplemented or modified from time to time in accordance with its terms, the “Shares Purchase Agreement”). The undersigned,
[●], a Japanese corporation (“TPH-A”) hereby agrees that this Joinder may be attached to each of the Joint Venture Agreement
and the Shares Purchase Agreement.
1. Joinder to Joint Venture Agreement. TPH-A, by executing and delivering this Joinder, hereby becomes a party to the
Joint Venture Agreement in the capacity of “TPH-A” as defined therein in accordance with Section 6.3 thereof, and agrees to be
bound by all of the terms and conditions thereof (including without limitation all of the representations and warranties and covenants
of TPH-A therein to be made or performed, as applicable, from and after the date hereof), in each case as if the undersigned were
a direct signatory thereto.
2. Joinder to Shares Purchase Agreement. TPH-A, by executing and delivering this Joinder, hereby becomes a party to the
Shares Purchase Agreement in the capacity of the “Purchaser” as defined therein in accordance with Section 5.3.2 thereof, and
agrees to be bound by all of the terms and conditions thereof (including without limitation all of the representations and warranties
and covenants of the Purchaser therein to be made or performed, as applicable, from and after the date hereof), in each case as if
the undersigned were a direct signatory thereto.
3. Representations and Warranties. TPH-A hereby represents and warrants that:
a. TPH-A has all requisite power and authority to enter into this Joinder and to perform its covenants and
obligations hereunder; and
b. The execution and delivery of this Joinder and the performance by TPH-A of its covenants and obligations
hereunder have been duly authorized by all necessary action on the part of TPH-A and no further action is required on the part of
TPH-A to authorize this Joinder or the performance by TPH-A of its covenants and obligations hereunder.
[SIGNATURE PAGE FOLLOWS]
-Exhibit A-1-Confidential
Execution Version
IN WITNESS WHEREOF, the undersigned has caused this Joinder to be duly executed and delivered by its officer
thereunto duly authorized as of [● ●], 2017.
[●], a Japanese corporation
By:
Name:
Title:
-Exhibit A-2-Confidential
Execution Version
APPENDIX 1
Key Employees
Department Employee
ID
Name Date of hiring Title
[***] [***] [***]
[***] [***] [***]
[***] [***] [***]
[***] [***] [***]
[***] [***] [***]
[***] [***] [***]
[***] [***] [***]
[***] [***] [***] Manager
[***] [***] [***]
[***] [***] [***]
[***] [***] [***]
Name Current Employment
[***] Seconded to TPH-J
[***] Seconded to TPH-J
[***] TPH-J
[***] Seconded to TPH-J
[***] Seconded to TPH-J
[***] Seconded to TPH-J
[***] TPH-J
[***] Seconded to TPH-J
[***] Seconded to TPH-J
[***] Seconded to TPH-J
[***] Seconded to TPH-J
[***] Seconded to TPH-J
-A1-1-Confidential
Execution Version
APPENDIX 2
GaN Equipment
No Asset ID Tool name Tool ID Application
1 I12026102439 [***] [***] [***]
2 I12016100800 [***] [***] [***]
3 I12016100427 [***] [***] [***]
4 I12016100801 [***] [***] [***]
5 I14086159094 [***] [***] [***]
6 I14086159092 [***] [***] [***]
Invoice Amount
Item Specification Last Invoice Month 2017/06 2017/07 2017/08 2017/09 2017/10 2017/11 2017/12 2018/01 2018/02 2018/03 2018/04 2018/5 2018/6 2018/7 2018/8 2018/9 2018/10 2018/11 2018/12 2019/01 2019/02 2019/03 2019/04
[***] [***] 201804 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201802 [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201803 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201804 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201807 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201802 [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201802 [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201802 [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201804 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201804 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201804 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201802 [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201802 [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201804 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201804 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201803 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201803 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201802 [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201803 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201803 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201803 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201803 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201810 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201812 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201902 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201904 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201904 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201904 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201904 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201904 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201904 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201904 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]
[***] [***] 201711 [***] [***] [***] [***] [***] [***]
-A2-1-Exhibit 10.28
[*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if
publicly disclosed.
JOINT VENTURE AGREEMENT
BETWEEN
KIROMIC BIOPHARMA Inc., a Delaware Company, Fannin South Professional Building, 7707, Fannin St. Suite 140, Houston TX 77054 USA, in
person of the Legal Representative of the Chief Executive Officer dr. Prof. Maurizio Chiriva Internati, PhD
AND
MOLIPHARMA S.R.L. an Italian Company stated in Campobasso, Via del Castello n. 3, FISCAL CODE AND VAT NUMBER: 01655870705 in person
of the Legal Representative Avv. Giovanni Meliadò;
each a Party and, together, the Parties.
WHEREAS
A. Kiromic is a Company active in the fields of:
Research and development, in the field of immunotherapy, immuno-oncology, infectious diseases, cardiovascular disease, auto immune diseases,
inflammatory diseases and gene editing that develops highly effective and safe immuno-therapies to address and defeat different types of cancer
and serious diseases and unmet medical needs;
Research and development of Artificial Intelligence technologies and a multi-purpose computational platform capable of identifying new cancer
immunological targets for T and B cells.
B. Molipharma s.r.l. is a spin-off of the Università Cattolica del Sacro Cuore and active in the fields of:
research, development, production and marketing, also through licensing, of new products, synthetic drugs and applications, new technologies
and innovative process and product applications in the pharmaceutical, pharmacological, clinical and therapeutic fields, also
-1-protectable under the regulations for intellectual property, with the consequent possibility of exploitation and industrial exploitation;
analysis, research, reports, pre-clinical and clinical studies, consultancy, technical development activities, on its own behalf or for third parties, in
the field of genetic, muscular, immune, haematological, oncological, gynecological, urological pathologies
C. The Parties wish to collaborate for the common purposes about the research and development of at least two clinical trial programs:
a. Pre-clinical validation and clinical trial development of several targets in different clinical indications, and particularly in Ovarian
Cancer
b. Pre-clinical validation and clinical trial development of countermeasures against Covid19 Sars CoV2 outbreak, including oral vaccines,
as well as therapeutic and diagnostic solutions.
NOW, THEREFORE, the Parties agree as follows:
1. SCOPE AND AREAS OF THE JV
The Parties wish to collaborate to the Joint Venture (“JV”), with their respective efforts and possibilities of support, assistance, advice, co-operation,  and
resources for the common purposes about the research and development of the pre-clinical and clinical trial programs mentioned above.
2. PARTIES OBLIGATIONS
Notwithstanding as referred to the point 1, the Parties wish to collaborate to the JV in the respective R&D areas; for the firsts two clinical trial programs,
they undertake to collaborate as follow:
Topic 1. Clinical trial program in Oncology.
With regard to the JV between the Parties about the Clinical trial program in Oncology, the respective obligations are regulated below:
- Molipharma, through a separate agreement with UCSC, undertakes to provide the tissue samples and parts of tumors;
- Molipharma undertakes to make UCSC the site for clinical trials and in particular Molipharma undertakes to make UCSC the main site for
clinical trials in cancer using
-2-the specific isoforms CAR (Chimeric Antigen Receptor) and/or check inhibitor technology, Exhibit A
- Kiromic is committed to bear all costs necessary for R&D, including all clinical development costs, according to the terms and conditions
set out in point n. 3;
Topic 2. Clinical trial program in Covid19 Sars CoV2 Vaccine
With regard to the JV between the Parties about the clinical trial program in Covid19 Sars CoV2 Vaccine, the respective obligations are regulated below:
- Kiromic is committed to sharing patents and know-how in relation to the following products which will be licensed to the JV exclusively for
the application in the specific and limited field of sars-cov-2  threat and relative disease COVID-19:
(i) VAPAs-Viral Antigen Proteins Associated © (Kiromic-2020) derived from Diamonds AI - Artificial Intelligence Platform for Discovery
and Prediction Antigen Protein
(ii) Platform of DC Vaccines (dendritic cell vaccine) - for therapeutic purposes - nominated BSK 01;
(iii) Oral Delivery Platform for Prophylactic Vaccine - accompanying immuno-boosting therapy - therapeutic vaccine administration -
nominated BSK02
(iv) Other patents eventually applicable in the specific field.
- Molipharma provides skills, competencies, relationships, financial resources and means for development;
- Molipharma is committed to ensuring that the development and testing of the vaccine and any associated clinical trial studies are carried
out through the specialized structures of the UCSC.
- Molipharma provides skills, competencies, relationships, financial resources and means for development;
- Molipharma is committed to ensuring that the development and testing of the vaccine and any associated clinical trial studies are carried
out through the specialized structures of the UCSC.
- Molipharma undertakes to make UCSC the site for clinical trials and in particular
- Molipharma, through a separate agreement with UCSC, undertakes to provide the biological samples necessary to carry out the Research
and Development, such as, but not limited, blood, serum, saliva, clinical data, tissues samples of living and dead patients etc ;
- Molipharma is committed to bear all costs necessary for R&D, including all clinical development costs, according to the terms and
conditions set out in point n. 3;
3. STEERING COMMITTEE AND TECHNICAL CO-ORDINATION COMMITTEE
The Parties agree to establish a “Steering Committee”, which will remain in force for the entire period of the JV, composed of two members for each
Company [e.g. Americo Cicchetti - To Be Nominated and Maurizio Chiriva – Gianluca Rotino], with the task of identifying the strategic objectives of the
collaboration and providing general guidelines.
The Steering Committee shall appoint, within 30 days of the signature of this JV, a Technical Committee composed of one representative of each of the
Parties in relation to each specific
-3-clinical trial program, which shall have the function of coordinating the technical and administrative activities to be undertaken in the framework of this JV.
The tasks assigned to the Technical Committee are to:
a. propose any new project to be developed to the Steering Committee;
b. define the specific guidelines for each project and check the execution processes and timelines implemented under this JV;
c. check at least quarterly the progress of the clinical development programs, the correct implementation of the commitments undertaken,
including the economic ones; in the event of failure by one of the Parties to comply with these commitments, the Technical Committee shall
promptly inform the Steering Committee;
d. report, every six months, to the Steering Committee on the activities carried out and the results achieved under the Agreement;
e. propose to the Steering Committee any changes in the projects referred to in point 2 and/or any changes in the economic commitments
made and their utilization.
The parties undertake, within 30 days from the signing of this JV, to grant a specific written and notarial mandate, which gives Molipharma the power to
represent the JV vis-à-vis third parties for the performance of ordinary and extraordinary acts deemed necessary for the quickest and most profitable
achievement of the objectives set forth in point 2, including the right to enter into partnership and/or collaboration contracts with external entities.
4. JV FUND
Kiromic undertakes to financially support the entire research program in oncology;
By way of example, Kiromic undertakes to finance the following items:
a. The expenses for the supply of equipment and materials, as well as those related to their ordinary and extraordinary maintenance, necessary
for the development of the program;
b. Medical and subsistence expenses in favor of the patients who will be selected for the clinical trials and any expenses necessary for third
party vendors (such as Contract Research Organizations, central labs, couriers, etc…) necessary for planning and executing such clinical
trials;
-4-c. Funding of scholarships and/or research grants for the staff who will be assigned to the research and development of the projects referred
to in point 2;
d. Funding of educational or training initiatives.
Subsequent contributions will be provided by Kiromic to the common fund upon presentation of individual purchase orders and/or proofs of expenditure
—which will be paid for each time starting upon the successful IPO (Initial Public Offering) of the Kiromic’s common shares.
Molipharma undertakes to financially support the entire research program against sars-cov-2.
By way of example, Molipharma undertakes to finance the following items, either directly or indirectly through research grants or other non-diluting
funds, awarded by European and/or Italian Institutions:
a. The expenses for the supply of equipment and materials, as well as those related to their ordinary and extraordinary maintenance, necessary
for the development of the program;
b. Medical and subsistence expenses in favour of the patients who will be selected for the clinical trials and any expenses necessary for third
party vendors (such as Contract Research Organizations, central labs, couriers, etc…) necessary for planning and executing such clinical
trials;
c. Funding of scholarships and/or research grants for the staff who will be assigned to the research and development of the projects referred
to in point 2;
d. Funding of educational or training initiatives.
Subsequent contributions will be provided by Molipharma to the common fund upon presentation of individual purchase orders and/or proofs of
expenditure - which will be paid for each time.
5. STAFF ACCESS
Molipharma allows Kiromic’s staff in charge of the above research programs to have access to its own structures, identified from time to time, as well as
the possible use of its own equipment, in compliance with the law provisions and the regulations therein applied, in compliance and observance of the
protection, safety and health standards therein applied.
Alternatively, Kiromic allows Molipharma’ staff in charge of the above programs to have access to its own structures and to its laboratory equipment,
identified from time to time, in compliance
-5-with the law provisions and the regulations therein applied, in compliance and observance of the protection, safety and health standards therein applied.
The staff of each of the Parties to this JV who, by this Agreement, have access to the structures and equipment of the other company, shall be liable for
any damage caused to such equipment and to third parties.
The Parties shall provide civil liability insurance cover to their own personnel with respect to accidents and damages charged to them.
6. INTELLECTUAL PROPERTY RIGHTS AND PROHIBITION OF TRANSFER TO THIRD PARTIES
The Parties undertake to promptly notify each other about the achievement of the Scope, as mentioned in point 2 (“the Results”) , that may be subject to
Industrial and Intellectual Property Rights, within 30 days from the achievement of such Results and to cooperate in the evaluation of the existence of the
necessary requirements for the patenting/registration of such Results.
The Industrial Property Rights on the Results, as well as the Intellectual Property Rights realized in the research activities covered by this JV, are due
jointly to the parties in equal shares (50% for each Party), without prejudice to the possibility of agreeing in writing, during the course of every specific
activity, about the modification of the respective shares of co-ownership,  based upon the actual contribution of each of the Parties to the research
activities, and also without prejudice to the recognition of the intellectual rights due to each inventor pursuant to current legislation.
The parties will agree, by separate agreement, on the specific discipline relating to the management of rights in co-ownership;  it is agreed that
Molipharma may always use the Results for teaching and research purposes.
If one of the Parties has no interest in applying for a patent, it will inform the other Party within 30 days from the communication of the Results referred to
in paragraph 1. In this case the Party concerned shall have the right to proceed with the submission of the application on the Results at its own expense
and in co-ownership  with the other Party, subject to written notice. The Party which is not interested in the application shall undertake to transfer its own
share of ownership to the other Party, free of charge once it has obtained the patent title.
-6-Each Party is the owner of the Industrial and Intellectual Property Rights relating to its own:
a. “Background”: All knowledge, information and intangible assets protected under national Law System and international intellectual and
industrial property laws and regulations, created or otherwise obtained by a Party prior to the begin of the activity covered by this
Agreement.
b. “Sideground”: All knowledge, information and intangible property protected under national Law System and international intellectual and
industrial property laws and regulations made or otherwise obtained by a Party during the term of this Agreement but not in the execution
of this Agreement.
Notwithstanding the foregoing, the Parties shall grant each other, free of charge, a non-exclusive right to use their respective Backgrounds in connection
with the activities which will be carried out by this JV and by reason of their execution. This right is granted for the duration of the Agreement only, with
the express denial of sublicensing or transferring it to any third party for any reason whatsoever.
The Sideground of each Party may not be used by the other Party without the express written authorization of the owner.
The sale, licensing or any other type of agreement providing for the transfer, even temporary, to third parties of intellectual and industrial property rights
deriving from the research programs referred to in point 2 is excluded, unless there is prior agreement between the Parties.
Kiromic assigns to Molipharma all the rights of publication of the research, unless they are considered confidential for patenting. To this purpose, before
each publication, Molipharma will send in advance the text of the publication to Kiromic for approval. The consent of Kiromic will be tacitly granted after
30 days from receipt of the request for authorization of disclosure.
The same procedure indicated in the previous paragraph will be also applied to Kiromic in case it wants to perform a publication on the research.
7. ECONOMIC RIGHTS
The commercial rights arising from the research programs referred to in point 2 are divided as follows:
Oncology
All economics rights are solely owned by Kiromic Biopharma.
Kiromic will grant to Molipharma the follows royalties:
- *% of the realized turnover by the marketing of Ovarian Cancer research results in Italy;
-7-- *% of the realized turnover by the marketing of Ovarian Cancer research results in Europe.
Sars-cov-2
- The economic rights for Europa will be an exclusive ownership of Molipharma
- The economic rights in the U.S. will be an exclusive ownership of Kiromic.
- For the rest of the world, the economic rights will be divided as follows: *% Kiromic; *% Molipharma.
8. DURATION
This JV Agreement shall become effective on the signing date and shall have a duration of * years, extendable for a further * years, unless notice of non-
renewal is sent one year before the natural expiry date.
This JV shall automatically cease to be effective on the date when the JV is wound-up  or is the target of any kind of insolvency procedure.
Termination of this JV Agreement shall not relieve the Parties of their obligations due at the time of such termination, nor shall such termination prejudice
any claim of either Party accrued, or to accrue, on account of any default or breach by the other Party.
9. WITHDRAWAL AND RESOLUTION
The Parties may withdraw from this JV only for serious and justified reasons or by mutual consent. The withdrawal must be exercised by written notice, to
be sent to the other Party by certified letter or PEC, with minimum notice of 30 days.
Withdrawal or termination by mutual consent shall only have effect for the future and shall not affect the part of the Agreement already executed.
In case of withdrawal according to the previous paragraph, Kiromic is obliged to cover Molipharma for the expenses incurred and for those committed,
related to the research programs being developed, until receipt of the notice of withdrawal.
-8-Pursuant to art. 1456 of the Italian Civil Code, this JV shall be terminated by right in the following cases:
a. Breach of confidentiality obligations;
b. Unilateral and unagreed variation of the Scope of the JV;
c. Failure of each Party to comply with its obligations, including the economic commitments.
The Party concerned must communicate by registered letter with return receipt, or PEC, its intention to avail itself of the termination clause.
In the event of termination of the Agreement pursuant to this clause or, in any case, to termination due to Kiromic’s default, the same is required; in
addition, Kiromic undertakes to the reimbursement of expenses incurred and/or committed by Molipharma, and agrees to recognize financially the
additional damage suffered by Molipharma by such a default.
Upon termination of the contract, the agreement set forth in clause 5 (“Intellectual property rights and prohibition of transfer to third parties”) and clause
6 (“Economic rights”) will remain into force.
10. TERMINATION
Each Parties shall have the right to terminate its obligations, if one of the following events occurs: the Company (i) applies for or consents to the
appointment of a receiver, trustee, custodian or liquidator of itself or substantially all of its property, (ii) becomes subject to the appointment of a receiver,
trustee, custodian or liquidator of itself or substantially all of its property, (iii) makes an assignment for the benefit of creditors, (iv) institutes any
proceedings under or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, or files a
petition or answer seeking reorganization or an arrangement with creditors to take advantage of any insolvency law, or files an answer admitting the
material allegations of a bankruptcy, reorganization or insolvency petition filed against it, or (v) becomes subject to any involuntary proceedings under
the state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, when proceeding is not
dismissed within thirty (30) days of filing, or have an order for relief entered against it in any proceedings under Bankruptcy Code.
-9-11. SENSITIVE INFORMATION
The Parties shall keep confidential any information exchanged between them in connection with the negotiation, execution and performance of this JV
Agreement; it is agreed that these confidentiality obligations shall not apply with respect to any information which:
(a) becomes generally available to the public other than as a result of an unauthorised disclosure by a Party,
(b) was available to a Party prior to its disclosure by the other Party,
(c) is disclosed pursuant to a requirement of a court or other public authority or for the purpose of enforcing the rights and obligations set
forth in this Agreement.
12. GENERAL PROVISIONS
All notices, demands, requests or other communications which may be or are required to be given, served or sent by any Party to any other Party
pursuant to this JV Agreement shall be in writing and shall be hand delivered, sent by DHL (or by comparable international air courier) or mailed by first-
class, registered or certified mail, return receipt requested, postage prepaid, or transmitted by telecopy, and shall be addressed as follows:
(i) If to KIROMIC:
To the attention of the managing director
Telephone
(ii) if to MOLIPHARMA:
To the attention of Mr. Giovanni Meliadò
Telephone
Each Party may designate by written notice an address to which any notice, demand, request or communication may thereafter be so given, served
or sent.
Each of the communications mentioned herein, given in the way described herein, shall be deemed sufficiently given, served, sent, received or
delivered for all purposes at the time it is received, if made by hand delivery, or at the time indicate in the return receipt if made
-10-by mail or courier, or at the time indicated in the answer-back of the telefax machine of the receiving Party in case it is made by telefax.
No delay or failure on the part of any Party hereto in exercising any right, power or privilege under this JV Agreement or under any other
documents in connection with or pursuant to this Agreement shall impair any such right, power or privilege or be construed as a waiver of any
default or any acquiescence therein. No single or partial exercise of any such right, power or privilege shall preclude the further exercise of such
right, power or privilege, or the exercise of any other right, power or privilege. No waiver shall be valid against any Party hereto unless made in
writing and signed by the Party against whom enforcement of such waiver is sought and then only to the extent expressly specified therein.
If any part of any provision of this JV Agreement or of any other document given pursuant to or in connection with this JV Agreement shall be
invalid or unenforceable in any respect, such part shall be ineffective to the extent of such invalidity or unenforceability only, without in any way
affecting the remaining parts of such provision or the remaining provisions. The void provision shall be substituted by a valid provision, the nature
and economic consideration of which comes as close as possible to the void provision. In the event that matters relevant to the subject matter of
this JV Agreement are not addressed herein, the Parties shall negotiate in good faith to agree a provision or provisions which, given the nature and
economic considerations of the JV Agreement and related agreements, the Parties would have agreed upon had they considered the matter at the
time of the execution of this JV Agreement. If the invalidity or unenforceability of any provision hereof is due to the excessive scope of such
provision, such provision shall be deemed valid and enforceable to the greatest extent permitted by applicable law.
This JV Agreement cannot be assigned by a Party, also as a result of the transfer of a business as a going concern, of a merger, of a de-merger or of
a spin-off, without the prior written consent of the other Party. Subject to the above, this JV Agreement shall be binding upon and shall inure to the
benefit of the Parties hereto and their respective successors, heirs, executors, administrators, legal representatives and assigns.
Each of the Parties hereby agrees to take or cause to be taken such further actions, to make and receive or cause to be made and received any legal
declarations, execute, deliver and file or cause to be executed, delivered and filed such further documents, and will obtain
-11-such consents, as may be necessary or as may be reasonably requested in order to fully effectuate the purposes, terms and conditions of this JV
Agreement mentioned. Without limiting the generality of the foregoing, in case the Commission of the European Union, or any other competent
regulatory authority, both national and supranational, makes the clearance of any of the transactions contemplated by this JV Agreement
conditional upon changes or additions to the regulation herein set forth, the Parties shall negotiate in good faith all those amendments that are
necessary or proper to comply with such requests by keeping unaltered the spirit of this JV Agreement and the balance of interests herein
reflected.
Each of the Parties hereto guarantees to the other Party that it has not engaged any broker, finder or agent in connection with the transactions
contemplated by this JV Agreement and has not incurred (and will not incur) any unpaid liability to any broker, finder or agent for any brokerage
fees, finders’ fees or commissions, with respect to the transactions contemplated by this JV Agreement. Each Party agrees to indemnify, defend and
hold harmless the other Party from and against any and all claims asserted against it for any such fees or commissions by any persons purporting
to act or to have acted for or on behalf of the indemnifying Party.
Each Party hereto shall pay its own expenses incident to this JV Agreement and the transactions contemplated hereunder, including all legal and
accounting fees and disbursements.
13. CONFIDENTIALITY
In this Clause, Confidential Information means (without limitation) the existence and contents of the Documents and the existence and contents of
any agreement or arrangement entered into pursuant to any of the Documents and information relating to:
- the customers, suppliers, business, assets or affairs (including financial information) of any Party,
including information relating to the marketing of any products or services (for example, customer names and lists and any other details of
customers, sales targets, sales statistics, market share statistics, prices, market research reports and surveys and advertising) and other
promotional materials; future projects; business development or planning; and
-12-commercial relationships or negotiations, but excluding in any case the information in Clause 6.2.
Information is not Confidential Information if:
(a) it is or becomes generally available to the public (other than as a result of its disclosure in breach of this Agreement);
(b) the disclosing Party can establish to the reasonable satisfaction of the other Party that it found out the information from a person not
connected with the other Party or its Associated Companies or the Company and that such person is not under any obligation of
confidence in respect of the information; or
(c) the disclosing Party can establish to the reasonable satisfaction of the other Party that the information was known to the disclosing Party
before the date of this Agreement and that it was not under any obligation of confidence in respect of the information.
Each Party irrevocably agrees, undertakes and covenants with the other Party and the Company and any Subsidiary of the Company that it shall at
all times keep confidential (and use all reasonable endeavours to ensure that its employees, agents and Associated Companies, and the employees
and agents of such Associated Companies, and the Company shall keep confidential) any Confidential Information and shall not use such
Confidential Information except for the purpose of exercising or performing its rights and obligations under or in connection with this Agreement,
and shall not disclose such Confidential Information except:
(a) to an Associated Company or to a Party’s professional advisers where such disclosure is for a purpose related to the operation of this
Agreement;
(b) with the written consent of such of the Company or the Party or any Associated Company to which the information relates;
(c) as may be required by law or by the rules of any recognized stock exchange, or governmental or other regulatory authority or by a court or
other authority of competent jurisdiction, provided that, to the extent it is legally permitted to do so, it gives the other Party as much notice
of such disclosure as possible;
-13-(d) a Party may, provided it has reasonable grounds to believe that the other party is involved in activity that may constitute a criminal offence
under the Anti-Corruption Rules, disclose Confidential Information to the relevant governmental or other regulatory authority without first
informing the other party of such disclosure;
(e) to any tax authority to the extent reasonably required for the purposes of the tax affairs of the party concerned or any of its Associated
Companies; or
(f) Confidential Information relating to the Company and any Subsidiary of the Company (including copies of the Documents) to a bank or
financial adviser of a Shareholder and/or to any potential Buyer(s) in connection with a proposed sale pursuant to Clause 20, provided that:
(i) such bank, financial adviser and/or potential Buyer shall first have entered into confidentiality undertakings for the benefit of the
Company and any Subsidiary of the Company upon terms no less stringent that those set out in this Clause 10or otherwise in a form
reasonably satisfactory to the Board; and
(ii) the disclosing Party gives notice to the other Shareholder specifying, in general terms, the information to be disclosed.
Each Party shall inform (and shall use all reasonable endeavors to procure that any of its Associated Companies and the Company shall inform)
any officer, employee or agent or any professional adviser advising it in relation to the matters referred to in this Agreement, or to whom it provides
Confidential Information, that such information is confidential and shall require them:
(a) to keep it confidential; and
(b) not to disclose it to any third party (other than those persons to whom it has already been disclosed in accordance with the terms of this
Agreement).
On termination of this Agreement, each Party shall (and shall use all reasonable endeavors to procure that its Associated Companies, and its
officers and employees and those of its Associated Companies and the Company shall):
(a) return to the other Party all documents and materials (and any copies) containing, reflecting, incorporating or based on the other Party’s
Confidential Information; and
-14-(b) erase all the other Party’s Confidential Information from computer and communications systems and devices used by it, including such
systems and data storage services provided by third parties (to the extent technically and legally practicable),
provided that a recipient party (and/or the Company, as the case may be) may retain documents and materials containing, reflecting, incorporating
or based on the other Party’s Confidential Information to the extent required by law or any applicable governmental or regulatory authority.
The provisions of this Clause shall continue to apply after termination of this Agreement for any cause.
14. ANTI-CORRUPTION RULES
Each Party recognizes and acknowledges that it is obliged to comply with the Anti-Corruption Rules.
Kiromic acknowledges receipt of a copy of MOLIPHARMA’s Anti-Corruption Policies and confirms that it has Anti-Corruption Policies in place
that are at least comparable to MOLIPHARMA’s.
Each Party warrants and undertakes to the other that:
(a) it has not, and to its best knowledge and belief none of its current or former directors, managers, officers or employees has, and, so far as it
is aware, no other person who otherwise is or has been one of its Associated Persons has, at any time in the last [five (5)] years before the
date of this Agreement:
(i) made, given, authorized or offered, or promised to make, give, authorize or offer any Prohibited Advantage to any person in order to
assist it or any of its Subsidiaries in improperly obtaining or retaining business for or with any person, in improperly directing
business to any person or in securing any improper advantage;
(ii) taken any other action which would violate applicable Anti-Corruption Rules;
(iii) been the subject of any investigation, inquiry or litigation, administrative or enforcement proceedings by any Authority or any
customer or other person regarding any offence or alleged offence under any Anti-Corruption Rules and no such investigation,
inquiry, litigation or proceeding has been threatened or is pending and, so far as it is aware,
-15-there are no circumstances likely to give rise to any such investigation, inquiry, litigation or proceeding;
(b) for so long as it is a Party to this Agreement it will not, and to the extent it is legally able will procure that none of its Associated Persons
will, engage in any of the conduct described in sub-Clauses  (a)(i) or (a)(ii);
(c) it is not ineligible or, so far as it is aware, treated by any Authority as ineligible to tender for any contract or business with, or be awarded
any contract or business by, such Authority, or to tender for or perform any sub-contracting  work under a contract with such Authority;
(d) it has in place, and for so long as it is a Party to this Agreement will maintain, and, to the extent it is legally able will procure that the
Company will maintain, adequate Anti-Corruption Policies;
(e) it requires its Associated Persons to act in accordance with the requirements of applicable Anti-Corruption Rules and uses all reasonable
endeavors to procure that they do so. So far as it is aware, each of its Associated Person which is a legal person has in place policies,
systems, controls and procedures designed to prevent, and which are reasonably expected to continue to prevent it and its Associated
Persons from violating applicable Anti-Corruption Rules; and
(f) in performing its obligations under and carrying out the transactions contemplated by this Agreement and any other Document, neither it,
nor any of its Subsidiaries nor any of their respective Associated Persons has engaged or will engage in any conduct described in sub-
Clauses (a)(i) or (a)(ii).
15. DATA PROTECTION RULES PURSUANT TO REG.EU 679/2016 (GDPR)
Pursuant to and for the purposes of the Privacy Code and EU Reg. 679/2016 (“GDPR”) (“Law”) on “Protection of persons and other subjects with
regard to the processing of personal data”, the Parties - as autonomous Data Controllers - acknowledge that they have exchanged information on
the use of their personal data.
The Parties undertake to communicate to each other - in execution of this Contract - only the common and/or sensitive personal data of third parties
to whom they have given prior information and from whom they have previously acquired (where necessary) their
-16-consent, in accordance with the Privacy Code. and EU Reg. 679/2016 (“GDPR”) In particular, such consent must be informed, expressed, specific;
documented in writing, in the case of common data; given in writing under penalty of nullity, in the case of sensitive data.
Each Party shall be individually responsible for any communication of common and/or sensitive data made without the prior fulfilment of the
aforementioned obligations. The Party to whom the communication is addressed will therefore be released from any responsibility and/or claim of
third parties, related to the possible communication of common and/or sensitive data made in breach of the provisions of this clause and the
Privacy Code and EU Reg. 679/2016.
16. GOVERNING LAW AND DISPUTE ACCORDANCE
All disputes arising out of or in connection with this Agreement shall be finally settled under the Rules of Arbitration of the International Chamber
of Commerce by one or more arbitrators appointed in accordance with the said Rules. Any such arbitration shall (i) be subject to the application of
the Italian Law, (ii) take place in Paris, France and (iii) be conducted in English.
Each of the parties to this Agreement consents to personal jurisdiction for any emergency injunction sought in the Court of Rome. However,
subsequent to the emergency injunction hearing, the merits of the matter will be decided by the ICC as per the procedure set forth above.
IN WITNESS WHEREOF, Parties have severally subscribed to these articles, or caused them to be subscribed in their name and on behalf by their
respective officers thereunto duly authorized.
Rome/Houston, 2 April 2020
Kiromic Biopharma Inc. Molipharma s.r.l.
Prof Maurizio Chiriva Internati Avv. Giovanni Meliadò
-17-Exhibit 10.1
JOINT VENTURE AGREEMENT
BETWEEN
NOVO INTEGRATED SCIENCES INC.
(“NVOS”)
AND
HARVEST GOLD FARMS INC.
(“HGF”)
FOR THE DEVELOPMENT,
MANAGEMENT AND OPERATION OF
HEMP FARMING AND MEDICINAL CROPSJOINT VENTURE AGREEMENT
Dated as of December 19, 2019
This Joint Venture Agreement (the “Agreement”) is entered into between Novo Integrated Sciences Inc., a Nevada Corporation with offices located
at 11120 NE 2nd Street, Suite 200, Bellevue, Washington 98004, U.S.A (herein referred to as “NVOS”) and Harvest Gold Farms Inc., a corporation
organized under the laws of New Brunswick, Canada with offices located at 866 E. H. Daigle Blvd, Grand Falls, New Brunswick, E3Z 3E8, Canada
(herein referred to as “HGF”). NVOS and HGF may be referred to herein collectively as the “Parties” and separately as a “Party.”
RECEITALS
WHEREAS, NVOS is willing to assist in development, assist in management and purchase biomass resulting from open field farming for
health-related cash crops, in particular medicinal cannabis and industrial hemp;
WHEREAS, NVOS is willing to develop and construct processing facilities as well as finished goods manufacturing and packaging
facilities;
WHEREAS, NVOS is willing to provide the Joint Venture access to its distribution pathways established either directly or indirectly
through NVOS or its wholly or partially owned subsidiaries;
WHEREAS, NVOS is willing to establish reasonable commercial cost bases to product processing and packaging ensuring a profitable and
fully transparent Joint Venture;
WHEREAS, NVOS is willing to utilize all applicable HGF tools and offerings for the purposes of developing a fully comprehensive North
American business platform;
WHEREAS, HGF is willing to work towards a mutually acceptable Joint Venture;
WHEREAS, HGF is willing to engage to its fullest potential in the licencing, employment harvesting, legal right consulting, business
development within its geographical jurisdiction;
WHEREAS, HGF is willing assist in transport and distribution of raw and finished goods in both domestic and international jurisdictions;
WHEREAS, HGF is willing to provide certified biomass to the JV on pre-determined, mutually agreed price per acre and participate on a net
revenue split of products offered to market directly or indirectly through NVOS channels;
NOW THEREFORE, the Parties agree to sign this Agreement for the purposes of developing, managing and arranging medicinal farming
projects involving hemp and cannabis cash crops (hereinafter referred to as the “Primary Project”) under the following terms set out in this
Agreement for the noted project (herein, referred to as the “Primary Contract”).ARTICLE 1 - DEFINITIONS AND INTERPRETATION
1.1 For the purposes of this Agreement, unless the context otherwise requires, the following terms shall have the respective meanings set
forth below and grammatical variations of such terms shall have corresponding meanings:
(a) “Action” means any legal action, suit, claim, investigation, hearing or proceeding, including any audit, claim or assessment for Taxes or
otherwise.
(b) “Agreement” means this Joint Venture Agreement, dated December 19, 2019.
(c) “Company” means the Joint Venture entity which will be registered and incorporated in a Canadian jurisdiction with its operating name as
Novo Earth Therapeutics Inc.
(d) “Cost” means cost of goods sold as defined in the financials of the Primary Project.
(e) “Effective Date” is the date of the most recent final signature on this Agreement.
(f) “EPC” means engineering, procurement, construction contracts.
(g) “HFG” means Harvest Gold Farms Inc.
(h) “Joint Venture” means a business arrangement where NVOS and HGF have agreed to pool their resources for the purpose of the Primary
Project.
(i) “Law” means any domestic or foreign, federal, state, provincial, municipal or local law, statute, ordinance, code, rule, or regulation having
the force of law.
(j) “NHL” means Novo Healthnet Limited.
(k) “NVOS” means Novo Integrated Sciences Inc.
(l) “Parties” means collectively, Harvest Gold Farms Inc. and Novo Integrated Sciences Inc.
(m) “Party” identifies, separately, either Harvest Gold Farms Inc. or Novo Integrated Sciences Inc.
(n) “Primary Contract” means the terms set out in this agreement for the Primary Project.
(o) “Primary Project” means this agreement that outlines the development, management and arranging of medicinal farming projects involving
hemp and cannabis cash crops.
(p) “Tax(es)” means any federal, state, provincial, local or foreign tax, charge, fee, levy, custom, duty, deficiency, or other assessment of any
kind or nature imposed by any Taxing Authority (including any income (net or gross), gross receipts, profits, windfall profit, sales, use,
goods and services, ad valorem, franchise, license, withholding, employment, social security, workers compensation, unemployment
compensation, employment, payroll, transfer, excise, import, real property, personal property, intangible property, occupancy, recording,
minimum, alternative minimum, environmental or estimated tax), including any liability therefor as a transferee (including under Section
6901 of the Code or similar provision of applicable Law) or successor, as a result of Treasury Regulation Section 1.1502-6 or similar
provision of applicable Law or as a result of any Tax sharing, indemnification or similar agreement, together with any interest, penalty,
additions to tax or additional amount imposed with respect thereto.(q) “Taxing Authority” means the Internal Revenue Service, the Canada Revenue Agency and any other Authority responsible for the
collection, assessment or imposition of any Tax or the administration of any Law relating to any Tax.
(r) “Tax Return” means any return, information return, declaration, claim for refund or credit, report or any similar statement, and any
amendment thereto, including any attached schedule and supporting information, whether on a separate, consolidated, combined, unitary
or other basis, that is filed or required to be filed with any Taxing Authority in connection with the determination, assessment, collection or
payment of a Tax or the administration of any Law relating to any Tax.
1.2 Interpretive Provisions. Unless the express context otherwise requires:
(a) the words “hereof,” “herein,” and “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as
a whole and not to any particular provision of this Agreement;
(b) terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa;
(c) references herein to a specific Section, Subsection, Recital, Schedule or Exhibit shall refer, respectively, to Sections, Subsections, Recitals,
Schedules or Exhibits of this Agreement;
(d) wherever the word “include,” “includes,” or “including” is used in this Agreement, it shall be deemed to be followed by the words
“without limitation”;
(e) references herein to any gender shall include each other gender;
(f) references herein to any contract or agreement (including this Agreement) mean such contract or agreement as amended, supplemented or
modified from time to time in accordance with the terms thereof;
(g) with respect to the determination of any period of time, the word “from” means “from and including” and the words “to” and “until” each
means “to and including”;
(h) references herein to any Law or any license mean such Law or license as amended, modified, codified, reenacted, supplemented or
superseded in whole or in part, and in effect from time to time; and
(i) references herein to any Law shall be deemed also to refer to all rules and regulations promulgated thereunder.ARTICLE 2 - ENTERPRISE NAME
2.1 The Joint Venture has been registered and incorporated in a Canadian jurisdiction mutually acceptable to both parties and will be referred
to as the “Company”, the Company shall have all the liabilities of the project in relation to finance and operation with HGF having no
liability in relation to the project.
ARTICLE 3 - RELATIONSHIP OF PARTIES
3.1 The parties will work in a Joint Venture relationship with NVOS providing the development and operation of the project including sales and
HGF providing the land, farming expertise, biomass and necessary approvals for the development of the agricultural project.
ARTICLE 4 - OFFICE LOCATION
4.1 The Company shall have an office in the NVOS head office location as well as an office on the Primary Project location and if necessary,
offices in international jurisdictions for the purpose of sales and promotion.
ARTICLE 5 - START UP CAPITAL AND CONTRIBUTIONS
5.1 Each of the Parties shall contribute to the start-up as follows:
5.1.1 NVOS
● Complete and finalize a business plan and layout plans, a detailed procurement project binder and an implementation and roll-out plan.
● Make arrangements for construction and financing options of any facilities required for the profitable farming of medicinal crops or related
facilities.
● Direct project finance model and selection of EPC and management service providers.
● Arrange for product purchase contracts.
5.1.2 HGF
● Will provide the land and approvals for greenhouse (if necessary), open field farming and other facilities as required.
● Arrange for all required titled land for greenhouses and outdoor agriculture platforms.
● Arrange for all building permits, environmental approvals and HGF internal approvals including confirmation of tax-free Company status
for the duration of the proposal (if possible).
● Provide elite farming expertise for the purposes of maximizing potential profits, inclusive of harvesting techniques and process flow and
engineering.
ARTICLE 6 - HGF AND NVOS COMMITMENTS SCHEDULE
6.1 Upon execution of the proposal, HGF will provide necessary documentation for all land intended for use in the Primary Project including
beneficial owners, addresses, and parcel size.6.2 Upon execution of the proposal, HGF will provide necessary documentation (allocated land) required for the completion of the
construction and management package.
6.3 Harvesting schedule occurs as dictated by determined cash crop selection. Accompanying cash flow projections will be completed upon
binding buyer contract receipt.
ARTICLE 7 - PRINCIPLE AND LINE OF CREDIT RETURNS
7.1 Priority is given to all debt service requirements with principle pay-back schedule adherence based on cash flow actual conditions.
Distribution to Parties as per agreement on a “last to issue” basis.
ARTICLE 8 - TERM OF AGREEMENT
8.1 The initial term of this Agreement shall, unless sooner terminated by consent of all parties, expires in five (5) years from the date of
Effective Date. NVOS and HGF may renew the Agreement within two (2) years of the expiry of the initial term upon mutual understanding.
8.2 It is understood that a subsequent renewal of a five (5) year term will be negotiated in good faith and shall carry terms very close to the
original Agreement.
8.3 Both parties may enter into buyout negotiations with the other Party on terms agreeable to both Parties.
ARTICLE 9 - OBLIGATIONS OF NVOS
9.1 To maintain all financial records of the Company and provide quarterly and annual reporting to all Company stakeholders. All records are
kept under US GAAP compliance standards.
9.2 Assign and direct operational staff from onset to agreement termination.
9.3 To remunerate HGF on the basis of thirty percent (30%) of net Company income basis on an annual basis commencing 12 months after the
first full 12-month revenue period.
9.4 To purchase product from the Company at a price of cost plus five percent (5%).
9.5 To issue two (2) million NVOS common stock upon successful target of twenty-five million dollars ($25M) of net profit achieved by the
Company each fiscal year. NVOS common stock will be delivered to HGF via Novo Healthnet Limited (“NHL”) exchangeable preferred
shares. All parties understand NVOS is a U.S. reporting publicly traded corporation and that any NVOS common shares issued, from
exchanging the NHL exchangeable preferred shares, will be provided under the guiding U.S. rules and regulations. Furthermore, all parties
understand these shares will carry the same rights and conditions, with no special terms or conditions, as all NVOS common shares
authorized for issue under the companies’ Nevada Articles of Incorporation. Any NVOS common stock issued to HGF, on or after the date
hereof, is subject to pro-rata adjustment in the event that NVOS shall, prior to the issuance date, approve any forward stock split, reverse
stock split or other capitalization re-structure.ARTICLE 10 - OBLIGATIONS OF HGF
10.1 To assist the Company in any way deemed necessary by the Company in the marketing and sales of all cash crops associated to the
Primary Project both domestically and internationally.
10.2 To maintain positive relations with agencies (government and environmental) ensuring continuing land use and development.
10.3 To promote and maintain positive public relations activities ensuring positive Company public opinion.
10.4 To grow medicinal agriculture crop at the highest standard, subject to independent third party biomass testing.
10.5 To grow in the most profitable manner while maintaining the standards of excellence required to maintain elite status.
10.6 To provide a minimum of seven thousand (7000) acres for the Primary Project to be identified by each individual lot, including size, and its
placement in the annual rotation as per SCHEDULE A.
ARTICLE 11 - MANAGEMENT PERSONNEL
11.1 All staffing, including but not limited to, management, specialized or general labor requirements for farming will be the sole responsibility
of HGF.
ARTICLE 12 - DIVIDEND DISTRIBUTIONS
12.1 The distribution will be based on NVOS audited review and will be made within three months of annual considerations on the basis of a
seventy percent (70%) of net profit to NVOS and thirty percent (30%) of net profit to HGF.
12.2 The distribution will be based on NVOS audited review and will be made within three months of annual considerations.
ARTICLE 13 - CURRENCY
13.1 Except where otherwise expressly provided, all amounts of monies referenced are in US dollars.
ARTICLE 14 - BANKING AND ACCOUNTING
14.1 The Company will have a segregated bank account controlled by NVOS for general operating expenses and a segregated investment
account for passive short-term secured investments.
ARTICLE 15 - FINANCIAL STATEMENTS
15.1 The Company will prepare quarterly statements for review by the Parties, released on the 15th day of each subsequent quarter.15.2 The Company’s audited annual filing will be prepared in accordance to NVOS requirements for the purposes of consolidation on a US
GAAP accounting basis.
15.3 The Company’s fiscal year is September 1 through August 31.
ARTICLE 16 - TAXES
16.1 The Company will ensure timely remittance of all tax liabilities and ensure specific adherence to any specific tax considerations. HGF will
ensure maximum tax reduction and where possible elimination of any tax consideration.
ARTICLE 17 - PRESERVATION OF RECORDS
17.1 All company records will be kept for a minimum of five (5) years unless otherwise required by federal or provincial law.
ARTICLE 18 - ASSIGNMENT BY NVOS
18.1 During the term of this agreement NVOS shall have the right to assign, transfer or sell all or part of its interest in the agreement upon the
terms and conditions herein, subject only to prior written notice to HGF.
ARTICLE 19 - ASSIGNMENT BY HGF
19.1 During the term of this agreement HGF shall have the right, upon written approval of NVOS, to assign, transfer or sell all or part of their
interest in this agreement.
ARTICLE 20 - BEST EFFORTS
20.1 NVOS and HGF covenant and agree to make their best efforts to fully develop the Primary Projects as well as all projects associated to this
agreement as per this agreement at all times faithfully, honestly and diligently perform or cause to be performed their obligations hereunder
and to continuously exert best efforts to promote and enhance the business and in that regards they hereby covenant and agree, so long
as this Agreement shall remain in effect, to operate the business, as to preserve, maintain and enhance the reputation of NVOS and HGF
through the Company.
ARTICLE 21 - DISPUTES
21.1 The Parties shall negotiate in good faith and make every effort to settle any dispute, or claim, that may arise out of, or relate to, the
Agreement. If agreement cannot be reached, an aggrieved Party shall, if he intends to proceed further in terms of Section 21.2 hereof,
advise all other Parties in writing that negotiations have failed and that he intends to refer the matter to mediation in terms of Section 21.2.
21.2 Not earlier than ten (10) working days after having advised the other Party, in terms of Section 21.2, that negotiations in regard to a dispute
have failed, an aggrieved Party may require that the dispute be referred, without legal representation, to mediation by a single mediator.
The mediator shall be selected by agreement between the Parties. The costs of the mediation shall be borne equally by the Parties.The mediator shall convene a hearing of the Parties and may hold separate discussions with either Party and shall assist the Parties in
reaching a mutually acceptable settlement of their differences through means of reconciliation, interpretation, clarification, suggestion and
advice. The Parties shall record such agreement in writing and thereafter they shall be bound by such agreement.
The mediator is authorised to end the mediation process whenever in his opinion further efforts at mediation would not contribute to a
resolution of the dispute between the Parties.
21.3 Where a dispute or claim is not resolved by mediation, it shall be referred to arbitration by a single arbitrator to be selected by agreement
between the Parties. The Party requiring referral to arbitration shall notify the other Party, in writing, thereof, not later than thirty (30)
calendar days after the mediator has expressed his opinion, failing which the mediator’s opinion shall be deemed to have been accepted by
the Parties and shall be put into effect.
Arbitration shall be conducted in accordance with the provisions of the Arbitration Act No. 42 of 1965, as amended, and in accordance
with such procedure as may be agreed by the Parties or, failing such agreement, in accordance with the rules for the Conduct of
Arbitrations published by the Association of Arbitrators and current at the date that the arbitrator is appointed.
The decisions of the arbitrator shall be final and binding on the Parties, shall be carried into immediate effect and, if necessary, be made an
order of any court of competent jurisdiction.
ARTICLE 22 - INDEMNIFICATION
22.1 The Parties agree to mutually defend, indemnify and save one another harmless from and against any claims, demands, actions, losses,
damages, costs, charges, liabilities and any expenses, including legal fees of whatever kind arising out of or in connection with each
parties’ activities conducted pursuant to this Agreement.
ARTICLE 23 - CONFORMITY WITH LAWS
23.1 In this Agreement, the singular includes the plural and the masculine includes the feminine and neuter and vice versa unless the context
otherwise requires.
23.2 If any provision or part of any provision in this Agreement is void for any reason or found to be unenforceable, it may be severed without
affecting the validity and enforceability of the balance of the Agreement.
23.3 This Agreement binds and benefits the parties and their respective heirs, executors, administrators, personal representatives, successors
and assigns.
23.4 This Agreement contains the sole and entire agreement between the parties and supersedes any and all other agreements, both verbal and
written, between them.23.5 The parties agree that neither of them has made any representations with respect to the subject matter of this Agreement, or any
representations inducing the execution and delivery hereof, except such representations as are specifically set forth herein.
ARTICLE 24 - CONFIDENTIALITY
24.1 The parties shall keep confidential all business terms and conditions of this Agreement and neither shall release such information to any
other party without the express written consent of the other, in the case of NVOS, it is understood that NVOS will be filing this Agreement
with the Security Exchange Commission of the United States of America in a matter compliant to publicly listed company rules.
ARTICLE 25 - ENTIRE AGREEMENT
25.1 No waiver or modification of this Agreement or of any covenant, condition or limitation herein contained shall be valid unless in writing
and duly executed by the party to be charged therewith.
25.2 Furthermore, no evidence of any waiver or modification shall be offered or received in evidence in any proceeding, arbitration, or litigation
between the parties arising out of or affecting this agreement, or the rights or obligations of any party hereunder, unless such waiver or
modification is in writing, duly executed as aforesaid.
25.3 The provisions of this paragraph may not be waived as set forth herein.
[Signatures Appear on Following Page]ARTICLE 26 - AFFIRMATION AND EXECUTION
Novo Integrated Sciences Inc.
By: /s/ Robert Mattacchione
Name: Robert Mattacchione
Title: CEO
Date: December 19, 2019
Address for Notices:
119 Westcreek Drive Unit 1
Woodbridge, Ontario, Canada, L4L 9N6
Email: xxxxxxxxx@xxxxxxx.com
Harvest Gold Farms Inc.
By: /s/ Michael Scully
Name: Michael Scully, BBA J.D.
Title: President
Date: December 19, 2019
Address for Notices:
866 E. H. Daigle Blvd.
Grand Falls, New Brunswick, Canada, E3Z 3E8
Email: xxxxxxxxx@gmail.comSCHEDULE A
Acreage Identification for the Primary Project
Disclosed in certificate of Robert Mattacchione, dated December 18, 2019.Exhibit 10.65
 
JOINT VENTURE AGREEMENT
MINDA IMPCO TECHNOLOGIES LIMITED
 
This Joint Venture Agreement (Agreement) is made and executed on this the 18th day of May, 2001
 
BETWEEN
 
IMPCO Technologies Inc., a company incorporated under the laws of the State of Delaware U.S.A. and having its principal office of business at
16804 Gridley Place, Cerritos, California 90703, U.S.A. (hereinafter referred to as ‘IMPCO’, which terms shall unless repugnant to the subject or
context mean and include its successors and permitted assigns), through Ms. Pearl Kamdar a duly authorized person and Director of Asia-Pacific
Operations,
 
AND
 
MINDA INDUSTRIES LIMITED, a company incorporated under the Companies Act, 1956 having its registered office at 36-A, Rajasthan Udyog
Nagar, Delhi-110 033, India, (hereinafter referred to as ‘MIL’, which terms shall unless repugnant to the subject or context mean and include its
successors and permitted assigns), through Mr. Nirmal K. Minda its Managing Director,
 
AND
 
Mr. Nirmal K. MINDA, s/o. Mr. S.L. Minda, r/o. A-15, Ashok Vihar, Phase-I, New Delhi-110 052 on in his individual capacity and on behalf of his
relatives and associates listed in Schedule-I (hereinafter referred to as ‘ MINDA’, which terms shall unless repugnant to the subject or context mean
and include his heirs, executors, administrators or successors and permitted assigns).
 
WHEREAS IMPCO is engaged in the business of development, manufacture and sale of alternate fuel management systems and components for
operating motor vehicles, forklifts, industrial engines and other engines of various horsepower; and
 
WHEREAS MIL is engaged in the manufacturing and sale of auto electrical parts such as switches, lamps and horns; and
 
WHEREAS IMPCO and MIL/MINDA have entered into a joint venture to promote a company under the name of MINDA IMPCO LIMITED for
manufacturing and selling alternate fuel management systems and components, including but not limited to CNG, LPG and Propane Kits for
operating motor vehicles, forklifts, industrial engines and other engines of various horsepower in India ; and
 
WHEREAS, MIL represents that it has the technical, marketing skills and financial wherewithal to install, sell and service the alternate fuel systems
and components manufactured by MINDA IMPCO Limited and enjoys a respected business relationship with
 
1cognizant governmental and industrial authorities, all of which may be advantageously employed in the safe and professional marketing of MINDA
IMPCO Limited products, as specified above, in India with the approval of and in compliance with such governmental authorities; and
 
WHEREAS the Parties hereto have agreed, subject to obtaining all necessary approvals, permissions, consents, validations, confirmations,
licenses and any other authorizations required to incorporate a company in India ( “the Joint Venture Company” or the “JVC”) with the main
object of inter alia marketing and selling of alternate fuel management systems, including but not limited to CNG, LPG and Propane Kits and its
components for automobiles and other associated and incidental services to customers; and
 
WHEREAS IMPCO will contribute to the JVC in cash and the JVC will issue equity shares to IMPCO; and
 
WHEREAS MIL/MINDA will contribute to the JVC in cash and subject to IMPCO’s consent in kind and the JVC will issue equity shares to
MIL/MINDA; and
 
WHEREAS the Parties hereto are ready, willing and able to assist each other and cooperate in the manner set out hereinafter, to ensure the
establishment and success of the JVC. The Parties shall cooperate with each other in the highest degree in the performance of all such acts and the
passing of all resolutions as are required for the purpose of achieving the terms, purposes and intent of this Agreement and the Parties shall in
particular exercise their respective voting and other rights and power of control over the JVC so as to give effect to the rights conferred upon the
respective Parties by the terms of this Agreement.
 
NOW THEREFORE in consideration of the mutual promises and covenants hereby contained, this Agreement witnesses and the Parties hereto
have agreed as follows:
 
2ARTICLE – 1
DEFINITIONS
 
1.1   In this Agreement, unless the context otherwise requires, the following shall have the meaning as set forth against them below:
 
“Act” shall mean the Companies Act, 1956, and includes, where the context so requires, any re-enactment or statutory modifications
thereof for the time being in force.
 
“Affiliate(s)” shall mean with respect to any Party to this Agreement any entity which controls, is controlled by, or is under common
control with such Party. An entity controls another entity when it owns or controls, directly or indirectly, fifty-one percent (51%) or
more of the equity share capital issued and outstanding of the other entity or when it controls, on its own or jointly, the majority of the
composition of the Board of Directors of such other entity.
 
“Agreement” or “this Agreement” shall mean this joint venture Agreement, alongwith all attachments annexed hereto, and shall
include any subsequent modifications, alterations and additions and deletions therefrom made in writing after the date of execution of
this Agreement.
 
“Approval(s)” shall mean all government, statutory and/or regulatory permissions, consents, validations, confirmations, licenses and
any other authorizations required to be obtained in order to implement the provisions of this Agreement including, but not limited to, all
necessary approvals of the Government of India and the Reserve Bank of India.
 
“Articles” or “Articles of Association”  shall mean the Articles of Association of the MINDA IMPCO Technologies Limited. 
 
“Alternate Director” shall mean an Alternate Director appointed in terms of Article 3.7 herein to act for a Director during his absence
for a period of not less than three (3) months from the State in which the registered office of the JVC is situated and such Alternate
Director shall not hold office as such for a period longer than that permissible to the Director in whose place the Alternate Director has
been appointed and shall vacate office when the Director returns to such State.
 
“Financial Institutions” shall mean Indian financial institutions, including but not limited to, ICICI, Industrial Development Bank of
India, Industrial Finance Corporation of India and shall also include foreign financial institutions.
 
“Joint Venture Company” or “the JVC” shall mean the Indian company to be established and incorporated under the laws of India
pursuant to the terms of this Agreement and, subject to the approval of the Registrar of Companies, Delhi and Haryana, with the name
“MINDA IMPCO Technologies Limited” or such other name as may be agreed by the Parties, with the main object of,  inter alia,
marketing and selling of alternate fuel management systems, including but not limited to, CNG,
 
3LPG and Propane Kits and its components for automobiles and other associated and incidental services to customers.
 
“Memorandum” or “Memorandum of Association” shall mean the Memorandum of Association of the MINDA IMPCO Technologies
Limited.
 
“Products” shall mean alternate fuel management systems, including but not limited to, CNG Kits, Propane Kits and its components for
automobiles to be marketed and sold by the JVC, adopting the existing, as well as future development(s) in the technical know-how of
IMPCO, as per terms of the Technical Assistance Agreement and any other products as may be mutually agreed from time to time by
the Parties to this Agreement.
 
“Effective Date” shall mean the date on which the Parties sign and execute this Agreement .
 
“Board” or “Board of Directors” shall mean the Board of Directors MINDA IMPCO Technologies Limited.
 
“Parties” shall mean IMPCO, MIL and MINDA collectively, and the term “Party” shall individually refer to IMPCO, MIL and/or
MINDA, as the case may be.
 
“RBI” shall mean the Reserve Bank of India.
 
“Technical Know-How” shall mean available secret, specialized and proprietary know-how, technical information, drawings, data,
charts, graphs, procedure books, operation manuals and data, technical processes and other technical literature including but not
limited to information of the type listed on Appendix A to the TAA, tangible or intangible, necessary for manufacture and testing of the
Products which (i) is possessed and controlled by IMPCO at the date of this Agreement and (ii) IMPCO has the right to grant licenses
to MINDA-IMPCO LTD. during the term of this Agreement.
 
“Territory” shall mean the geographical area under the jurisdiction of the Government of the Republic of India.
 
1.2   Interpretation: 
 
In this Agreement, unless the contrary intention appears, a reference to:
 
i)   an “amendment” includes a supplement, novation, replacement or re-enactment and “amended” is to be construed accordingly;
 ii)   “assets” includes properties (both present and future and whether tangible or intangible and including Intellectual Property and Intellectual
Property Rights), revenues, investments, cash flows, rights, benefits, interests and titles of every description;
 iii)   an “authorisation” includes an authorisation, consent, clearance, approval, resolution, license, permit, exemption, filing, registration or
notarisation;
 
4iv)   “control” means:
 
  (a)   the ability to appoint more than one half of the members of the board of directors or board of management (howsoever described) of an
entity or to control more than 50 per cent of the voting rights of the members of such board; or
 
  (b)   the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting capital,
by contract, laws and regulations or otherwise;
 v)   a “law” includes any constitution, statute, law, rule, ordinance, judgment, order, decree, authorisation, or any published directive, guideline,
requirement or governmental restriction having the force of law, or any determination by, or interpretation of any of the foregoing by any
judicial authority, whether in effect as of the date of this Agreement or thereafter and each as amended or re-enacted from time to time;
 vi)   a “month” is a reference to a period starting on one day in a calendar month and ending on the date immediately before the numerically
corresponding day in the next calendar month, except that if there is no numerically corresponding day in the month in which that period
ends, that period shall end on the last day in that calendar month;
 vii)   a “person” includes:
 
 
a)   any individual, corporation, partnership, joint venture, association of persons, trust, unincorporated organisation, government (central,
state or otherwise), sovereign state (or any agency, department, authority or political subdivision thereof), international organisation,
agency, authority or other entity (in each case whether or not having separate legal personality) and includes any of its successors,
transferees and assigns and, in particular:
   b)   in the case of an individual, any legal representative, administrator, executor and heir of that individual; and
   c)   in the case of a trust, any trustee of that trust;
 
viii)  a “regulation” includes any applicable regulation, rule, official directive, order, decree, request, guideline, requirement or restriction (whether
or not having the force of law but if not, being of a kind with which it is customary for companies within the relevant industry to comply) of
any governmental, inter-governmental or , agency, department or regulatory, self-regulatory or other authority or organisation, each as
amended or re-enacted from time to time;
 ix)   a clause, a schedule or an annex is a reference to a clause of or a schedule or annex to this Agreement;
 
x)   a schedule, an appendix or an annex to or of a document forms an integral part of that document;
 
5xi)   the singular includes a reference to the plural (and vice versa);
 xii)   the masculine includes a reference to the feminine and neuter;
 xiii) a time of day is a reference to Indian Standard Time.;
 xiv)  the term “including”, “include” or “includes” shall be deemed to be followed by the phrase “but not limited to”;
 xv)   the index to and the headings in this Agreement are for convenience only and are not to be relied upon in construing this Agreement.
 
ARTICLE – 2
INCORPORATION OF JVC AND ITS SHARE CAPITAL
 
2.1   The Parties hereby agree to incorporate the JVC in accordance with the laws of India for the purpose of marketing and selling the Products.
Subject to the approval of the Registrar of Companies, Delhi and Haryana, the name of the company will be ‘MINDA IMPCO Technologies
Limited’ or such other name as may be agreed by the Parties. MINDA will take all necessary steps for the incorporation of MINDA-IMPCO
Technologies Limited.
 
2.2   It is further agreed between the Parties that in order to fulfill the requirement of a minimum of seven (7) shareholders under the Act, the
Memorandum and Articles of Association (hereinafter referred to as “M&A”) of the JVC shall be subscribed to by seven (7) subscribers.
 
2.3   All reasonable costs, fees and other expenses necessary for the incorporation of the JVC, such as registration fee etc., excluding any legal
fees, shall be paid by MIL and will be reimbursed by the JVC upon ratification by a resolution of the Board of Directors of the JVC.
 
2.4   The principal activities of the JVC shall be carried out in accordance with its object clause incorporated in the Memorandum and Articles of
Association (M&A).
 
2.5   The initial authorized capital of the JVC shall be Rs. 5,00,000/- (Rs. Five lacs only) divided into 50,000 equity shares of the nominal value of Rs.
10 each. The initial seven (7) subscribers shall collectively subscribe to 50,000 equity shares of face value of Rs. 10 each.
 
2.6   Subject to the approval of the Government of India (`GOI’), Reserve Bank of India (`RBI’) and other Government agencies, if any, the shares in
the JVC shall be issued to the Parties in the following percentage of the total paid-up capital of the JVC.
 
MIL, MINDA and its associates   – 40% – In cash and /or in Kind.
IMPCO   – 60% – In cash
 
6In consideration thereof, the JVC will issue equity shares either at par or at premium as mutually agreed by the Parties.
 
2.7   Subject to regulatory approvals, if any, and the provisions of the Act, the issue, transfer and/or transmission of shares or any other dealing
with the shares of the JVC, shall be in the manner prescribed in the M&A.
 
2.8 (a)   If in future the Parties agree that it is necessary for the JVC to raise finances by loans and/or equity or otherwise, the Board of the JVC
shall decide the mode of contribution ( cash or kind ) and the extent of debt and equity. All capital contributions will be made by the
Parties in proportion to their shareholding as mentioned in Article 2.6. In the event a Party fails to make its respective capital
contribution to such extent, the other Party (‘Acquiring Party’) shall have the right to make additional capital contributions to such
extent . The Party who failed to make contribution of additional capital shall provide full cooperation and assistance to the Acquiring
Party in obtaining government and regulatory approvals, if any, and in executing necessary documents, including consents and no-
objection certificates as may be required. In case finances are to be raised by way of loans, the Parties agree to take necessary steps to
arrange for the same, including execution of corporate guarantees in favor of Financial Institutions, as and when required.
 
 
(b)   In future, subject to the terms of this Agreement and the M&A, if the share capital of the JVC increases as a result of issue of shares to
a third party or to the public, the Parties hereto shall acquire shares of the JVC in the same proportion as mentioned in Article 2.6 or as
otherwise mutually agreed in writing by them. It is understood that in case of a public issue of equity shares of the JVC, the percentage
shareholding of MIL/MINDA and IMPCO will be reduced to the extent of additional shares allotted to the public. Provided, however,
that in such a case the Parties hereto shall endeavor to avoid any substantial dilution of their collective control over the JVC.
   (c)   Issue of shares in the JVC to IMPCO shall be after taking the requisite approval of RBI and/or other regulatory authorities if any.
 
ARTICLE – 3
MEMORANDUM & ARTICLES OF ASSOCIATION OF THE JVC
AND
GOVERNANCE OF JVC
 
3.1   The M&A shall be in accordance with the law for the time being in force in India. Those provisions of this Agreement which are in conformity
with the Act, shall be reflected in the M&A.
 
3.2   The Parties agree that the M&A shall,  inter alia, to the extent possible and as permitted by law, incorporate and reflect the understanding
contained in this Agreement and the Parties expressly agree that whether or not the M&A fully incorporates the stipulations hereof, or any of
them, the Parties’ rights and
 
7obligations inter se shall be governed by this Agreement which shall also prevail in the event of any ambiguity or inconsistency between the
two documents.
 
3.3   Unless otherwise agreed, between the Parties, the Board of Directors of the JVC shall consist of not less than five (5) and not more than
twelve (12) Directors, including the Managing Director (MD). Out of the minimum number of five (5) Directors, the Parties shall be represented
in the ratio of 3 : 2, i.e., three (3) Directors shall be nominated by IMPCO and two (2) Directors shall be nominated by MIL and MINDA The
Directors nominated by MINDA and MIL will be referred as MINDA Directors and Directors nominated by IMPCO will be referred as IMPCO
Directors. Subject to the terms of this Agreement, the representation of MIL/MINDA and IMPCO on the Board of the JVC shall always be
maintained in the above mentioned ratio and IMPCO will always have a majority on the board.
 
It is further agreed that the first four (4 ) Directors of the JVC shall be nominated by IMPCO .
 
3.4 a)   IMPCO shall designate one (1) of its Directors as the Managing Director (‘MD’) of the JVC in accordance with the provisions of the
Act. The MD shall have substantial powers of management of the JVC, subject to the supervision and control of the Board.
   b)   The other Directors will hold appropriate positions in the JVC, as may be decided by the Board.
 
3.5   Subject to the supervision and control of the Board, the MD shall be in-charge of all day to day management of the JVC, including but not
limited to all aspects of marketing, operations, sales promotion,, after sales services, personnel, employment or termination as well as
remuneration of key executives, personnel, information services, customer services, marketing and sales, accounting, finance and credit
collections. The MD and such other Director(s) shall conduct the business and the management operations of the JVC and the MD may, in
writing, authorize officers in this behalf.
 
3.6   The remuneration of the MD and/or other whole time Director(s) shall be fixed and may be varied from time to time by the Board within the
limits prescribed under the Act/Guidelines issued by the Government of India and subject to the approval of the shareholders and of the
appropriate authorities.  
 
3.7 a)   In the event an IMPCO Director (hereinafter called “Original IMPCO Director”) is away for a continuous period of not less than three
(3) months from the State in which the registered office of the JVC is located, the IMPCO Director shall, during his absence, nominate a
person to act as an Alternate Director on behalf of the Original Director. The Alternate Director shall not hold office for a period longer
than that permissible to the Original IMPCO Director in whose place he has been appointed.
 
8b)   If the term of office of the Original IMPCO Director is determined before he so returns to the State as aforesaid, any provision for the
automatic re- appointment of retiring Director, in default of another appointment, shall apply to the Original IMPCO Director and not to
the Alternate Director.
 
3.8   The Parties to this Agreement shall at all times co-operate, act and vote at all meetings in support of the election of the nominee Directors to
the Board.
 
ARTICLE – 4
GENERAL MEETINGS
 
4.1   The JVC shall hold the General Meeting in the manner prescribed in the Act and the Articles. The remuneration payable to the, Managing or
whole-time Directors and Managers shall be determined, in accordance with and subject to the provisions of the Act.
 
4.2   The quorum for a General Meeting shall be five (5) members present in person or through a duly authorised representative in case of a
member which is a company, provided that there shall be no quorum unless one (1) representative of IMPCO and one (1) representative of
MIL/MINDA is present.
 
If within half an hour from the time appointed for holding a General Meeting a quorum as specified above is not present, the General Meeting
shall stand adjourned by seven (7) days on the same time and place or to such other day and such other time as the Board may determine and
if at such adjourned General Meeting a quorum is not present within half an hour from the time appointed for holding the General Meeting,
the members present shall constitute a valid quorum .
 
ARTICLE – 5
BOARD MEETING
 
5.1   It is hereby agreed and understood between the parties that the Directors present at the Board meeting will elect the Chairman of the Board
(“the Chairman”), who shall be a IMPCO Director. The Chairman shall have a second vote or a casting vote as per the provisions of the Act.
 
5.2   The Board shall decide all important matters pertaining to the management and administration of the JVC subject to the provisions of this
Agreement, the M&A and the Act.
 
5.3   The Board meeting shall be convened and conducted in the manner laid down in the M&A.
 
5.4   The quorum at and throughout meetings of the Board, including adjourned meetings, shall be one third of its total strength or two Directors,
whichever is higher, of which at least one will be a MIL/MINDA Director and one will be an IMPCO Director. Provided that if an MIL/MINDA
or an IMPCO Director fails to be present for two consecutive meetings of the Board as a result of which a meeting of the Board
 
9cannot be held for want of quorum, then either the three IMPCO or the two MIL/MINDA Directors shall constitute the requisite quorum.
 
5.5   All management decisions of the JVC shall require the simple majority vote of the Board either at a meeting of the Board or by resolution
passed by circulation subject to the provisions of the Article 5.6 Meetings of the Board shall take place in Delhi or such other place as may be
decided by the Board. For calling a Board meeting, a notice of at least fourteen [14 ] days in advance in writing shall be given to each of the
Directors, including those outside India. However, a meeting of Directors may be called by giving a shorter notice provided it is mutually
agreed by the Directors. Subject to the provisions of the Act, a resolution circulated and signed by all Directors shall be effective, as a
resolution duly passed at a meeting of Directors. Sitting fees, travel and stay expenses (incurred by the Directors) for attending the Board
meeting, if claimed by the Director(s) shall be met by the JVC as per Articles of Association of the JVC.
 
5.6   IMPCO shall at all times be entitled to invite any of its Affiliates, managerial, technical or financial personnel to attend the Board meetings of
the JVC.
 
ARTICLE – 6
TRANSFER OF SHARES
 
6.1 (a)   Each party hereto agrees not to transfer, sell, pledge, mortgage or make other disposition (whether by way of fixed or floating charge)
or encumbrance on its shares in the JVC except as otherwise provided in this Agreement and/or except by consent of the Parties to
this Agreement and in the manner laid out in the M&A.
 
  (b)   It is agreed that MIL/MINDA may, inter se, transfer their shares in the JVC amongst their relatives and associates as mentioned in
Schedule- I annexed hereto. .
 
  (c)   No party hereto may transfer its shares in the JVC for a period of five (5) years from the date of allotment except as provided above.
 
6.2   After the expiry of the five (5) year period, if a Party intends to sell any or all of its shares of the JVC (the “Transferor”), it shall first make an
offer by a written notice to the other Parties (the “Transferee”) to purchase such shares and the other Parties shall have the right to purchase
the offered shares in proportion of their existing shareholding. . If any of the Transferees intends to purchase all or any portion of the said
shares so offered, such Party shall dispatch a written notice of acceptance to the transferor describing the number of the shares it intends to
purchase within three (3) weeks after the date of receipt of the offer. The sale price of the shares shall be determined in terms of Article 6.3(c)
hereof.
 
106.3 a)   Pursuant to Article 6.2, if a Transferee does not, in whole or in part, accept to purchase the shares offered in terms of Article 6.2 by the
Transferor, the other Transferee may purchase all the shares offered by the Transferor at a price determined as per Article 6.3(c) hereof.
If no Transferee accepts to purchase the shares offered by the Transferor, in whole or in part, the Transferor may sell such shares to a
third party on terms and conditions no more favourable than those offered to the Transferees, including the price of the shares.
 
  b)   Any transfer of the shares of the JVC to a third party shall be subject to the full unconditional assumption in writing by such third party
of all obligations of the Transferor as provided in Article 6.4.
 
 
c)   The transfer of shares, as stated hereinabove, shall be subject to all the regulatory approvals that may be required in this behalf. Such
shares shall be transferred at a price which shall be the price indicated in the offer notice to the extent the same is in accordance with,
the regulations of the Securities and Exchange Board of India or the Reserve Bank of India, if applicable.
 
6.4   Transfer of shares to a Third Party 
  In case of transfer of shares by the Transferor to any third party in pursuance of the above Articles, the following conditions will apply:
   i)   The third party shall enter into a deed of adherence agreeing to be bound by the provisions of this Agreement; and
   ii)   The third party shall not have a conflict of interest and should not be strategically incompatible to the other Parties to the Agreement.
  Notwithstanding the restriction on transfer of shares stipulated hereinabove, IMPCO and MIL/MINDA may transfer any of its holdings in the
JVC to an Affiliate, without requiring the consent of the other Parties, provided that, such an Affiliate shall also be bound by the provisions
of this Agreement and shall execute a deed of adherence as mentioned above.
  It is expressly agreed by MINDA and MIL that, in order to give effect to the provisions of Articles 6.4, they shall provide all necessary co-
operation to IMPCO, including but not limited to assistance for obtaining the necessary RBI/FIPB and other regulatory or government
approvals. Further, MINDA and MIL agrees to sign/execute/file any and all documents with the Government of India or its agencies,
departments or any other third party to give effect to any transfer of shares in accordance with the provisions of this Agreement.
 
116.5   Pledge of shares 
  The Parties agree that the shares held by them shall not be pledged to a third party or otherwise encumbered during the term of this
Agreement. In the event the pledge of shares of any Party is necessitated for the purposes of the JVC, such pledge will be made only
with the prior written consent and on terms acceptable to the other Parties.  
 
ARTICLE – 7
BUSINESS ACTIVITIES
 
7.1   General Purpose: IMPCO and MIL/MINDA have entered into this Agreement for the purpose of establishing the JVC with the main objects of,
inter alia, marketing and selling of the Products and providing other associated and incidental services to customers, and undertake other
activities as mentioned in its M&A.
 
7.2   The JVC will be permitted to use the following words in Products which are manufactured by MINDA IMPCO Limited. “Manufactured by
MINDA IMPCO Limited, an Indo American Joint Venture”. Subject to the provisions of this Agreement, all products, will carry the trademark
of MINDA IMPCO.
 
ARTICLE – 8
ROLE OF CONTRACTING PARTIES
 
8.1   Each of the Parties to this Agreement shall give their assistance to the JVC according to their respective roles to make the JVC a successful
venture.
 
8.2   MIL/MINDA at its sole discretion will assist without any legal obligation the JVC in the following:
   -   Business contacts in India and the neighboring countries;
   -   Access to Indian Know-how;
   -   Procurement of Indian equipment;
   -   Financing from Indian sources;
   -   Personnel recruitment; and
   -   Administration and fiscal.
   -   Support for additional business from Indian/Foreign customers; and
   -   Setting up of the business of the JVC.
 
8.3 a)   IMPCO, at its sole discretion and without any legal obligation may assist the JVC with the following:
   i)   Sales and service training
   ii)   After sales services .
 
  b)   IMPCO may assist the JVC in getting quotations from itself and from its Affiliates for equipment and components. IMPCO and MINDA
agree to assist the JVC in adopting the most economical methods of procurement.
 
12c)   IMPCO may make available to the JVC the services of its international marketing and distribution network and of its Affiliates.
 
 
d)   IMPCO will provide, on the basis of a program to be mutually agreed with the Parties as to people and time, training to the JVC
personnel in various fields like manufacturing, design, quality, testing, etc. IMPCO will not charge any cost from the JVC. However, all
the travelling, boarding and lodging expenses of the personnel of MINDA IMPCO Technologies Limited will be borne by the JVC.
 
ARTICLE – 9
EXPORTS
 
9.1   IMPCO understands and appreciates that the cost of production of products in India based on IMPCO technology could be attractive and
competitive. IMPCO is confident that with their support and backing, the potential for export of the Products is likely to increase further.
IMPCO may arrange for considerable export from India, subject to price competitiveness and quality. IMPCO may undertake to buy back
substantial Products, subject to price competitiveness and quality. IMPCO also agrees that in accordance with their policy of global sourcing
they might consider sourcing other products/components from the JVC.
 
9.2   Subject to the agreement of the Parties, the JVC may export the Products. Such export shall be through IMPCO. The Parties agree that any
direct export of the Products would only be with the prior written consent of IMPCO. IMPCO agrees that they may consider sourcing the
Products from the JVC for their Asia-Pacific operations.
 
9.3   Compliance with Laws. The Parties agree to comply with the Export Control Regulations of the United States Department of Commerce and
other United States Government Regulations relating to the export and re-export of technical data and equipment and products produced
therefrom.
 
Each Party agrees that it will not take any action in violation of, and will not cause the Company to take any action in violation of:
   (i)   applicable laws, rules and regulations of United States of America related to the subject matter of this Agreement, or
 
 
(ii)   the U.S. Foreign Corrupt Practices Act, 15 U.S.C. Sections 78dd-1 et seq. Which, in general, prohibits any person from making any
payment of money or anything of value, directly or indirectly, to any government official and which requires the keeping of financial
records in connection with foreign activities, or
 
  (iii)   the export control laws of any country, with respect to products, services and technology obtained from such country, to the extent that
any of such laws shall be applicable, or
 
13(iv)   the laws of the United States prohibiting or restricting business dealings with Persons of or in Cuba, Iran, Iraq, Libya, Federal Republic of
Yugoslavia (Serbia and Montenegro), Republic of Bosnia and Herzegovina, North Korea and UNITA (Angola) or persons owned or
controlled by any of the foregoing (including any of the “specially designated nationals” specified under such laws.
 
ARTICLE – 10
BUSINESS INFORMATION
 
10.1  Books of Accounts, Records and Reports: The JVC will make and keep all books of accounts, records and reports in accordance with (i)
Generally Accepted Accounting Principles and (ii) as required under the Companies Act, 1956 and other applicable laws.
 
10.2  Financial Statements: Promptly after the end of each financial year (as defined in 9.6 below) and without any charge, the JVC will submit to
IMPCO and MIL/MINDA the annual financial statement including Balance Sheets and Profit and Loss account, related Auditors Reports for
such year.
 
10.3  Availability of Business Records: During reasonable business hours IMPCO and MIL/MINDA will have the right to inspect, and make copies
of any and all of the JVC ‘s business records, including but not limited to financial records, books, accounts and reports. In exercising such
right IMPCO and MIL/MINDA will be reasonable.
 
10.4  Plant Inspection: During reasonable business hours IMPCO and MIL/MINDA will have the right to visit, enter and inspect each plant and
other establishment at which the JVC manufactures and/or processes the Products. In exercising such right, the Parties will be reasonable.
 
10.5  The financial year of the JVC shall be from 1st April to 31st March of each year.
 
ARTICLE – 11
SUCCESSORS & ASSIGNS
 
Successors & Assigns: All provisions of this Agreement shall inure to the benefit of and be binding upon the respective successors,
representatives, heirs and permitted assigns of the Parties hereto.
 
ARTICLE – 12
INDEMNIFICATION
 
12.1  Indemnification by IMPCO: IMPCO hereby indemnifies MIL/MINDA and the JVC and agree to defend, and hold each of them harmless from
and against any and all liabilities, damages, losses, claims, costs and expenses (including attorneys fees) arising out of or resulting from any
misrepresentation or breach of covenant by
 
14IMPCO or the non- performance of any obligation to be performed on the part of IMPCO under this Agreement.
 
12.2  Indemnification by MIL/MINDA: MIL/MINDA hereby jointly and severally indemnifies IMPCO and the JVC agree to defend and hold each of
them harmless from and against any and all liabilities damages, losses, claims, costs and expenses (including attorney fees) arising out of or
resulting from any misrepresentation or breach of covenant by MIL/MINDA or non performance of any obligations to be performed on the
part of MIL/MINDA under this Agreement.
 
ARTICLE – 13
TRADE MARK
 
13.1  MINDA IMPCO Limited shall register the Trademarks “IMPCO” and “MINDA-IMPCO”, or such other Trademark as may be mutually decided.
 
13.2  MINDA IMPCO Limited has agreed to allow the JVC, the right to use the two trade marks in respect of the products, the first being under the
name of “IMPCO” and the second being in the name of “MINDA IMPCO”. Unless otherwise agreed between the parties, the MINDA IMPCO
trademark will be used on the products for sale within the Territory and the products exported would be sold with the trademark IMPCO.
 
13.3  LEGEND: The JVC shall have the option to carry the following legend in product advertisements, on labels or packaging of Products
manufactured by MINDA IMPCO Limited under this Agreement – “Manufactured by MINDA-IMPCO Limited, an Indo-American Joint
Venture”
 
ARTICLE – 14
NON-COMPETITION AND EXCLUSIVE RIGHTS
 
14.1  IMPCO expressly agrees that during the existence of this Agreement, IMPCO shall not enter into any other Joint Venture Agreement or
Marketing/Distribution Agreement, with any company or person(s) in the Territory with respect to the Products.
 
14.2  MINDA/MIL, since it will have access to the Technical Know-How which it would not have had otherwise, expressly agree that:
 
 
(a)   during the term of the Agreement, and thereafter for a period of five (5) years after the termination of the Agreement (such termination
being termination by IMPCO due to default by MINDA/MIL), MIL/MINDA shall not, directly or indirectly, either alone or collectively or
through any of its associates, affiliates, including subsidiaries or any entity owned or controlled by it enter into another joint venture
agreement or marketing/distribution agreement with any company or persons in respect
 
15of the marketing and sale of goods similar to the Products in the Territory. by using the Technical Know-How
 
 
(b)   the damages that would be suffered by IMPCO as a result of breach of the provisions of this Article may not be calculable and that an
award of a monetary judgment for such a breach would be an inadequate remedy. Consequently, IMPCO shall have the right, in addition
to any other rights it may have, to obtain, in any court of competent jurisdiction, injunctive relief to restrain any breach or threatened
breach of any provision of this Article or otherwise to specifically enforce any of the provisions hereof. This remedy is in addition to
any remedy for, and not in lieu of damages, directly or indirectly suffered by IMPCO and reasonable attorney’s fees.
 
 
(c)   the duration for which the covenants in this Article are to be effective is reasonable. In the event that any court finally determines that
the time period or the geographic scope of any such covenant is unreasonable or excessive and any covenant is to that extent made
unenforceable, the parties agree that the restrictions of this Article shall remain in full force and effect for the greatest time period and
within the Territory that would not render it unenforceable. The Parties agree that each of the covenants in Article shall be deemed to be
a separate or independent covenant.
 
ARTICLE – 15
EVENTS OF DEFAULT AND CONSEQUENT TRANSFER OF SHARES
 
15.1  A party shall be deemed to be in default if:
 
  a)   such party makes a material breach of any provision of this Agreement and fails to cure such breach within thirty (30) days after having
received notice and demand for cure of such breach from one or more of the non-defaulting Parties;
   b)   such party becomes insolvent; or
 
  c)   such party passes a resolution to dissolve, to liquidate whether voluntary or involuntary (except for the purpose of bonafide
reconstruction or amalgamation).
 
15.2  If any event of default provided in Article 15.1 above happens with respect to a party:
  If any event of default provided in Article 15.1 above occurs with respect to a party:
 
 
a)   The non-defaulting Party shall after the expiry of the thirty (30) day period referred to in Article 15.1 above, at its option, be entitled to
purchase all of the shares of the JVC owned by the defaulting party. For this purpose, the non-defaulting Party would make a written
offer to purchase the shares of the defaulting Party at the price determined in terms of Article 15.3, and the defaulting Party will be
obliged to transfer its shares within one (1) month of
 
16the receipt of the written notice from the non-defaulting Party. It is clarified that the time period required to obtain Government
approvals, if any, for such transfer will not be included for the purpose of calculation of the period of one (1) month stated above. It is
further clarified that such transfer shall be free of all liens, charges and encumbrances in return for the payment of the purchase price
stated in the offer.
 
OR
 
After the expiry of the thirty (30) day period referred to in 15.1 (a) above, the non-defaulting Party at its option, shall be entitled to sell
all the shares owned by it in the JVC to the defaulting Party at the price determined in accordance with Article 15.3 below.
 
 
b)   The Parties agree that they will render full co-operation and execute all necessary documents, including consents and no-objection
certificates to the Government of India, to ensure that all necessary government approvals can be procured to give effect to the
provisions of this Article.
 
15.3  The price per share in the sale described in Article 15.2 above shall be i) the price determined in accordance with the regulations of the
Securities and Exchange Board of India or the Reserve Bank of India, if applicable or, ii) in case no Government Regulations apply to price
determination, then fair market price as determined by an international auditing firm or other expert designated by the party who would
purchase shares from the defaulting party, whichever is lower; and
 
ARTICLE – 16
TERM AND TERMINATION
 
16.1  This Agreement shall become effective on the date of execution and shall continue in force and effect for an indefinite term thereafter unless
terminated pursuant to the provisions of Article 16 or by all the Parties in writing.
 
16.2  A party shall be automatically excluded from the provisions of this Agreement if it ceases to be a shareholder in the JVC. In such event, such
party shall cause all its Directors and other nominees and representatives to resign from their positions held in the JVC, immediately.
 
16.3  Even if this Agreement is terminated or a party is excluded from this Agreement, the claims and the liabilities of each party, existent at the time
of the termination or exclusion or which shall be subsequently incurred by the cause(s) existent at the time of termination or exclusion, shall
survive and be effective until they are fully performed/discharged.
 
16.4  If the JVC fails to sell [one million dollars (US$ 1,000,000.00)] worth of Products in the Territory within [eighteen (18)] months from the date of
execution of this Agreement, both the Parties will mutually discuss whether to continue or terminate the Agreement.
 
1716.5  In addition to anything contained hereinabove, this Agreement may be terminated by either Party upon the following:
 
 
(i)   in the event of an enactment of any law or regulation in India, or the adoption by the Government of India or any political subdivision
thereof of any policy, guideline or other similar direction which would have the effect of requiring any change in the terms of this
Agreement adverse to IMPCO; or
 
  (ii)   in the event that all or any portion of the facilities or other assets of the JVC are nationalised or expropriated by, or taken over for a
period in excess of one (1) month by the Government of India or any political subdivisions thereof; or
   (iii)   an event of Force Majeure preventing the JVC from carrying on its business for a continuous period of six (6) months.
 
  (iv)   if any Party is required, other than in accordance with the provisions of this Agreement, to transfer all or part of its shares or to reduce
its percentage of shareholding in the JVC due to a change in or enactment of any law or regulation in India.
 
ARTICLE – 16A
 
USE OF TECHNICAL KNOW-HOW AFTER TERMINATION
 
16A.1  The Parties agree that in the event of termination of this Agreement due to any of the reasons mentioned in Article 16 above (and
consequent termination of the TAA) the JVC and/or MINDA/MIL will not be entitled to use the Technical Know-How for any reason
whatsoever. Provided, however, that in the event the termination of this Agreement is followed by a sale of all of the shares held by IMPCO
in the JVC to MINDA/MIL, the JVC will have a right to continue to use the Technical Know How already received and absorbed on the
condition that royalty payments under the TAA have been paid by the JVC to IMPCO or will be paid, as the case may be, for a minimum
period of five (5) years, as provided in the TAA.
 
16A.2  The Parties agree that in the event of termination of the JVA (and consequently the Technology License Agreement) neither Party is
agreeable to the sale of its shareholding to the other party or conversely the purchase of the shareholding of the other party, the parties will
proceed to dissolve the JVC by the mechanism of voluntary winding up. For this purpose, each party will provide full cooperation and
execute necessary documents and make necessary filings with any Government authorities and/or judicial bodies to ensure that JVC can be
voluntarily wound up in the most time and cost efficient manner. The Parties agree that during the pendency of the winding up, the JVC will
be allowed to use the Technical Know How to the extent the same is necessary for the purpose of implementing any orders pending in
favour of its customers.
 
18ARTICLE – 17
REPRESENTATIONS AND WARRANTIES
 
17.1  As of the date of this Agreement, IMPCO represents and warrants that it is a company duly incorporated and in good standing under the
laws of the State of Delaware USA with an office and legal address at 16804 Gridley Place, Cerritos, California 90703 USA; that it has full legal
power and authority to execute this Agreement and to form and subscribe to the Venture under the terms of this Agreement; and that
performance of and compliance with the terms, provisions, and conditions of this Agreement do not conflict with or will not result in any
violation of any applicable bylaw, mortgage, indenture, contract, agreement, instrument, franchise, permit, judgment, decree, order, statute,
rule or regulation.
 
17.2  As of the date of this Agreement, MINDA and MIL, hereby represent and warrant to IMPCO as follows:
 
Warranties as to the Authority
 
This Agreement has been validly executed by MINDA and MIL and constitutes a valid and binding obligation of MINDA and MIL,
enforceable in accordance with its terms. The execution and performance by MINDA and MIL of this Agreement will not:
 
  (a)   conflict with, or result in any breach, violation of or default under the Articles or any note, bond, mortgage, lease, license, permit,
agreement or other instrument or obligation to which MINDA and MIL are a party; or
 
  (b)   to the best of MINDA and MIL’s knowledge, violate any law, order, rule or regulation applicable to the them.
 
All actions, consents, conditions and things required to be taken, fulfilled and done (including the obtaining of any necessary consents or
approvals) in order to enable MINDA and MIL to enter into, execute, and exercise its rights and perform and comply with its obligations
under this Agreement as well as to ensure that those obligations are legally binding and enforceable have been obtained, fulfilled and done.
 
That MINDA and MIL acknowledge that IMPCO has entered into this Agreement in reliance on the warranties and representations made
herein, collectively and severally, by MINDA and MIL. MINDA and MIL represents and warrants that the statements given in this Agreement
are correct.
 
Warranties as to Organisation and Power
 
That MIL is a company limited by Shares, duly incorporated and existing under the laws of India. That MIL was incorporated on September
16, 1992 under the provisions of the Act and has its registered office at 36A, Rajasthan Udyog Nagar, Delhi 110 033 (India).
 
19That MIL has all requisite corporate power and authority to own and operate its properties and to carry out the Business. That MIL has all
permits, licenses and authorisations required by the concerned governmental authorities for the conduct of its Business.
 
Financial Information
 
All Financial Information furnished by MIL/MINDA is accurate and complete. The Financial Statements of MIL/MINDA have been prepared
in accordance with the generally accepted accounting principles, consistently applied, in India and present a true and fair representation of
the financial position of MIL/MINDA as of March 31, 2001. The net worth of MIL/MINDA as at that date is equal to at least RS 100 million.
 
Tax and other matters
 
That MIL/MINDA has duly and timely filed all tax returns required to be filed by it and has paid all taxes which are due and payable and has
paid all assessments and reassessments, and all other taxes, governmental or municipal charges or levies, penalties, interest and fines due
and payable by MIL/MINDA on or prior to the date hereof, which will result in any liability on its part after the Effective Date. That MIL has
not incurred any liabilities for taxes since March 31, 2000 other than those in the ordinary course of business. There are no actions, suits,
proceedings, investigations or claims pending or, to the best knowledge MIL/MINDA, threatened against MIL/MINDA in respect of taxes,
governmental, provincial or municipal charges, levies or assessments, nor are there any matters under discussion with any governmental,
provincial or municipal charges, levies or assessments asserted by any such authority.
 
Legal proceedings
 
That no legal, administrative or other proceeding or governmental investigation or unresolved dispute is pending involving, directly or
indirectly, MIL/MINDA, and no legal, administrative or other proceeding or governmental investigation is threatened, which might adversely
affect the condition (financial or otherwise), Business, operations, prospects or properties of MIL/MINDA. That MIL/MINDA is not subject
to any judgement or court order which adversely affects or might reasonably be expected to adversely affect, the Business, operations,
prospects, properties or conditions (financial or otherwise) of MIL.
 
20ARTICLE – 18
CONFIDENTIALITY
 
18.1  During the term of this Agreement and for a period of three (3) years thereafter, all the Parties to this Agreement shall take reasonable steps to
prevent disclosure of any confidential or proprietary information to any third party, which it may have received from the JVC or other Parties
to this Agreement. They shall not use for any purpose (other than authorized by the supplying party) the confidential information marked or
designated as “confidential”, except for the following information:
   (a)   Which, at the time of disclosure, is in the public domain or publicly known or available;
 
  (b)   Which, after disclosure to the recipient, becomes part of the public domain or publicly known or available, except by breach of the terms
of this Agreement.
 
  (c)   Which the recipient can establish by conclusive proof that the information was in its possession at the time of disclosure to the
recipient;
 
  (d)   Which, the recipient received rightfully without any confidentiality obligation from a third party, who is not prohibited from disclosing
such information;
   (e)   Which is independently developed by the receiving party; and
 
 
(f)   Which is information required to be disclosed by law or as per request of any Governmental body or court of Law. Provided that the
disclosing party is given prior notice and such court or Government body is requested to keep such information confidential to the
extent permissible under law.
 
18.2  Information disclosed under this Agreement should remain the property of the disclosing party.
 
18.3  Without the prior consent of the disclosing Parties, no party will disclose to any third party the fact that any such information has been made
available to a Party hereto.
 
18.4  The Parties to this Agreement shall take all reasonable efforts to ensure that the officers, employees and agents of the JVC shall observe a
similar obligation of confidentiality.
 
ARTICLE – 19
ARBITRATION
 
19.1  Difference: All matters, questions, disputes, differences or claims arising between the Parties as to the effect, interpretation or application of
this Agreement or as to their rights, duties or liabilities hereunder, or as to any act, matter or thing arising out of consequent to, or in
connection with this Agreement (hereinafter called the Difference’) will be resolved amicably through negotiations. Such negotiations will
 
21commence within a period of seven (7) working days of the issue of notice in writing by either party calling for the same (hereinafter called
‘the Notice’).
 
19.2  Arbitration: In the event that such negotiations fail to so resolve the difference within a period of ninety (90) working days from the date of
receipt of the notice by the other party, such difference shall be finally settled under the rules of the International Chamber of Commerce by
arbitrator(s) appointed in accordance with the said Rules. The arbitration proceedings shall be conducted at London, United Kingdom, in the
English language.
 
19.3  Cost of Arbitration: The Parties hereto shall bear respective costs in connection with the arbitration proceedings.
 
19.4  Performance of undisputed obligations: The existence of the Differences between the Parties hereto, or the initiation or continuance of any
arbitration proceedings referred to above, will not delay or postpone the performance of the undisputed obligations of the Parties hereto and
the arbitrator will take full cognizance and give due consideration to such performance, if any, in the making of the final award.
 
ARTICLE – 20
FORCE MAJEURE
 
No Party shall be held liable or responsible to the other Party for failure or delay in fulfilling or performing any obligation in this Agreement in
case such failure or delays are caused by actions or events which are beyond the reasonable control of the affected party, the effect of which
is to prevent or interfere with that party’s performance hereunder, including, without limitation, (i) any Act of God or public enemy, fire,
explosion, accident, embargo, or any other circumstances of like or different character commonly referred to as force majeure; or (ii)
interruption of or delay in transportation or shortage or failure of supply of materials or equipment, breakdowns, strikes, or other labor strife
from whatever cause arising; or (iii) compliance by either party here to with any order, action, directive, or request of any governmental
official, department, agency, or authority. Each party agrees to give the other party prompt written notice of the occurrence of any such
condition, the occurrence and the extent to which the affected Party will be unable to fully perform its obligations hereunder. Each Party
further agrees to use all reasonable efforts to correct such conditions as quickly as possible and to give the other Party prompt written notice
when it is again fully able to perform such obligation. Provided further that, in the event of such prevention or delay as aforesaid, both Parties
hereto, instead of exercising the aforesaid option, may consult with each other in order to mutually determine the course of action to be taken,
in order to minimize the effects of such prevention or delay and continue the operation of this Agreement.
 
22ARTICLE – 21
WAIVER
 
Failure or delay by a party to require the performance of any provision of this Agreement shall not affect or impair that party’s right to require
full performance thereof at any time thereafter. Each party may specifically waive any breach of this Agreement by the other Party or Parties
but no such waiver shall constitute a continuing waiver of similar or other breaches by the other Party or Parties.
 
ARTICLE – 22
SEVERABILITY
 
If any provision of this Agreement is determined by judicial decision to be unlawful, unenforceable or invalid, or is discovered to be so, such
provision shall be severed from this Agreement. Such invalid provision(s) shall be replaced by a valid provision(s). Provided however, that
the remaining provisions of this Agreement shall remain in effect and be binding on the Parties.
 
ARTICLE – 23
NOTICES
 
All notices, requests and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if
delivered by hand, at the time of receipt or, if communicated by cable or similar electronic means, at the time receipt thereof has been
confirmed by return electronic communication or signal that the message has been clearly received, or if mailed seven (7) days after mailing,
registered airmail return receipt requested, with postage prepaid.
 
In case of IMPCO to:   Mr. Don L. Dominic,
    Vice President and General Counsel
    IMPCO TECHNOLOGIES, INC.
    6804 Gridley Place
    Cerritos, California 90703
    U.S.A.
    Fax No.: 562 860-5106
In case of MIL to:   Mr. Nirmal K. Minda
    Managing Director
    36-A, Rajasthann Udyog Nagar,
    Delhi-110033
    Fax No.: 0091 11 7241524
If to Nirmal K. Minda:   Mr. Nirmal K. Minda and/or relatives & associates
    A-15, Ashok Vihar, Phase-I,
    Delhi-110 052.
    Fax No.: 0091 11 7241524
 
23Provided, however, that if the party shall have designated a different address by notice to the other party, then to the last address, so
designated.
 
ARTICLE – 24
MISCELLANEOUS
 
24.1  English shall be used in all correspondence and communications between the Parties. This Agreement and the Associated Agreements shall
be prepared and executed in English. Translation of this Agreement into any other language shall be for the convenience of the Parties and all
questions arising from this Agreement shall be determined by reference to the official English-language version of the Agreement.
 
24.2  Governing Law: This Agreement shall be governed by and construed in accordance with the laws of India and the Delhi Courts shall have
exclusive jurisdiction over any legal proceedings in respect of this Agreement. The Parties hereby stipulate irrevocably that they hereby
submit to the exclusive jurisdiction of the above-referred courts and for such purpose hereby waive all and any challenges to the exclusive
jurisdiction of the above referred courts.
 
24.3  Schedule or Exhibit: Each of the Schedule(s) or Exhibit(s) referred to herein be attached hereto as an integral part of this Agreement.
 
24.4  Entire Agreement: This Agreement sets forth the entire agreement between the Parties and supersedes all prior other agreements and
understandings between the Parties, and their officers, directors, or employees as to the subject matter hereof. None of the Parties has relied
upon any oral representation or oral information given to it by any representative of any of the other Parties. No change in this Agreement
shall be effective either as a result of a course of conduct or oral statements, other than by an agreement in writing duly authorized by the
representatives of each of the Parties hereto.
 
24.5  Counterparts: the Parties shall execute this Agreement hereto, in four counterparts and each executed copy thereof shall be deemed an
original without production of the others.
 
24.6  Any amendment(s) to this Agreement shall be made in writing and signed by the Parties to this Agreement.
 
24.7  Legal Costs: The Parties agree that all legal costs, expenses and fees would be borne by the respective Parties.
 
24.8  Winding Up: In the event of termination of this Agreement and consequent winding up of the JVC, the Parties agree to cooperate with each
other for adequate discharge and fulfillment of the JVC’s liabilities, commitments and obligations as may be necessary.
 
24ARTICLE – 25
NO THIRD PARTY PAYMENT
 
25.1  Definition of Third Parties. The Parties represent to each other that it has not made, and agrees that it will not make, in connection with the
transactions contemplated by this Agreement, or in connection with any other business transactions involving the JVC, any payment or
transfer of anything of any value, directly or indirectly, to the following:
   (a)   to any government official or employee (including employees of government corporations), or to any political party or candidate; or
   (b)   to any officer, director, employee or representative of any actual or potential JVC customer; or
 
  (c)   to any other person or entity if such payment or transfer would violate the laws of the country in which such payment or transfer is
made or violate the laws of the United States.
 
25.2  Anti-Kickback. It is the intent of the Parties that no payment or transfers of value shall be made which have the purpose or effect of public or
commercial bribery, acceptance of or acquiescence in extortion, kickbacks or other unlawful or improper means of obtaining business. This
section shall not, however, prohibit normal and customary business entertainment or the giving of business momentos of nominal value.
 
25.3  Anti-Government Official Ownership. MIL/MINDA affirms that it has disclosed to Company that no government official has an ownership
interest, director indirect, in MIL/MINDA or in the contractual relationship established by this Agreement. In the event that during the term of
this Agreement, there is the acquisition of an interest in MINDA/MIL, or in this Agreement by a government official, MIL/MINDA agrees to
make immediate disclosure to IMPCO and agrees that this Agreement may become subject to immediate termination. For the purpose of this
Article, “government official” means any officer or employee of the government or any department, agency, corporation or instrumentality
thereof, or any political party, and includes immediate family members and nominees of such governmental officials.
 
25IN WITNESS WHEREOF, the Parties hereto have executed this Agreement and caused their respective corporate seals to be affixed by their
officers thereunto duly authorized as of the day and year first written above.
 
Signed for & on behalf of :
 
MINDA INDUSTRIES LIMITED
/s/ Nirmal K. Minda
Nirmal K. Minda
Managing Director
 
 
 
MR. NIRMAL K. MINDA & ASSOCIATES
/s/ Nirmal K. Minda
Nirmal K. Minda
 
 
 
IMPCO TECHNOLOGIES INC.
/s/ Pearl Kamdar
Pearl Kamdar
Director, Asia Pacific Operations
 
 
WITNESS:
 
1.
 
/s/ Rob Mercer
2.
 
/s/ Don Dominic
3.
 
 
 
26SCHEDULE – I
 
Schedule I to the Joint Venture Agreement (JVA) dated May 18, 2001
 
 
DETAILS OF MINDA AS REFERRED IN JVA;
 A.   MINDA FAMILY
   A.1   MR. S.L. MINDA & FAMILY
   1.   MR. S.L. MINDA
   2.   MRS. SAVITRI DEVI MINDA
   3.   S.L. MINDA & SONS (HUF)
 
 
  A.2.  MR. NIRMAL K. MINDA & FAMILY
 
  1.   MR. NIRMAL K. MINDA
 
  2.   MRS. SUMAN MINDA
 
  3.   PALAK MINDA
 
  4.   PRIDHI MINDA
 
  5.   NIRMAL K.MINDA (HUF)
 
 
  A.3.  1. MR. AND MRS. SHISHIR AGARWAL
 
      2. MR. AND MRS. GAGAN AGARWAL
 
B.   ASSOCIATE COMPANIES
 
  B1.   SWITCH AUTO PVT.LTD.
 
  B2.   SOPAN INVESTMENT & AGRO FARMS PVT. LTD.
 
  B3.   LATTU FINANCE & INVESTMENTS PVT.LTD.
 
  B4.   PJPS FINANCE & INVESTMENTS PVT.LTD.
 
27Signed for & on behalf of :
 
 
MINDA INDUSTRIES LIMITED      IMPCO TECHNOLOGIES INC.
/s/ Nirmal K. Minda
 
 
 
/s/ Pear Kamdar
Nirmal K. Minda      Pearl Kamdar
Managing Director      Director, Asia Pacific Operations
MR. NIRMAL K. MINDA & ASSOCIATES       
/s/ Nirmal K. Minda
Nirmal K. Minda  
 
 
 
 
28